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Tight control of blood glucose and blood pressure (BP) reduces cardiovascular risk 
in early Type 1 diabetes mellitus (T1DM).  Increased BP normally increases renal 
medullary perfusion and sodium excretion.  This is called acute pressure natriuresis.  
Inadequate acute pressure natriuresis disrupts circadian regulation of BP, which 
predicts hypertension.  The peptide, endothelin-1 (ET-1), regulates BP via ETA and 
ETB receptors.  ETA receptor antagonists reduce BP and restore its circadian rhythm.  
Two hypotheses were investigated.  First, that acute pressure natriuresis is impaired 
in early T1DM, prior to established nephropathy, and this is associated with elevated 
BP.  Second, that the mechanism is an ETA receptor-mediated blunting of medullary 
perfusion which can be reversed with insulin and ETA receptor antagonism. 
 
Experimental acute pressure natriuresis was induced in young, early T1DM  
(2-3 weeks post streptozotocin) Sprague Dawley rats and healthy controls. Despite 
maintaining glomerular filtration rate, early T1DM suppressed urinary flow (UV, 
22.9±2.9 v. 93.7±11.1µl/min/gkw) and sodium excretion (UNaV, 3.2±0.7 v. 
22.7±3.3µmol/min/gkw) rates by >80%, and reduced gradients of pressure diuresis 
(linear, 1.9 to 0.3) and natriuresis (non-linear k, 0.05 to 0.01) curves. Insulin 
treatment lowered blood glucose (16.8±1.8 to 9.3±0.6mmol/l) and restored gradients 
of the responses. Tissue and urine analyses did not suggest structural nephropathy. 
 
In early T1DM rats, changes in BP on radiotelemetry were consistent with impaired 




(92.3±0.4 to 97.1±0.5mmHg), and the circadian dip in diastolic BP fell (6±1 to 
2±1%).  Atrasentan (ETA receptor antagonist, 5mg/kg/day orally) reduced diastolic 
dipping in early T1DM (3±1 to 1±1%) while additional ETB receptor antagonism  
(A-192621, 10mg/kg/day orally) reversed this, suggesting that ETA, and not ETB 
receptors, mediate impairment of acute pressure natriuresis.  To address this, renal 
blood flow was measured during experimental acute pressure natriuresis and ET 
receptor antagonism.  Early T1DM suppressed the normal rise in medullary 
perfusion (flux, 227.2±26.7 v. 115.4±10.3%) by ~90%.  Suppressed medullary flux 
was unaffected by insulin (112.2±6.8%), despite restoration of UV and UNaV.  In 
controls, atrasentan reduced UV (15.7±4.9 v. 38.6±6.2µl/min/gkw), UNaV (1.7±0.5 
v. 16.7±1.4µmol/min/gkw), FENa (3.4±1.4 v. 15.0±2.4%) and medullary flux 
(122.2±26.7%) by 60 to 90% of control values, while A-192621 increased UNaV 
(26.6±6.9µmol/min/gkw) and FENa (21.6±3.4%), but not medullary flux, by ~50%.  
ET receptor antagonism did not modify early T1DM+/-insulin effects.  Diabetic 
status had no effect on renal ET-1 and ET receptor expression.  
 
These results support the first hypothesis but disprove the second.  Early T1DM 
blunts medullary perfusion and acute pressure natriuresis, and increases diastolic BP.  
Insulin restores natriuresis but not medullary flow.  Therefore, targeting medullary 
perfusion may reduce cardiovascular risk in early T1DM, but this is not achievable 
with selective ETA receptor antagonists.  Novel natriuretic (ETA) and anti-natriuretic 
(ETB) roles for ET receptors, which are not apparent in early T1DM during severe, 
experimental rises in BP, appear to contribute to daily regulation of BP, and may 





People with Type 1 diabetes (high blood sugar due to lack of insulin) have a higher 
risk of cardiovascular disease such as heart attacks, stroke and kidney failure, even 
when their blood glucose is lowered with insulin.  Cardiovascular risk can be 
monitored by measuring blood pressure (BP), which is regulated by the kidneys.  It is 
thought that high BP, especially at night, indicates greater cardiovascular risk, and 
results from reduced blood flow through the kidneys causing sodium and water 
retention.  A new class of medicine, called endothelin A (ETA) blockers, can correct 
abnormal BP and reduce kidney damage.  These effects are countered by ETB 
blockers.  So, this thesis investigated whether rats with diabetes retain salt and water 
because of abnormal kidney blood flow, and also whether ETA blockers and insulin, 
but not ETB blockers, can reverse these effects and restore normal BP.   
 
BP in experimental rats was artificially increased by tying major abdominal arteries 
using a technique that had been perfected beforehand.  During this procedure, the 
kidneys of diabetic rats filtered blood normally but salt and water retention increased 
by 80% and central kidney blood flow decreased by around 90%.  Insulin restored 
normal salt and water excretion in diabetic rats, although central kidney blood flow 
remained decreased.  Analysis of tissue and urine showed that these effects had 
occurred before the kidneys had developed structural damage from the diabetes.   
 
To find out if salt and water retention in diabetes affects BP, surgically-implanted 
radiotransmitters were used to measure BP in rats over several days.  Diabetic rats 




was higher overall and failed to drop when the rats were resting.  Surprisingly, this 
was made worse by an ETA blocker but improved with an ETB blocker, suggesting 
that the ETA blocker was causing rather than correcting the salt and water retention in 
diabetic rats.  This theory was tested by repeating the first set of experiments but this 
time rats were injected with ETA and ETB blockers.  In normal rats, the ETA blocker 
halved central kidney blood flow and increased salt and water retention by up to 90%, 
while the ETB blocker reduced salt and water retention without changing kidney 
blood flow.  Despite these effects, none of these changes was observed in diabetic 
rats.    
 
In summary, these experiments in diabetic rats confirm that diabetes causes salt and 
water retention by reducing central kidney blood flow, and that this is associated 
with increased BP.  However, although insulin reduces salt and water retention, it 
doesn’t do this by increasing central kidney blood flow but by another mechanism, 
not yet identified.  This means that further reductions in cardiovascular risk might be 
achieved in diabetics by using new medicines that increase central kidney blood flow.  
However, ETA blockers will not be the agents to do this.  They unexpectedly reduced 
central kidney blood flow and increased salt and water retention in healthy rats.  
Although this did not occur immediately in diabetic rats, the changes in BP that the 
ETA blockers caused in the diabetics over several days were consistent with this 
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Type 1 diabetes mellitus (T1DM), a chronic disease in which an absolute lack of 
insulin results in persistent hyperglycaemia 1,2, could hardly be described as an 
emerging disease, since it has accompanied mankind through the rise and fall of 
civilisations.  It was recognised as a separate disease entity in Ancient Egypt and was 
first named diabetes meaning “passing through” by the Ancient Greeks 2.  The term 
mellitus, meaning “sweet or honeylike”, was coined in 17th century England by 
Thomas Willis, although the sugary urine that sufferers produced, and which 
attracted ants, had already been recognised in ancient India and medieval Persia 3.  
From antiquity up until the early 20th century, T1DM was almost always lethal as a 
consequence of ketoacidosis, and it was not until the latter half of the 19th century 
that significant advances were made in identifying the aetiology of the disease.  
Following the discovery by Langerhans of the eponymous pancreatic islets, von 
Mering and Minkowsky successfully induced and reversed hyperglycaemia in 
experimental dogs by removing and then regrafting the pancreas 4.  The mysterious 
pancreatic agent responsible for regulating blood glucose was named insulin by the 
Belgian physicist de Mayer, in reference to Langerhans’s islets or insulae 3.  Once 
isolated, insulin was famously used therapeutically for the first time in 1922, when 
Frederick Banting and colleagues successfully treated a sick, ketotic, 14-year-old boy, 
Leonard Thomson 5,6, who then lived for a further 13 years.  Banting received the 
Nobel Prize for medicine, in recognition of a scientific breakthrough in a disease 
prevalent within the general, and in particular the younger, population.   
 
To this day, T1DM remains one of the most common chronic diseases in children 




from insulin resistance, is usually associated with obesity, and has, in modern times, 
attained greater notoriety as an epidemic of the Western world, affecting more than 
400 million people worldwide 8.  Yet T1DM still accounts for 10% of all cases of 
DM, affecting one in every 500 children under the age of 16 in the United Kingdom 
(UK) 9.  Furthermore, its incidence is increasing by approximately 3.5% per year, 
with the highest prevalence in northern European countries 10,11.  The reason for this 
increase is not known, but such a prevalent, incurable and lifelong condition exerts 
an ever-increasing strain on health services.  Currently, T1DM consumes more than 
£1bn (1%) of the annual budget of the National Health Service (NHS) 12, with an 
additional estimated yearly cost to the UK economy of £1bn, in the form of social 
and productivity costs 12.   
 
Despite the historical and economic importance of T1DM, many of the pathological 
features of the disease have not been fully explained.  It is known that it is an 
immune-mediated condition, in which insulin-producing pancreatic islet β cells are 
attacked early in life by autoantibodies 13 and destroyed by infiltrating T cells 14, but 
the triggering stimulus to this process remains unknown.  Furthermore, despite 
instigating insulin replacement therapy to successfully reduce blood glucose, life 
expectancy for people with T1DM, who are in their early twenties, is reduced by  
11-13 years 15, and devastating long-term complications still occur, usually in the 
form of cardiovascular disease (CVD) 7.  Therefore, there is a great unmet need to 






This introduction will firstly consider the cardiovascular complications of T1DM and 
the risk factors for their development, namely, hyperglycaemia, nephropathy and 
hypertension.  Thereafter, pre-clinical and clinical studies of T1DM, including those 
that support therapeutic intervention with the endothelin (ET) receptor antagonists, 
will be discussed. 
 
1.1 Cardiovascular complications of T1DM 
1.1.1 Macro- and microvascular disease 
The risk of CVD is four to ten times greater in patients with T1DM than the general 
population 16,17, and macro- and microvascular complications contribute significantly 
to morbidity and mortality.  Macrovascular disease can lead to angina and 
myocardial infarction 18, limb ischaemia often necessitating amputation 19, and 
cerebrovascular disease resulting in stroke 20.  Microvascular complications include 
loss of vision from retinopathy 21, loss of limb sensation, limb ulceration and 
gastroparesis from neuropathy 22, and the development of nephropathy.  In diabetic 
nephropathy, early glomerular damage, defined as microalbuminuria 
(≥40mg/24hours), can progress to macroalbuminuria (>300mg/24hours) and  
end-stage renal failure requiring dialysis or transplant 23. 
 
Although these complications do not usually occur in T1DM patients until later in  
life 24, functional and structural abnormalities in the cardiovascular system develop 
very early in the course of the disease 25,26.  T1DM is most frequently diagnosed in 




strategies to reduce CVD risk must also be suitable for use in younger patients.  This 
poses a significant therapeutic challenge.   
 
1.2 Cardiovascular risk and blood glucose 
1.2.1 Longitudinal studies assessing cardiovascular risk 
When replacement insulin therapy was first introduced, it successfully met the 
therapeutic goals of preventing ketoacidosis and alleviating polyuria, polydipsia, 
lethargy and weight loss.  This strategy limited glycosuria by lowering blood glucose 
below the renal threshold of maximal capacity for glucose reabsorption 28 but blood 
glucose still exceeded physiological levels of 4.0-6.0 mmol/l 24.  Seventy years after 
Banting’s breakthrough, two clinical studies set out to determine whether macro- and 
microvascular complications of T1DM could be reduced by more intensive insulin 
therapy that maintained blood glucose close to physiological parameters. 
 
The Diabetes Control and Complications Trial (DCCT) 29 was a controlled clinical 
trial in which 1,441 normotensive patients with T1DM were recruited over six years 
with a minimum follow-up of 6.5 years.  Approximately half of the patients were 
randomised to conventional management with insulin.  The other half was 
intensively managed with either three daily insulin injections or insulin infusion 
pump therapy, according to self-monitored blood glucose levels and monthly 
glycated haemoglobin (HbA1c, a marker of the mean glucose over the previous two 
to three months) 30.  Interim analysis discovered that intensively managed patients 
had a lower HbA1c (7% versus 9%) and a 35-76% reduction in the development or 




striking reduction in microvascular risk led to the premature termination of the study.  
All DCCT patients were then invited to take part in the follow-on Epidemiology of 
Diabetes Interventions and Complications (EDIC) study 24.  Unlike DCCT, EDIC 
was only observational but all patients, including those previously managed 
conventionally, were now under an intensive management regimen that removed the 
glycaemic separation between the two original DCCT cohorts (HbA1c=8% in both 
cohorts).  Surprisingly, though, the difference in microvascular risk between cohorts 
continued to widen.  The ongoing EDIC study continues to demonstrate long-term 
improvement in CVD risk in the intensively managed DCCT patients 31, who have 
reduced carotid intima thickness 32, reduced computed tomography (CT)-measured 
coronary artery calcification 33 and a 58% reduction in CVD events after ~18 years of 
follow-up 24.  However, these landmark studies also show that maximal reductions in 
macro- and microvascular risk are only achievable in the long term when intensive 
insulin therapy is instigated at an early stage.   
 
1.2.2 Difficulties arising from intensive blood glucose management 
The clinical need to lower blood glucose in T1DM has to be offset against the 
threefold increased risk of potentially life-threatening hypoglycaemia that occurs 
with intensive management 34, the practical difficulties of tight blood glucose control 
and monitoring in young patients, and the development of resistance to 
neuroglycopaenia (unawareness of hypoglycaemia) 35.  Furthermore, despite clear 
benefits from a lower blood glucose, 6% of intensively managed patients in the 
DCCT still experienced a cardiovascular event (non-fatal stroke, acute myocardial 




18 years, 90% had retinopathy, 19% had some form of nephropathy, and 24% 
demonstrated signs of clinical neuropathy 31.  Thus, it can be concluded that 
alternative treatment strategies, which complement insulin therapy, are required to 
remove cardiovascular risk in T1DM.  Suitable therapeutic targets are nephropathy 
and hypertension, both risk factors for CVD. 
 
1.3 Diabetic nephropathy 
1.3.1 The worldwide importance of chronic kidney disease 
Chronic kidney disease (CKD) is defined as renal damage leading to abnormal 
urinary excretion of albumin, or a reduction in measured or estimated glomerular 
filtration rate (GFR <60ml/min per 1.73m2), that persists for a period of at least three 
months 36.  CKD is a major clinical and financial burden worldwide.  This is partly 
because of its high prevalence (~11%) within the United States (US) and Western 
Europe 37,38 but also because of the high morbidity and mortality associated with it.  
Patients with advanced CKD are most likely to die from CVD 39.  Indeed, CKD is so 
strongly associated with CVD 40 that the US Kidney Foundation Task Force on CVD 
in CKD recommends that patients with CKD should be considered in the highest risk 
group for subsequent cardiovascular events 41.   Dialysis and renal transplantation in 
patients, who do not succumb to CVD prior to end-stage renal disease (ESRD), 
consumes around 2% of the NHS’s annual budget 42.  
 
DM is the single most common cause of CKD, and is responsible for ~25% of all 
cases of renal failure in the UK 43.  Diabetic nephropathy is similar in T1DM and 




consisting of five stages: renal hypertrophy with glomerular hyperfiltration, 
mesangial expansion, microalbuminuria, macroalbuminuria, and ESRD 44.   
 
GFR is usually kept constant, or autoregulated, despite fluctuation in arterial blood 
pressure (BP) 45.  Autoregulation is a consequence of an endogenous myogenic 
response within the afferent and efferent arterioles of every glomerulus.  The 
myogenic response is modified by ligands, such as angiotensin II (AngII), and by the 
macula densa in response to changes in luminal sodium concentration called 
tubuloglomerular feedback (TGF) 46.  Impaired autoregulation of GFR increases the 
risk of hyperfiltration and injury to the glomerular filtration barrier of podocytes, 
endothelial cells and glomerular basement membrane (GBM) 47.  Once the 
glomerular filtration barrier is breached, small plasma proteins, including albumin, 
leak into the tubule and initiate a vicious cycle of neutrophil and macrophage 
infiltration, progressive glomerulosclerosis, and mesangial cell hyperplasia and 
migration 48 .  The consequences are ever greater perfusion and hyperfiltration of 
neighbouring glomeruli, and their subsequent injury 48.  Tubulointerstitial ischaemia 
and fibrosis ensue because peritubular blood supply is downstream of the glomerulus 
and impaired by glomerular destruction 49,50.  Therefore, hyperfiltration is a suitable 
therapeutic target for reducing glomerular injury and functional nephron destruction 
in T1DM, and albuminuria is an independent predictor of ESRD and cardiovascular 
mortality 51.  In many of the pre-clinical and clinical studies of diabetic nephropathy 




1.3.2 Hyperfiltration and the salt paradox 
Studies in rats have demonstrated that hyperfiltration in T1DM is a consequence of 
increased activity of the sodium/glucose co-transporter in the proximal convoluted 
tubule (PCT) which lowers the concentration of sodium in luminal fluid at the 
macula densa, reducing TGF and increasing GFR 52.  In T1DM, increasing oral salt 
intake paradoxically reduces GFR because sodium reabsorption in the PCT is 
reduced and TGF is increased 53.  The opposite effect is achieved with a low salt  
diet 54.  The mechanistic basis to the bidirectional changes in sodium reabsorption 
that underpin the “salt paradox” has not been fully resolved but translation to a 
clinical setting has demonstrated that renal handling of dietary salt may be crucial to 
nephroprotection in people with T1DM 55,56 .  However, restricting dietary salt as a 
therapeutic strategy in T1DM remains controversial 57.  For example, in the  
two-kidney one-clip Goldblatt rat model of T1DM renal injury, in which one renal 
artery is clipped to induce unilateral renal ischaemia, high salt intakes do not reduce 
susceptibility to injury in the unclipped, hyperfiltering kidney 58. Furthermore, 
clinical outcomes in people with T1DM do not have a linear relationship with urinary 
sodium excretion.  Rather, the relationship is U-shaped, with increased mortality 
occurring with salt intakes at opposite ends of the spectrum 59.  Because CVD risk 
rises with salt intake 60, there is currently no consensus on increasing dietary salt to 
delay or prevent diabetic nephropathy in T1DM 57.  Instead, medical management of 
hyperfiltration in T1DM focuses on targeting the renin-angiotensin-aldosterone 




1.3.3 Hyperfiltration and the renin-angiotensin-aldosterone system 
AngII and aldosterone, individual components of RAAS, play a vital role in the 
regulation of BP by controlling extracellular volume and sodium concentrations, and 
peripheral vascular resistance 61.  Sympathetic stimulation and exposure of the 
macula densa to reduced luminal concentrations of sodium stimulate release of renin 
from the juxtaglomerular (JG) cells of the afferent arteriole.  Renin converts 
circulatory angiotensinogen to AngI, which in turn is converted to AngII by 
angiotensin converting enzyme (ACE).  AngII, a potent vasoconstrictor, stimulates 
release of aldosterone from the adrenal cortex, which promotes sodium and water 
retention from the renal collecting duct by increasing activity of the epithelial sodium 
channel (ENaC).   
 
Once ACE inhibition had demonstrated a direct role for AngII in hyperfiltration, 
glomerular injury and proteinuria in T1DM Munich-Wistar rats 62, the ACE inhibitor 
captopril was trialled clinically.  It reduced the risk of doubling of serum creatinine 
(a marker of impairment to GFR), renal transplantation and death in >200 T1DM 
patients compared to placebo 63.  This landmark study showed that blocking RAAS 
to reduce hyperfiltration could significantly reduce the risk of developing ESRD.  
The effects were observed in patients already receiving medication to control 
hypertension, suggesting that the benefits of ACE inhibition stemmed from 
modulation of afferent and efferent arteriolar tone 64, in addition to lowering BP.  
The success of ACE inhibition also challenged the hypothesis that hyperfiltration due 
to hypertension was the source of nephropathy.  Further doubt was cast by the 




time albuminuria is first detected, hypertension is already present 65.  In T1DM, 
however, albuminuria precedes the development of hypertension, suggesting that in 
T1DM, hypertension is a consequence of nephropathy rather than its cause.  It made 
sense, therefore, that ACE inhibitors would be most beneficial after albuminuria had 
developed rather than before.  ACE inhibitors are also known to possess potent  
anti-inflammatory and anti-fibrotic properties 66 and they remain the mainstay of 
treatment of nephropathy in T1DM, with a significant cost:benefit ratio if instigated 
once microalbuminuria has developed 67.   
 
1.3.4 Hypertension and initiation of nephropathy 
Despite the renoprotective benefits of ACE inhibition 63, creatinine clearance still 
declines by >10% over three years 63.  In the EDIC study, ACE inhibition failed to 
narrow the gap in macro- and microvascular complication rates between the DCCT 
intensively- and conventionally-treated cohorts 24.  This raised the possibility of 
hypertension playing an important role in hyperfiltration at an earlier stage of T1DM 
than previously imagined.   
 
Hypertension, defined as systolic BP ≥140mmHg and/or diastolic BP ≥90mmHg, 68 
is the single largest contributor to the global disease burden 69.  Hypertensive 
nephrosclerosis constitutes approximately 30% of all cases of ESRD 70 and 
hypertension exacerbates all forms of CKD by driving further glomerular injury 71.  
The importance of hypertension to the development of diabetic nephropathy is 




resistant to developing nephropathy unless they are hypertension-prone or 
hypertension is induced 72,73. 
 
In another landmark study, designed to investigate the discrepancy between onset of 
hypertension and appearance of microalbuminuria in T1DM and T2DM, Lurbe et al. 
recorded ambulatory BP and 24-hour urinary albumin excretion in 61 
normalbuminuric T1DM patients over a mean follow-up period of 63 months 74.  By 
the end of the study, 19% of the patients had developed microalbuminuria. 
Interestingly, a rise in nocturnal systolic BP of ~5mmHg had preceded 
microalbuminuria by at least three years.  By contrast, the 81% of patients whose 
nocturnal systolic BP had not been elevated, were still not microalbuminuric by the 
end of the study.  Comparison of nocturnal with diurnal systolic BP gave additional 
insight into the relationship between BP and albuminuria.  A 10% or more dip in BP 
at night was associated with a 70% reduction in the risk of developing 
microalbuminuria.  Therefore, not only was increased risk of diabetic nephropathy 
associated with increased BP, but changes to BP, which would be undetected by a 
single “in office” measurement, preceded nephropathy.  Furthermore, a subgroup of 
patients, whose glycaemic control was suboptimal, but whose systolic BP dipped by 
10% or more at night, still failed to develop microalbuminuria.  Thus, the importance 
of elevated nocturnal BP, as well as hyperglycaemia, to the development of diabetic 
nephropathy, early in the course of the disease, was established.  To understand why 
nocturnal BP rather than diurnal BP might be elevated in early T1DM, prior to 




1.4 Regulation of BP 
1.4.1 Short-term regulation of blood pressure 
Arterial BP is generated by the expulsion of stroke volume by the left ventricle 
against the resistance of the arterial tree.  It is tightly regulated in the short term by 
the autonomic nervous system 75, which, in response to central inputs and peripheral 
baroreceptors, modifies heart rate, cardiac contractility, and arteriolar tone.  This 
ensures adequate perfusion of the vital organs (heart, brain and kidneys) as well as 
meeting metabolic or survival requirements such as “fight or flight”.  Perfusion of 
organs can be further modified by fluctuations in endothelium- and  
non-endothelium-dependent arteriolar tone and pre-capillary constriction by 
pericytes.  These are usually in response to autocrine and paracrine agents released as 
metabolic by-products or inflammatory mediators, and following autonomic 
stimulation and changes in vascular wall stress 76,77.  Usually, acute rises and falls in 
BP are short-lived, whereas, in the state of hypertension, BP is inappropriately 
elevated over the long-term.   
 
1.4.2 Long-term regulation of blood pressure 
Central to the long-term regulation of BP are the kidneys, which control plasma 
volume by controlling sodium balance 78.  This has been confirmed through a series 
of renal transplantation experiments in several rodent models of hypertension.   
 
BP in nephrectomised Dahl salt-sensitive (DSS) rats normalises following 
transplantation of a single kidney from a Dahl salt-resistant (DSR) donor.  Similarly, 




kidney from a DSS rat donor 79-81.  Thus, the BP phenotype follows the genotype of 
the kidney donor rather than the genotype of the recipient.  Similar results have been 
reproduced in other hypertensive rodent models, such as the spontaneous 
hypertensive rat (SHR), and in studies with very young hypertensive rat donors 
whose kidneys show no evidence of structural injury 82,83.  When recipient rats 
develop hypertension, they also rapidly retain sodium 84 but do not have vascular 
dysfunction or elevated afterload due to RAAS 85,86.  This indicates that the kidneys 
regulate BP by regulating sodium excretion to control plasma volume. 
 
Renal handling of sodium can be influenced by external factors.  Nephrectomised 
wild-type (WT) mice, transplanted with a kidney from an AngII receptor knockout 
(AngIIR KO) donor mouse, are protected from hypertension during chronic infusion 
of AngII 87.  Conversely, nephrectomised AngIIR KO mice develop hypertension 
during AngII infusion when grafted with a WT mouse kidney.  Not only does this 
reaffirm the importance of the kidney to the regulation of BP, it also shows that 
renally-derived components of RAAS modify its role 88.  Combined with the clinical 
studies of Lewis et al. 63 and Lurbe et al., 74 which demonstrate the importance of 
hyperfiltration and BP, it is concluded that sodium balance is crucial to limiting 
progression of diabetic nephropathy.  The intrinsic ability of the kidneys to maintain 




1.5 Acute pressure natriuresis 
1.5.1 Regulation of sodium and blood pressure by acute pressure natriuresis 
Crucial to the kidney’s role in the long-term regulation of BP is its ability to modify 
excretion of sodium and water in response to short-term fluctuations in BP.  The 
mammalian kidney is incapable of actively secreting sodium into urine, and so 
urinary sodium and water excretion is dependent on a process of large-scale filtration 
followed by selective reabsorption.  The relationship between renal perfusion 
pressure (a surrogate marker of arterial BP) and urinary sodium excretion is a 
sigmoidal one.  However, with Western diets, which exceed maintenance salt 
requirements, the relationship is linear, so that increases in BP lead to corresponding 
increases in sodium excretion 78.  This physiological phenomenon is called acute 
pressure natriuresis and the relationship between BP and urinary sodium excretion, 
the acute pressure natriuresis curve 78.  The mechanism is vasculotubular and 
activated following ingestion of a meal 89.  Rapid sodium reabsorption from the 
gastrointestinal tract leads to an abrupt rise in plasma osmolality.  This stimulates 
neural osmoreceptors leading to the sensation of thirst, the ingestion of water, and 
dilution of the plasma osmolality at the expense of increased plasma volume 90.  The 
peritubular blood supply of the kidney is in series with, and downstream of, the 
glomeruli.  Autoregulation of GFR, therefore, transmits increased renal perfusion to 
the renal medulla.  The renal medulla is highly vascular, containing an extensive 
capillary network called the vasa recta.  Increased perfusion through this network 
increases medullary hydrostatic pressure and, through Starling’s forces, inhibits 
tubular sodium and water reabsorption 91, principally from the PCT 92.  Distal sodium 




sodium-chloride co-transporter (NCC) and ENaC may also be inhibited by paracrine 
agents such as nitric oxide (NO), endothelin-1 (ET-1) and adenosine triphosphate 
(ATP) 93-96.  The result is a diuresis/natriuresis appropriate for the degree of sodium 
and water ingestion, and that is self-limiting once an appropriate plasma volume has 
been restored 78.   
 
Consistent with the AngIIR KO renal transplant model 87, the acute pressure 
natriuresis curve can be modified by external influences such as RAAS activation, 
which shifts the acute pressure natriuresis curve to the right and decreases its 
gradient 78,93.  This response, though, can be overridden.  For example, in the 
phenomenon of “aldosterone escape”, sustained hypertension from 
hyperaldosteronism is prevented by compensatory adaptations to the tubular phase of 
acute pressure natriuresis that increase its sensitivity to BP and increases in BP 97.  
This is thought to result from downregulation 98 and inhibition of sodium transport 99.   
 
Many consider acute pressure natriuresis to be so important to the long-term 
regulation of BP, that in order for the state of hypertension to exist, acute pressure 
natriuresis must also be impaired 89.   
 
1.5.2 Nocturnal dipping 
Acute pressure natriuresis is activated soon after salt ingestion.  Salt ingestion varies 
over a 24-hour period, suggesting that an intact acute pressure natriuresis response is 
vital to maintaining a circadian rhythm in BP 100.  In populations with a high 




is tightly linked to increased nocturnal BP and reduced dipping in BP 101.  A similar 
failure of BP to dip in people with T1DM 74 suggests that daytime acute pressure 
natriuresis is also impaired in T1DM and has to be maintained during the night at the 
expense of increased BP 100.   
 
In essential hypertension, loss of nocturnal dipping is associated with a higher risk of 
target organ damage 102-104, suggesting that nocturnal dipping may be necessary for 
organ recovery from the haemodynamic stresses of the daytime systemic arterial load.  
In the kidney, which is highly perfused and receives approximately 25% of cardiac 
output, elevated nocturnal BP could induce a form of hyperfiltration that initiates 
glomerular injury.  Thus, there are potential benefits from therapeutic targeting of 
hypertension to re-establish nocturnal dipping as well as simply lowering BP.  This is 
the rationale behind the recommendation by the American Diabetes Association to 
dose anti-hypertensive medication at bedtime 105 and there is already evidence that 
this may reduce cardiovascular risk 106.  Alternatively, acute pressure natriuresis 
could be targeted directly.  Protocols for inducing acute pressure natriuresis in animal 
models have been developed to identify the mechanistic basis to acute pressure 
natriuresis and potential therapeutic targets.   
 
1.5.3 Induction of acute pressure natriuresis through volume expansion 
Rapid expansion of the vascular compartment induces acute pressure natriuresis.  
This can be achieved through water immersion 107 or more usually, in animal models, 
by rapid intravenous (iv.) administration of isotonic saline.  Both approaches increase 




mechanism, and renal perfusion.  Either technique is simple and mimics the stimulus 
to acute pressure natriuresis following salt and water ingestion.  In experimental 
animals, the main disadvantage is the unpredictability of fluid distribution within the 
vascular compartment.  This makes it difficult to maintain BP and renal perfusion 
pressure within the narrow, predictable range required to facilitate comparisons 
between experimental cohorts.  Nevertheless, saline infusion, at levels far exceeding 
maintenance requirements, has induced sodium and water excretion rates in T1DM 
Sprague Dawley rats that only reach ~20% of those measured in controls 108,109.  
Interestingly, diuresis and natriuresis recover when T1DM rats are treated with 
insulin 108.  Since excretion of sodium following water immersion is halved in T1DM 
patients 110, this raises the possibility that the results of DCCT 24 might be linked to 
reversal of impaired acute pressure natriuresis.   
 
1.5.4 Pharmacological induction of acute pressure natriuresis 
Acute pressure natriuresis can be induced by increasing BP acutely through 
peripheral vasoconstriction.  In Sprague Dawley rats, adrenaline (at iv. infusion rates 
of 0.5-1.7µg/min) increases BP, and hence renal perfusion pressure, by 35-45mmHg 
up to a maximum of 147mmHg for 20-25 minutes 111.  Although glomerular 
autoregulation is maintained with this technique, systemic and renal effects of 
adrenaline due, in part, to activation of RAAS, make this protocol unsuitable for 




1.5.5 Ligature-induced acute pressure natriuresis 
This protocol is the current “gold standard” technique for inducing acute pressure 
natriuresis since it leads to more predictable, controllable and reversible increases in 
renal perfusion pressure which can be achieved in a stepwise manner.  This is 
advantageous because it permits multiple time points for sampling and hence more 
opportunity for comparing experimental cohorts 112.  Its major disadvantage is that it 
is surgically invasive, requiring laparotomy.  In rodents, there is the potential for 
significant and rapid hypothermia and hypotension because the surgical preparation 
is time consuming, and involves manipulation of the abdominal contents, which 
promotes extravasation of fluid into the abdomen.  However, a skilled, experienced 
operator can reduce surgical time and minimise extravasation of fluid.   
 
In ligature-induced pressure natriuresis, the major conducting arteries are acutely 
compressed by tightening pre-placed ligatures or inflating peri-arterial cuffs 112.  The 
volume of the vascular tree is immediately reduced.  Plasma volume is maintained 
because capillary beds, whose arterial supply has been removed, gradually drain into 
systemic veins.  As long as there is adequate myocardial function to overcome the 
acute increase in afterload, BP and renal perfusion pressure rise acutely.  The original 
technique, developed by Dresser et al. 113, combined bilateral carotid artery occlusion 
with vagotomy.  However, changes in autonomic outflow, in response to vagotomy 
and acute reductions in intracranial blood flow, mean that this technique has been 





Ligature-induced methods are now usually based on the protocol that Roman and 
Cowley developed 112 to demonstrate autoregulation of GFR and renal artery and 
cortical blood flow , and simultaneous increases in medullary blood flow and urinary 
sodium excretion during acute pressure natriuresis.  Their protocol included two 
stepwise increases in BP by, firstly, simultaneous ligation of the coeliac and cranial 
mesenteric arteries, and at a later time point, the aorta distal to the left kidney.  
Intravenous isotonic crystalloid fluids were supplemented with 1% BSA to increase 
plasma oncotic pressure, thereby reducing fluid extravasation.  A high iv. infusion 
rate (100µl/min) was double the rate typically used for renal clearance studies, and 
ensured replacement of fluid loss due to extravasation while, itself, inducing 
natriuresis.   
 
Since its publication, Roman and Cowley’s protocol has been applied to many rodent 
models of human disease with only minor adaptations.  Adjustments to the duration 
of equilibration and collection periods are made according to operator skill and the 
health status of the animal being studied.  Sympathetic innervation of the kidney 
promotes sodium and water retention, and Roman and Cowley demonstrated that 
renal sympathetic neurectomy shifted the pressure natriuresis curve approximately 
20mmHg to the left 112, allowing them to induce acute pressure natriuresis at lower 
BPs with a proximal aortic cuff.  Neurectomy has not been undertaken in other 
studies as it requires further organ manipulation and increases the duration of 
surgical preparation time.  Also, it is not required to induce the crucially important 




natriuresis response 114.  Neurectomy may, in some instances, actually shift the 
pressure natriuresis curve to the right 115. 
 
Attempts to minimise external endocrine effects include acute adrenalectomy, 
immediately prior to inducing acute pressure natriuresis, and infusion of a “hormone 
cocktail” of noradrenaline, aldosterone, hydrocortisone and vasopressin to maintain 
steady serum levels of these hormones 112.  However, “hormone cocktails” are often 
not employed as they can introduce additional confounding factors and result in 
serum levels that differ significantly from reference ranges 112.   
 
Acute pressure natriuresis can be induced in uninephrectomised rats and rats with 
both kidneys intact, with no appreciable differences in GFR, renal blood flow, 
natriuretic or diuretic responses on a per gramme kidney weight basis.   
 
1.5.6 Molecular pathways of acute pressure natriuresis identified by the  
ligature-induced protocol 
The ligature-induced protocol has been used to establish impaired acute pressure 
natriuresis as a source of salt sensitivity in DSS rats 116 and deoxycorticosterone 
acetate (DOCA)-salt-sensitive mice 117, and to probe for potential underlying 
mechanisms.  One important mechanism involves renal NO signalling.   
 
NO is a gaseous vasodilatory molecule synthesised by one of three isoforms of the 
enzyme nitric oxide synthase (NOS), and released from the endothelium in response 




demonstrated when NOS is inhibited with N-nitro L-arginine methyl ester (L-NAME) 
in Sprague Dawley rats, leading to a rightward shift in the acute pressure natriuresis 
curve 120.  Although this effect could, in part be explained by haemodynamic effects 
such as efferent arteriolar vasoconstriction and reduced medullary perfusion, it now 
appears that acute pressure natriuresis is dependent on NOS1 and NOS3 isoforms 
that are highly expressed in the inner medullary collecting duct 121, at levels which 
correlate with dietary salt intake 122.  Tubular NO has now been shown to modify 
sodium reabsorption, according to salt intake, at several sites along the nephron 96.  
In the inner medullary collecting duct, NOS co-localises at high concentrations with 
ENaC where NO, in combination with the peptide ET-1, plays an important role in 
inhibiting sodium reabsorption.  Again, the acute pressure natriuresis curve shifts to 
the right when this relationship is disrupted genetically or pharmacologically, and the 
ligation-induced protocol is applied 122.  Thus, ligature-induced acute pressure 
natriuresis has been instrumental in probing the complexity of the interplay between 
renal haemodynamics, glomerular autoregulation and tubular function, and has 
identified novel pathways that modulate sodium excretion. 
 
The technique has also identified a link between susceptibility to hypertensive renal 
injury in Fischer F344 rats and impaired acute pressure natriuresis prior to the onset 
of hypertension 123.  This would be consistent with impaired acute pressure 
natriuresis underpinning the loss of nocturnal dipping 124 and the development of 
microalbuminuria recorded by Lurbe et al. 74.  Despite this, the ligature-induced 
protocol has, somewhat surprisingly, never before been applied to either a T1DM or 




of the interplay between nephropathy, renal regulation of BP and CVD risk in T1DM, 
particularly since the ligature-induced acute pressure natriuresis protocol could be 
adapted to a suitable T1DM model. 
 
1.6 Pre-clinical studies on T1DM 
1.6.1 The streptozotocin-induced model of Type 1 diabetes mellitus 
Animal models of disease should have consistent, well-defined functional and 
pathological phenotypes that are good representations of some or all of the 
components of the corresponding human disease.  They should be amenable to 
pharmacological, molecular and genetic manipulation and probing without 
compromising animal welfare. 
 
The greatest contributions to understanding the aetiopathogenesis of T1DM have 
been made using spontaneous mutation 125, 126 and genetically engineered 127 rodent 
models.  However, such models are costly to develop and maintain, and onset of 
T1DM can be variable.  In T2DM, the cardiovascular complications are related to 
multiple factors such as dyslipidaemia and pro-inflammatory and pro-coagulant 
states 128.  However, in T1DM, the long term macro- and microvascular 
complications are a direct consequence of hyperglycaemia, hypoinsulinaemia and 
nephropathy.  These can be modelled simply and cheaply by destroying pancreatic β 
cells with a pharmacological agent 129.  Since rodent models of T1DM only develop 
nephropathy after several months of hyperglycaemia 130, pharmacological models of 
T1DM provide a large window of opportunity within which to investigate functional 




nephropathy.  This is of direct clinical relevance since reductions in cardiovascular 
risk in DCCT were obtained very early in the course of T1DM 29.     
 
The pharmacological agent most commonly used to induce T1DM is streptozotocin 
(STZ), an analogue of N-acetyl glucosamine.  It is selectively toxic against 
pancreatic β cells because it selectively inhibits β-cell O-linked β-N-acetyl 
glucosaminyl hydrolase (O-GlcNAcase).  This leads to irreversible O-glycosylation 
of intracellular proteins and β cell apoptosis 131.  Following iv. or intraperitoneal (ip.) 
injection, there is a transient phase of hyperinsulinaemia for which oral sucrose 
supplementation in the drinking water is required 129.  The degree of hyperglycaemia 
attained is related to the degree of β cell destruction.  Several dosing protocols exist 
including low dose injections for five consecutive days, medium-dose injections  
24-48 hours apart and high-dose single injections with additional increments as 
required 129.   
 
Most of what is known about how T1DM affects acute pressure natriuresis through 
promoting vascular dysfunction, tubular sodium reabsorption and hypertension and 
hyperfiltration has been learned from the STZ-induced T1DM rodent model.   
 
1.6.2 Changes to renal vascular function in Type 1 diabetes mellitus 
Vascular function describes the balance between local vasodilatory and 
vasoconstrictive effects that are mediated by autocrine and paracrine agents.  
Myographic studies of arteries from STZ-induced T1DM rodents have shown that 




(NADPH)-oxidase in response to hyperglycaemia, uncouple NOS3 and reduce 
vasodilatory NO bioavailability 132.  At the same time, increased epidermal growth 
factor receptor-tyrosine kinase (EGFR-TK)-mediated signalling raises intracellular 
calcium levels, increasing vasoconstrictive responses to norepinephrine, ET-1 and 
AngII 133.  Thus, the STZ model demonstrates both impaired vasodilation and 
increased vasoconstriction.  Alternative compensatory vasodilatory pathways are 
overwhelmed 134 and a shift towards increased vasoreactivity is observed at multiple 
points along the arterial tree 132,134 including the renal artery 133.   
 
Myographic studies are limited by vessel size but reduced urinary excretion of NO 
metabolites 135 and increased generation of renal reactive oxygen species (ROS) 136 
in STZ-induced T1DM rats suggest that vascular dysfunction also occurs distal to the 
renal artery.  However, the overall consequences for medullary perfusion and the rise 
that initiates acute pressure natriuresis are not clear.  Medullary blood supply is 
downstream of the glomeruli, and despite the trend towards reduced overall NO 
production within the kidney, NO levels within the glomerulus can increase rather 
than decrease and, thus, contribute to hyperfiltration 137.  This paradox, a 
consequence of increased glomerular NOS1 expression, varies with the degree and 
duration of hyperglycaemia 137.  Furthermore, medullary perfusion is not only 
dependent on the resistance of the medullary vascular bed but also the cortical 
vascular bed 138 and the distribution of flow between cortical and juxtamedullary 
glomeruli 139.  Therefore, to determine the overall contribution of vascular 
dysfunction to changes in acute pressure natriuresis in T1DM, renal artery and 




acute rises in BP.  This could be achieved in an STZ-induced T1DM rat since rats are 
large enough to accommodate several probes for measuring renal blood flow while, 
at the same, allowing access to major abdominal arteries for ligature-induced acute 
pressure natriuresis. 
 
1.6.3 Changes to renal tubular sodium reabsorption in Type 1 diabetes mellitus 
STZ models have provided conflicting evidence for the effect of T1DM on renal 
sodium reabsorption.  Microperfusion studies in rats have shown that sodium-glucose 
transport within the PCT progressively increases with rises in luminal glucose 
concentration 140.  It has been proposed that this response is the mechanism for 
glomerular hyperfiltration in T1DM 52, and it is the target for sodium-glucose 
transporter-2 (SGLT2) inhibitors 141,142.  By contrast, in vitro studies have 
demonstrated reduced sodium-glucose transport across renal microvilli 143 and 
downregulation of expression of SGLT2, the principal renal sodium-glucose 
transporter, within three days of STZ injection 144.  Increased abundance of  
sodium-hydrogen exchanger-3 (NHE3), NCC and ENaC subunits α, β and γ 145 
suggest that sodium reabsorption, independent of glucose transport, is increased 
along the nephron.  Overall, the amount of sodium reabsorbed in T1DM is dependent 
on the severity and duration of hyperglycaemia 140, hypoinsulinaemia 146  and oral 
sodium intake 53.  Unsurprisingly, therefore, the degree that acute pressure natriuresis 
is modified by T1DM for given increases in BP and medullary perfusion is not 




1.6.4 Consequences of hypertension and hyperfiltration in Type 1 diabetes mellitus 
Susceptibility to nephropathy, following development of T1DM, varies between 
rodent species and strains.  The C57Bl6/J mouse, on which background most KO 
models are constructed, appears to be particularly resistant 147.  The STZ-induced 
T1DM rodent model can be adapted to promote hyperfiltration by performing 
nephrectomy 148, or by using rodents that develop hypertension spontaneously 73,149 
or inducibly 72.  These techniques accelerate the development of nephropathy and 
illustrate the importance of hyperfiltration and hypertension to its development in 
T1DM.  For example, the NOS3 KO mouse combines hypertension with endothelial 
dysfunction, and the glomerular changes that develop are probably the most similar 
to those observed in diabetic patients 130,149.  Also, the Cyp1a1mRen2 rat, in which 
hypertension is induced by upregulating renin expression through dietary 
manipulation, is probably the best model for diabetes-induced tubulointerstitial 
fibrosis.  Its renal transcriptomic profile compares favourably with that from human 
T1DM 72 and is in agreement with the BP-independent role for RAAS in promoting 
diabetic nephropathy proposed by Lewis et al. 63.   
 
Once nephropathy develops, the renal and histopathological changes in STZ-induced 
rodents are similar to those in people.  In the glomeruli, there is sclerosis and 
hyalinosis, dilation and cast formation 150, and reduced numbers of podocytes and 
nephrin 150.  This is accompanied by mesangial expansion 150, inflammation 151,152 
and tubulointerstitial fibrosis 150,153.  The point at which these changes begin can be 
determined by expression of kidney injury molecule-1 (KIM-1), and pro-fibrotic 




detected by increased urinary protein excretion although the onset and severity of 
proteinuria can vary from 500mg/day only six weeks after STZ injection 154 to 
60mg/day after four months 150.  Therefore, the time course of T1DM following STZ 
injection can be divided into distinct, well-defined pre-nephropathy and nephropathy 
phases, offering the possibility of translating to clinical T1DM functional changes in 
sodium excretion that precede albuminuria and expression of renal injury markers.   
 
1.6.5 The relevance of the nephropathy phase to pre-nephropathy investigation  
The nephropathy phase in STZ-induced T1DM has demonstrated that RAAS has a 
key pro-inflammatory and pro-fibrotic role 155,156 and induces mesangial expansion, 
podocyte damage and apoptosis 157, and generation of ROS 158.  Reductions in 
pathological glomerular remodelling with ACE inhibition 150 have been translated 
into treatment of clinical T1DM nephropathy.  Similarly, the failure of ACE 
inhibitors to reverse glomerulosclerosis 150 agrees with the clinical findings of  
Lewis et al. 63, and emphasises the importance of intervention prior to the onset of 
nephropathy.  However ACE inhibitors also fail to prevent nephropathy from 
developing in both STZ-induced T1DM rats and in non-albuminuric T1DM  
patients 159-161.  This lack of success probably reflects the large number of signalling 
pathways that contribute to T1DM nephropathy, and changes in the degree to which 
individual pathways contribute over time.  These factors likely apply to most 
therapies.  As a consequence, the development of novel therapeutic agents, such as 





In 2009, Gagliardini et al. 150 adopted this strategy by administering the ACE 
inhibitor lisinopril and the selective ETA receptor antagonist avosentan to  
STZ-induced T1DM rats in the post-nephropathy phase.  Not only did this 
combination reduce glomerular pathology and albuminuria, glomerular remodelling 
was, for the first time, reversed.  Just four years after the publication of this paper, a 
Phase 3 clinical trial of the selective ETA receptor antagonist, atrasentan, began in 
patients with T2DM diabetic nephropathy (SONAR) 162.  To determine whether the 
benefits of ETA receptor antagonists extend to a much earlier stage of T1DM, this 
thesis will investigate the role of the renal endothelin system in the pre-nephropathy 
phase and its contribution to the risk of nephropathy and CVD.   
 
1.7 The endothelin system 
1.7.1 Endothelin-1 
ET-1 was first identified in 1988 as an extremely potent vasoconstrictor released by 
endothelial cells 163.  The concept that maintenance of vascular tone was 
endothelium-dependent was not new at the time 118.  However, ET-1 was the first 
endothelium-derived vasoconstrictor to be identified.  Since its discovery, it has 
naturally attracted a great deal of interest as a major player in CVD and hypertension.  
Initially considered as universally deleterious, it is now clear that ET-1 is important 
in homeostasis and organogenesis as well as in pathological states.  Although first 
identified as a vasoactive peptide released by endothelial cells, it likely plays a 
crucial role in long-term regulation of BP through its effects within the renal 
collecting duct 77. ET signalling also plays a pivotal role in glomerular injury and 




diabetic states. For this reason, ET receptors are now considered a viable therapeutic 
target, along with RAAS, in the long-term management of diabetic nephropathy. 
 
1.7.2 Physiology of the endothelins 
The ETs exist as three peptides– ET-1, ET-2 and ET-3.  Each is 21 amino acids  
long 164.  ET-1 is the predominant ET expressed in the vasculature 163 and although 
ET-2 and ET-3 are also present within the renal microvasculature and can regulate 
afferent and efferent arteriolar tone, ET-1 is the most potent 165,166.  The majority of 
publications on the role of ET in diabetic nephropathy relate to ET-1, so the 
remainder of this thesis will focus on this isoform.  
 
ET-1 is generated by a series of peptidase-mediated conversions of a prepropeptide.  
The immediate precursor, big ET-1, is an inactive 38 amino acid peptide that is 
rapidly converted into the smaller active peptide, ET-1 167, by endothelin converting 
enzymes (ECEs), chymase or neutral endopeptidase.  Any overspill of big ET-1 into 
the circulation is largely inactive with only 10% of ET-1’s biological activity 168.  
Although newly formed ET-1 can be stored temporarily in intracellular vesicles 169, it 
is more usually secreted immediately after translation.  The circulating half-life of 
ET-1 is limited to ~one minute 170 because of rapid clearance by pulmonary, 
splanchnic and renal circulations 171-173 and local degradation by neutral 
endopeptidase 172.  Thus, ET-1 is generally considered as an autocrine or paracrine 




1.7.3 Endothelin receptors 
ET receptors have been intensively researched and, despite alternatives to blocking 
the effects of ET-1, such as ECE inhibition 174, ET receptors currently remain the 
most investigated therapeutic target for manipulation of the ET system.  ET-1 binds 
to two G-protein-coupled receptors, ETA and ETB, which often mediate opposing 
effects.  This is exemplified by the biphasic change in BP after iv. bolus injection of 
ET-1 first observed by Yanagisawa et al. in anaesthetised rats 163.  A transient 
depressor response occurs as ET-1 binds to ETB receptors on endothelial cells, 
triggering local release of vasodilatory NO and prostacyclin 77.  This is followed by a 
prolonged hypertensive response due to ET-1 binding to ETA receptors (or less 
frequently ETB receptors) on vascular smooth muscle cells (VSMCs), inducing 
inositol trisphosphate-dependent contraction 77.  Webb and Haynes showed that 
potent ET-1/ETA receptor-mediated vasoconstriction plays an important homeostatic 
role in maintaining basal vascular tone when they demonstrated vasodilation and up 
to 64% increased blood flow in the forearm after infusing an ETA receptor antagonist 
into the brachial artery of healthy subjects 168.  ET-1/ETB receptor-mediated 
vasodilation serves to dampen this effect. 
 
Crucially, if attempting to determine whether renal ET-1 is important in initiating 
T1DM nephropathy, it is necessary to understand that the source of ET-1 that 
regulates BP is not simply the endothelium (Fig.1.1).  For example, transgenic mouse 
models over-expressing ET-1 do not develop hypertension, even when plasma ET-1 
is elevated, and develop only moderate salt-sensitive hypertension 175,176.  It has 




both the vascular and tubular components of acute pressure natriuresis from multiple 
sites within the kidney. 
 
Fig. 1.1. The role of vascular and renal endothelin-1 (ET-1) and its receptors in blood 
pressure (BP) homeostasis 
ET-1 regulates BP through its effects on vascular tone, and on sodium and water balance by 
regulating epithelial sodium channel (ENaC) and aquaporin-2 (AQP2) activity.  Lines blocking 
arrows represent inhibition. 
 
1.7.4 Regulation of blood pressure by collecting duct endothelin-1 
Since its initial discovery in the vasculature, expression of ET-1 and its receptors has 
been identified ubiquitously within the body 77.  However, ET-1 is most highly 
expressed within the inner medullary collecting duct of the kidney 177 where it co-
localises with ETB receptors 




evidence to date of the importance of ET-1/ETB receptor signalling to BP 
homeostasis (Fig. 1.1).  Collecting duct-specific ET-1 or ETB KO mice develop salt-
sensitive hypertension that can be rescued by selective inhibition of ENaC 180,181.  
This means that ET-1 regulates BP by controlling activity of a sodium transporter 
known to be modified in T1DM.  Thus, T1DM has the potential to modify the 
tubular sodium reabsorption phase of acute pressure natriuresis by modifying 
regulation of ENaC by ET-1.   
 
1.7.5 Endothelin-1 in the renal vasa recta 
The majority of studies on renal ET-1 have focused on the inner medullary collecting 
duct, where there is the greatest expression of ET-1, and the glomerulus, the obvious 
site of pathology in early diabetic nephropathy.  More recently, there has been 
additional interest in the medullary zone between these two sites, which contains the 
vasa recta and the thick ascending limb of the loop of Henle.  Each vas rectum is a 
single endothelial cell thick and supplies blood through the renal medulla.  Best 
known for contributing to the counter current exchange mechanism that establishes 
medullary hypertonicity, the vasa recta are also conduits of the increased medullary 
blood flow that initiates acute pressure natriuresis.   
 
Blood flow through the vasa recta is regulated at regular intervals along their length 
by contractile pericytes 182.  These mesenchymal cells respond to a variety of 
vasoactive peptides, including ET-1, by acting on ETA receptors 
183. Their 
responsiveness can be modified by factors released from the thick ascending limb 




and contribute to the shifts in cortico-medullary blood flow that precede acute 
pressure natriuresis 138.  The exact relationships between vasa recta, tubules and 
pericytes have not been fully defined but, clearly, regulation of pericyte constriction 
by ET-1/ETA has the potential to influence the acute pressure natriuresis response by 
reducing medullary blood flow.   
 
1.7.6 Endothelin-1 in the glomerulus 
ET-1 and its receptors are expressed by endothelial cells, podocytes and mesangial 
cells within the glomerulus.  Studies in juxtamedullary nephrons have identified ETA, 
and endothelial and VSMC ETB receptors within afferent and efferent arterioles.  
This suggests not only an important role in glomerular autoregulation 165,166,186, but 
also regulation of medullary perfusion, acute pressure natriuresis and subsequently, 
BP 187.  
 
1.7.7 Glomerular endothelin-1 and Type 1 diabetic nephropathy 
There is now a wealth of additional in vivo and in vitro evidence that glomerular, and 
subsequently tubular, ET-1 contributes heavily to progressive loss of renal function 
in T1DM by mediating cellular injury, inflammation 154,188-195, mesangial expansion 
and fibrosis 50,196-198 as well as through synergism with RAAS 199-203. 
 
In STZ-induced T1DM rats, glomerular expression of ET-1 increases as nephropathy 
develops 204 and urinary ET-1 excretion is increased by six weeks after STZ injection.  
Increased glomerular ET-1 expression by podocytes, endothelial cells 205 or 




Since urinary ET-1 is entirely renally derived 209, measurement of urinary ET-1 can 
be used, in addition to albuminuria, to mark when the pre-nephropathy phase of 
T1DM ends and the nephropathy phase begins.   
 
1.7.8 Endothelin-1 in Type 1 diabetic rodent models 
The wide-ranging effects of renal ET-1 during the nephropathy phase of T1DM are 
summarised in Fig. 1.2 but are beyond the scope of this thesis.  However, selective 
ET receptor antagonism in non-diabetic and T1DM rodent models suggests that most 
of the deleterious effects of ET-1 on renal function are mediated by ETA rather than 
ETB receptors.  In STZ-induced T1DM rodents, both ETA and ETB receptors mediate 
podocyte injury in T1DM 210 but only selective ETA receptor antagonists have  
anti-inflammatory and anti-fibrotic effects.  They attenuate severe urinary protein 
loss, expression of inflammatory markers intercellular adhesion molecule-1 (ICAM-1) 
and monocyte chemotactic protein-1 (MCP-1), macrophage infiltration, and urinary 
excretion of markers of transforming growth factor-β-1 (TGF-β1, pro-fibrotic) and 
prostaglandin E2 (PGE2, pro-inflammatory) expression 
154.   
 
Gagliardini et al. combined a selective ETA receptor antagonist with an ACE 
inhibitor in their landmark study 150 because earlier work had shown that ACE 
inhibition halved the rise in glomerular ET-1 messenger ribonucleic acid (mRNA) by 
24 weeks after STZ injection 211.  Two years after simultaneous ACE inhibition and 
ETA receptor antagonism had been shown to completely reverse proteinuria and 
glomerulosclerosis, and restore renal blood flow in STZ-induced T1DM Sprague 




early STZ-induced T1DM could be attenuated by selective ETA or non-selective ET 
receptor antagonism without ACE inhibition 154.  Ironically, having firmly 
established these effects by antagonising the most potent vasoconstrictor known, and 
justifying progression to clinical studies, the haemodynamic contribution to reversal 
of diabetic nephropathy following endothelial ET receptor antagonism remains 
unknown.   
 
1.7.9 The potential for endothelin receptor antagonists to prevent nephropathy in 
Type 1 diabetes mellitus: pre-clinical evidence 
DCCT/EDIC has demonstrated the importance of early intervention in T1DM to 
reduce cardiovascular risk.  Albuminuria is a significant risk factor for CVD in 
T1DM, so any therapeutic agent that can reduce albuminuria clinically is likely to be 
trialled at earlier and earlier stages of T1DM nephropathy.  The SONAR  
study 162 has been investigating the clinical benefits of the selective ETA receptor 
antagonist, atrasentan, in patients with T2DM.  The study was recently stopped, as a 
consequence of study design rather than an adverse effect of atrasentan.  However, 
even if reductions in albuminuria and cardiovascular risk can be demonstrated, the 
synergy between RAAS and ET-1 211, and the failure of ACE inhibitors to prevent 
the development of nephropathy in T1DM patients 159-161, suggest that ET receptor 
antagonists are unlikely to lower CVD risk or prevent progression of very early 
nephropathy unless ET-1 plays a key role in hyperfiltration.  Based on studies that 
demonstrate loss of nocturnal dipping prior to nephropathy, this means that ETA 





In most rodent models of renal hyperfiltration, with or without hypertension, ETA 
receptor antagonism does not appear to minimise renal injury by modifying GFR.  
Although proteinuria, glomerular hyalinisation and glomerulosclerosis are reduced in 
association with reductions in BP in DSS rats 212, podocyte injury is still observed in 
DSS rats when BP is reduced with hydralazine 213.  Furthermore, glomerular injury 
and inflammation, and interstitial fibrosis can be prevented by ETA receptor 
antagonists without reductions in BP, even when ET-1 is infused or  
overexpressed 176,214-216.  The conclusion from these models is that ETA receptor 
antagonists minimise renal injury by anti-inflammatory and anti-fibrotic effects and 





Fig. 1.2. Schematic diagram of the pathogenesis of nephropathy in Type 1 diabetes mellitus 
(T1DM) and the potential role of endothelin-1 (ET-1) and its receptors 
(1) In hyperfiltration, glomerular autoregulation fails to protect the glomerulus from the 
systemic vascular load. In this diagram, ET-1–mediated afferent arteriolar constriction and 
efferent arteriolar dilatation are inadequate.  
(2) Components of the glomerular filter, such as the glomerular basement membrane (GBM), 
are injured by hyperfiltration and inflammation.  Podocyte injury is mediated by ETA receptors 
but also ETB receptors, and allows proteins to leak into the proximal convoluted tubule (PCT).  
(3) Proteins in the PCT initiate an inflammatory cycle mediated by ETA receptors, which leads 
to further podocyte damage.  
(4) The inflammatory response with activated mesangial cells and interstitial fibroblasts leads to 




1.7.10 The potential for endothelin receptor antagonists to prevent nephropathy in 
Type 1 diabetes mellitus: clinical evidence 
Results from clinical studies of ET receptor antagonists in diabetic nephropathy 
mirror much of the pre-clinical data.  They demonstrate reductions in urinary 
albumin excretion, suggesting that glomerular injury and remodelling are slowed or 
reversed 217-219.  The majority of trials have recruited only patients with T2DM.  
However, in the first Phase 2 clinical study, approximately half of 286 diabetic 
patients had T1DM 220.  Despite no effect on creatinine clearance and BP, the higher 
doses of avosentan used in this study were associated with a 12% incidence of 
peripheral oedema. 
 
Although hepatotoxicity has been reported in small numbers of patients receiving 
sulphonamide-based ET receptor antagonists 221, sodium and water retention, 
resulting in oedema has consistently proved problematic to their clinical 
development 222, and has even led to premature termination of a Phase 3 clinical  
trial 223.  The degree of salt and water retention that occurs appears to be  
dose-related 220,224 but has been sufficient to postpone clinical development of the 
drug class in heart failure, in which patients are already prone to oedema.   
 
The most frequently cited explanations for sodium and water retention are inadequate 
ETA:ETB receptor selectivity and inappropriately high dose rates that lead to  
off-target antagonism of ETB receptors in the collecting duct and loss of inhibition of 
ENaC 181,222.  This mechanism would profoundly impair acute pressure natriuresis 225.  




sitaxentan (ETA:ETB selectivity ~6,000:1) was used in a randomised, three-way, 
double-blind crossover study in patients with non-diabetic CKD, sodium and water 
retention was not observed.  What was not expected was that nocturnal dipping in BP 
also recovered with sitaxentan but not with the calcium channel blocker,  
nifedipine 226.  This suggested that sitaxentan did not achieve its effect by lowering 
vascular resistance but rather by enhancing acute pressure natriuresis.  Furthermore, 
it means that the pre-clinical studies mentioned above (in which podocyte injury is 
not reduced by arteriodilation 213, and renal injury is prevented by ETA receptor 
antagonists without apparently reducing BP 176,214-216) are not valid predictors of the 
effect of ETA receptor antagonists on regulation of BP and hyperfiltration.  This 
conflict between pre-clinical and clinical data illustrates the clear need to measure 
the effect of selective ETA receptor antagonists on acute pressure natriuresis in both 
diabetic and non-diabetic states.   
 
The clinical development of novel classes of drug is costly and, with various 
setbacks at an advanced stage, including the recent early termination of SONAR, 
development of ET receptor antagonists has proved no exception.  Despite extensive, 
encouraging pre-clinical and clinical data, Phase 3 clinical trials have failed to lead to 
approval from the US Food and Drug Administration (FDA) for use of these agents 
in patients with hypertension or diabetic nephropathy.  As well as issues with study 
design, one of the principal reasons for this has been the sodium and water retention 
they can cause.  To date, the FDA only approves the use of ET receptor antagonists 
for scleroderma digital ulcers and pulmonary arterial hypertension 227.  In the case of 




phosphodiesterase-5 inhibitors 228, and with many ETA receptor antagonists close to 
losing their patent protection 227, the financial incentive to pharmaceutical companies 
to invest in further costly clinical trials is rapidly waning.  Measuring the effect of 
selective ETA receptor antagonism on acute pressure natriuresis is likely to make a 
significant contribution to understanding, and therefore, combatting, sodium and 
water retention, and determining the potential of this drug class to prevent T1DM 
nephropathy and reduce cardiovascular risk.  Without this information, and with the 
limitations to what can be gleaned from SONAR, it will be difficult to assess whether 
savings made from reduced CVD risk and ESRD will offset the costs of additional 
clinical development of ETA receptor antagonists in T1DM, their prolonged use from 
an early stage of T1DM, and the treatment of associated sodium and water retention.   
 
1.8 Summary 
Cardiovascular risk is increased in T1DM.  Tight control of blood glucose increases 
the risk of life-threatening hypoglycaemia and does not eliminate increased 
cardiovascular risk, so alternative therapies are required that target risk factors for 
CVD. 
 
Nephropathy and hypertension are major risk factors for CVD in T1DM and are 
intimately linked.  Failure of BP to dip at night is a precursor to nephropathy and 
implicates impaired acute pressure natriuresis, yet the effect of T1DM on acute 





ACE inhibitors have important beneficial anti-inflammatory and anti-fibrotic effects 
that reduce but do not reverse progression of diabetic nephropathy, and they have 
limited ability to modify acute pressure natriuresis.  A relatively new class of agent, 
the ET receptor antagonists, exerts similar remodelling effects.  When given with 
ACE inhibitors, they can reverse renal fibrosis in animal models, but when 
administered clinically, reductions in proteinuria can be offset by sodium and water 
retention.  
 
ET-1 induces profound vasoconstriction via ETA receptors but the consequences of 
ETA receptor antagonism on acute pressure natriuresis are unknown.  Understanding 
the effect of T1DM and ET receptor antagonists on acute pressure natriuresis is 
paramount to combatting sodium and water retention and determining whether ETA 
receptor antagonists might reduce the risk of CVD and nephropathy during the 
crucial period of early T1DM, at a significant cost:benefit ratio.  
 
1.9 Hypotheses and aims 
1.9.1 Hypotheses 
1) Pressure natriuresis is impaired in early T1DM, prior to the onset of 
established nephropathy, and is associated with elevated BP.   
2) The mechanism underlying this impairment is an ETA-receptor-mediated 






1) To adapt a protocol for measuring acute pressure natriuresis so that it can be 
applied to an STZ-induced rat model of early T1DM 
2) Using this protocol, to measure the effect of early T1DM on acute pressure 
natriuresis and determine whether it can be reversed with insulin. 
3) To determine whether changes in acute pressure natriuresis due to T1DM are 
reflected in changes in BP and its circadian rhythm 
4) To identify the role of ET-1 in acute pressure natriuresis, the receptors that 
mediate this role, and determine whether it is modified by early T1DM and 











2.1 Generation of a rat model of T1DM 
2.1.1 Animals 
All animal experiments were performed in adult male Sprague Dawley rats. 
Following purchase and transfer from Charles River Laboratories, Tranent, United 
Kingdom (UK), rats (250-300g) were acclimatised for a minimum of six days.  They 
were housed under a 12-hour light cycle (lights 7am-7pm), at 21±1ºC and 50% 
humidity, within Phase 2 of the University of Edinburgh Biomedical Research 
Facility, Little France, Edinburgh, UK.  Standard chow (0.25% sodium) and water 
were offered ad libitum.   
 
All procedures, assays and measurements were performed single-blind under a UK 
Home Office licence, following local approval by a University of Edinburgh 
veterinary surgeon.  Euthanasia was performed by a Schedule one technique, either 
exposure to a rising concentration of carbon dioxide gas followed by cervical 
dislocation, or overdose of general anaesthetic followed by confirmation of cessation 
of circulation. 
 
2.1.2 Induction of Type 1 diabetes mellitus 
Type 1 diabetes mellitus (T1DM, blood glucose >12mmol/l) was induced with one 
(30mg/kg) or two (additional 15mg/kg 48 hours later) intraperitoneal (ip.) injections 
of streptozotocin (STZ, 50mg/mL in 0.1M fresh, chilled citrate buffer 129;  
Sigma-Aldrich Company Ltd, Gillingham, UK).  Blood glucose was measured by a 
test strip and glucometer (Accu-Chek; Roche Diagnostics Ltd. (Limited), Burgess 




second injection of STZ if the blood glucose was <12mmol/l.  To confirm diabetic 
status throughout, blood glucose was measured again seven days after the first STZ 
injection and at the end of the experimental procedure.  Rats, in which 
normoglycaemia was re-established, were euthanased (Chapter 2.1, page 46) and not 
included in data analysis.   
 
2.1.3 Control rats 
Non-diabetic control rats received a single ip. injection of citrate vehicle.  Blood 
glucose was measured 48 hours later (Fig. 2.1) and at the end of the experimental 
procedure. 
 
2.1.4 Insulin-treated diabetic rats 
Selected experiments included a third cohort of insulin-treated T1DM rats 
(T1DM+insulin).  One slow-releasing insulin pellet (LinShin, Toronto, Canada) was 
implanted subcutaneously (sc.) into T1DM rats under brief general anaesthesia with 
isoflurane (IsoFlo; Zoetis Animal Health Ltd, Sandwich, UK), seven days after the 
first STZ injection (Fig. 2.1).  Blood glucose <12mmol/l from a tail nick sample two 
and four days after implantation confirmed an appropriate response to insulin.  Rats 
whose blood glucose was >12mmol/l by four days after implantation were 





Fig. 2.1. Timeline for generation of control, diabetic and insulin-treated diabetic rats 
Time points for streptozotocin (STZ) injections, inserting insulin implants and measuring blood 
glucose are shown, WK=week, EXPT=experiment. 
 
2.2 In vitro studies: collection of urine and renal tissue 
2.2.1 Urine collection 
Control, T1DM and T1DM+insulin rats were removed from normal housing to 
metabolic cages for 24 hours.  Every metabolic cage consisted of a wire mesh floor 
with ad libitum access to food and water, a collection system to prevent 
contamination of urine with spillage from the drinking water, and separate urine and 
faecal collecting tubes.  After 24 hours, rats were returned to standard cages.  
Volumes of water consumption and urine production were recorded.  Urine was 




2.2.2 Renal tissue collection   
Whole animal perfusion-fixation was performed within 72 hours of rats returning 
from metabolic cages.   
 
Each rat was anaesthetised with ip. thiopental (50mg/ml, 50mg/kg; Archimedes 
Pharma, Reading, UK) and maintained with inhalational isoflurane (IsoFlo; Zoetis 
Animal Health Ltd) administered via face mask (Fig. 2.2A, B).  The rat was placed in 
dorsal recumbency onto a heat pad, with the head pointing away from the operator 
(Fig. 2.2B).  A digital rectal thermometer was inserted and body temperature 
maintained at 38-39ºC by manually adjusting the power output of the heat pad.  The 
ventrum was clipped and the abdomen entered by a midline coeliotomy from the 










































Fig. 2.2. Equipment set-up and animal positioning 
A) Anaesthetic machine (1) and circuit (2), heat pad (3), syringe drivers (4), dissecting 
microscope (5), instruments (6) and data acquisition system (7) 
B) The rat is taped to paper towel on a heat pad (1), with its head in a weighted anaesthetic 












The abdominal contents were gently displaced manually and the left kidney exposed 
through gentle, blunt dissection.  The renal artery and vein were simultaneously 
ligated with 0.17mm silk suture thread (4/0; Interfocus, Linton, UK; Fig. 2.3A).  The 
left kidney was removed without delay (Fig. 2.3B) and placed onto a tile kept cold by 
dry ice.  The kidney immediately adhered to the tile and was sectioned sagittally, the 
uppermost half then being flipped onto the cold tile (Fig.2.3C).  With both halves of 
the left kidney now adhered to the tile, the cortex of each half was identified and 
sectioned with a scalpel blade using three straight cuts (Figs. 2.3D, E).  Following 
additional trimming to minimise the amount of residual cortex, the medulla of each 
half was sectioned approximately sagittally in a single cut (Fig.2.3F).  All tissues 
were immediately wrapped into tin foil, placed into 2ml Eppendorfs, snap-frozen in 































Fig. 2.3. Removal and preservation of the left kidney 
A) The kidney was exposed and the renal artery and vein ligated. 
B) The renal artery and vein were clamped distal to the ligature and the kidney removed. 
C) The kidney was sectioned sagittally on a cold tile. 
D) Samples of cortex and medulla were removed. 
E) Schematic diagram showing cutting planes for removal of cortex 














The distal aorta was identified and carefully dissected away from the caudal vena 
cava just cranial to the trifurcation, using straight DeBakey forceps and cotton buds.  
Once freed, the distal aorta was ligated with silk with the free ends of the ligature 
kept long.  A straight vessel clip (1.5 x 8mm, World Precision Instruments, Hitchin, 
UK) was placed across the aorta approximately 1cm cranial to the ligature, and a 
second ligature placed in between but not tightened.  The aorta was then penetrated 
between the two ligatures by a bent 23-gauge needle.  Polythene tubing, 0.86mm 
internal diameter and 1.27mm outer diameter (P90; Smiths Medical, Ashford, Kent), 
with a closed three-way tap on one end, was inserted through the arteriotomy into the 
aortic lumen and advanced up to the clamp (Fig. 2.4A).   The cranial ligature was 
now tightened around the aorta (and tubing) and the long ends of the first ligature 
tightened around the tubing (Fig. 2.4B).  The clamp was then released slowly, 













Fig. 2.4. Cannulating the distal aorta 
A) The polythene tubing was inserted into the aorta with cannulation forceps. 








Immediately following aortic cannulation, the rat was transferred to a fume cupboard 
(Fig. 2.5A), where anaesthesia was maintained.  A 500ml bag of medical 0.9% saline 
(Aqupharm Number 1; Animalcare Ltd, York, UK; Fig. 2.5B) was then connected to 
the three-way tap through a standard intravenous (iv.) giving set (Aqupharm).  At the 
instant this was connected, the caudal vena cava was cut and saline forced through 
the iv. line by a blood pressure (BP) cuff and sphygmomanometer placed around the 
saline bag and inflated to 180mmHg 229.  Blood was swabbed with paper towel as the 
rat exsanguinated into its abdomen.  The time to the liver turning clear (target within 
three minutes) was recorded.  After exactly three minutes, 4% paraformaldehyde 
(PFA) was forced through a separate iv. line connected to the same three-way tap, as 
described for the saline.  The time to fixation tremors (target within one minute) was 
recorded.  After an additional three minutes, the rat was checked for rigidity, and the 
PFA infusion was stopped.  The right kidney was then removed (Fig. 2.5C), 
sectioned sagittally (Fig. 2.5D) and stored in fresh 4% PFA, which was changed after 
24 hours.  After an additional 72 hours, the kidney was transferred to 70% ethanol 
























Fig. 2.5. Whole animal perfusion-fixation with paraformaldehyde (PFA) 
A) The rat was transferred to a fume cupboard. 
B) Pressure for PFA infusion through a giving set came from a blood pressure cuff around a 
fluid bag. 
C) After exsanguination and fixation, the pale right kidney was removed. 












2.3 In vitro studies: urine assays 
2.3.1 Urine biochemistry 
To determine glomerular integrity in relation to glomerular filtration rate (GFR), 
urinary albumin and creatinine concentrations  were measured by Dr. Forbes Howie, 
University of Edinburgh, on a Cobas Fara centrifugal analyser (Roche Diagnostics 
Ltd.) using adapted commercial kits based on immunoturbidimetric (Microalbumin 
Kit; Olympus Diagnostics Ltd, Watford, UK) and creatininase/creatinase specific 230 
enzymatic (Alpha Laboratories Ltd., Eastleigh, UK) methods.  Albumin was indexed 
to creatinine. 
 
2.3.2 Aldosterone assay 
Activity of the renin-angiotensin-aldosterone system (RAAS) was determined from 
urinary aldosterone concentrations measured by Dr. Christopher Kenyon, University 
of Edinburgh, with an in-house enzyme-linked immunosorbent assay (ELISA) 231.  
Aldosterone was indexed to urinary creatinine.   
 
2.3.3 Endothelin-1 assay 
Urinary endothelin-1 (ET-1) concentrations were measured by a sandwich ELISA 
(Biomedica Medizinprodukte, Vienna, Austria).  Samples were added to wells pre-
coated with mouse anti-ET-1 detection antibody.  Additional detection antibody was 
added, followed by an anti-mouse immunoglobulin G (IgG)-horse radish peroxidase 
conjugate and then a chromogenic substrate which turned the solution yellow.  Using 
a monochromator-based microplate reader (Infinite M1000 Pro; Tecan Group Ltd., 




for each sample and referenced to 630nm.  ET-1 concentrations were calculated from 
the equation of a contemporaneous standard curve of absorbance against six standard 
solutions of known concentrations of ET-1 ranging from 0-10 fmol/l (R2>0.9) and 
provided by the manufacturer.  All measurements were performed in duplicate. 
 
2.4 In vitro studies: quantitative real-time polymerase chain 
reaction 
2.4.1 Total ribonucleic acid extraction 
Snap-frozen renal cortex and medulla were placed on a Petri dish mounted on a bed 
of dry ice.  Samples approximately 2mm3 in size were cut using a scalpel blade 
cooled in dry ice.  Harvested tissue was placed into 2ml nuclease free tubes 
containing 5mm stainless steel beads (Qiagen, Manchester, UK) and a lysis buffer 
(RLT plus buffer; Qiagen) before being pulverised for two minutes at 30Hz in a 
mixer mill (MM301; Retsch UK Limited, Hope, UK).  Ribonucleic acid (RNA) was 
then extracted using a commercial kit (RNA Easy Plus Mini Kit; Qiagen) in which 
genomic deoxyribonucleic acid (gDNA) was removed with an extractor column and 
RNA was isolated with an ethanol-based protocol, according to manufacturer’s 
instructions.   
 
The yield of total RNA was determined from absorbance of 260nm during 
spectrophotometry (Fig. 2.6A; Nanodrop 1000; Thermo Scientific, Wilmington, 
United States (US)) and the purity by the ratio of 260:230nm absorbance (>1.8 of 





Samples were assessed for RNA degradation by the ribosomal RNA 28S:18S ratio.  
2µl RNA were mixed with 2µl cyanine dye (SYBR safe; ThermoFisher Scientific Inc, 
Glasgow, UK) and 8µl RNAse-free water (ThermoFisher Scientific Inc) and 
separated through a trisaminomethane (Tris) borate EDTA gel by electrophoresis 
(90V for 30 minutes). Gels were inspected under ultraviolet light and the 18S and 
28S bands assessed subjectively, with a ratio of intensity of around 2:1 being 
acceptable.  Extracted RNA was stored at -80ºC before further processing. 
 
2.4.2 Reverse transcription 
Stored RNA samples were thawed on ice.  1000ng of RNA were pipetted into 
nuclease free Eppendorfs.  The volume required for each sample was calculated 
according to the following equation and made up to 12µl with RNAse-free water: 
Volume RNA (µl) =    1000   
  concentration of RNA (ng/ml) 
 
gDNA was eliminated by incubation with a DNAse at 42ºC for two minutes before 
transfer back to ice.  First-strand complementary DNA (cDNA) was reverse 
transcribed with a buffered reverse transcriptase-random primer mastermix 














Fig. 2.6. Yield, purity and degradation of messenger ribonucleic acid (mRNA) isolated from 
tissue samples 
A) Spectrophotometry of mRNA from 10 tissue samples, the data in the column on the  
right-hand side refers to sample “19M”, containing 1604.95ng/µl of mRNA.  The ratio of 
260:230nm absorbance is 2.25. 
B) Gel electrophoresis of RNA from 12 tissue samples viewed under UV light, there is 








2.4.3 Semi-quantitative polymerase chain reaction 
Samples of cDNA were slowly thawed on ice and loaded onto multiwell plates.  To 
each well was added a mastermix of DNA polymerase, deoxynucelotide 
triphosphates (Perfecta qPCR Fastmix II; VWR International Ltd, Lutterworth, UK) 
and appropriate, exon-spanning, unlabelled, rat-specific primers mixed with a 
fluorescein amidite (FAM) dye-labelled Taqman probe (ThermoFisher Scientific Inc).  
Plates were subjected to 50 cycles of 10 seconds at 95ºC and 30 seconds at 60ºC, to 
amplify DNA.  After each cycle, fluorescence of the FAM probes was measured 
(Lightcycler 480; Roche Diagnostics Ltd.).  
 
Concentrations of mRNA were calculated from the equation of a contemporaneous 
standard curve of the points at which the threshold of background fluorescence was 
exceeded (CT) in serial dilutions (1:8 to 1:512) of a mix of all cDNA samples.  
R2>0.9 was considered acceptable.   
 
CT values for renal cortical and medullary reference (housekeeper) genes, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and thymine-adenine-
thymine-adenine (TATA) box binding protein (TBP) 232, were compared between 
cohorts to confirm they were unchanged by diabetic status.  After subtracting CT 
values for genes of interest from CT values for reference genes, delta CT (ΔCT) values 
were compared between cohorts (Chapter 2.8).  Where significant differences were 
observed, the fold change was calculated from the difference in mean ΔCT between 




2.5 In vitro studies: histology 
2.5.1 Sectioning and mounting 
Fixed tissues were processed and stained by the histology department of the shared 
university research facilities (SuRF), University of Edinburgh, using standard 
protocols.  Briefly, tissues were paraffin-embedded and cut into 4µm-thick sections 
with a microtome (RM2235; Leica Biosystems Limited, Milton Keynes, UK), 
mounted onto glass microscope slides (VWR International Ltd) and dried overnight 
at 37ºC.  Sections were stained with haematoxylin and eosin (H&E), and the  
pan-collagen marker, picrosirius red.   
 
2.5.2 Staining with haematoxylin and eosin 
In a fume cupboard, renal tissue sections were dewaxed in xylene (five minutes 
twice), rehydrated through a series of graded alcohols (100%, 95%, 90% and 70%, 
five minutes in each) and immersed in distilled water (five minutes).  The sections 
were then immersed in the following solutions: Mayer’s haematoxylin  
(Sigma-Aldrich Company Ltd.) for five minutes, distilled water for 30 seconds, 1% 
hydrochloric acid (HCl) in 70% ethanol for 30 seconds, distilled water for  
30 seconds, aqueous eosin stain (Eosin Y; Sigma-Aldrich Company Ltd) for three 
minutes and finally distilled water for 30 seconds.  Slides were then dehydrated 
through graded alcohols and xylene before being mounted in a xylene-based medium 





2.5.3 Staining with picrosirius red  
Picrosirius red staining solution was prepared by dissolving a polyazo dye (Direct 
Red 80; Sigma-Aldrich Company Ltd) and a plasma counter-stain consisting of sea 
green triarylmethane food dye (Fast Green FCF; Sigma-Aldrich Company Ltd) in 
saturated aqueous picric acid (Sigma-Aldrich Company Ltd) according to 
manufacturer’s instructions, giving a 1% solution of both agents.   
 
In a fume cupboard, renal tissue sections were dewaxed in xylene (five minutes 
twice), rehydrated through a series of graded alcohols (100%, 95%, 90% and 70%, 
five minutes in each) and then immersed in distilled water (five minutes).  Following 
an additional immersion in picrosirius red solution for two hours, slides were rinsed 
in distilled water (30 seconds) and then dehydrated through graded alcohols and 
xylene before being mounted in a xylene-based medium (DePeX; Gurr-BDH 
Chemicals Ltd).   
 
2.5.4 Objective assessment of renal sections 
Stained sections were viewed single-blind under a 20x objective lens (Carl Zeiss Ltd., 
Cambridge, UK) connected to a desktop computer using specialist imaging software 
(MCID Basic; Interfocus) and, where appropriate, images were saved as tagged 
image format (TIF) files.   
 
For each rat, the glomerulosclerosis index was calculated from all glomeruli in one 





The percentage of picrosirius red positive staining in 20 randomly selected TIF files 
(10 cortical, 10 medullary) was determined using Photoshop software (Adobe 
Systems Incorporate, San Jose, US).  A reference level of positive staining was 
defined by selecting an area of collagen-dense connective tissue with a colour 
sampler tool.  Positive pixels were identified within the reference area as 
superimposed flashing white areas.  The width of the reference scale was then 
adjusted manually to modify the sensitivity of detection.  This ensured detection of 
positively stained areas but not negatively stained areas, such as the lumens of blood 
vessels.  The rest of every section was then analysed automatically and the number of 
positive pixels recorded.  For every additional section, the reference level of staining 
was reset and a new reference defined.   
 
2.6 In vivo studies: surgical techniques and sample collection 
2.6.1 Jugular vein cannulation 
The right jugular vein was exposed by cutdown and cannulated by introducing fine 
bore polythene tubing of internal diameter 0.58mm, external diameter 0.96mm (P50; 
Smiths Medical International Ltd, Hythe, Kent, UK) through a venotomy made with 
a bent 23 gauge needle (Fig. 2.7A, B).  Using a syringe driver (World Precision 
Instruments), the rat was infused intravenously through this line with a balanced 
electrolyte solution, pH7.4 (0.01ml/gbw/hour; Chapter 2.8) containing 2% bovine 
serum albumin (BSA, Sigma-Aldrich Company Ltd) and 0.25% fluorescein 
isothiocyanate (FITC)-inulin (Sigma-Aldrich Company Ltd) for measurement of 




injections of sodium thiopental solution (0.02-0.03ml of 50mg/ml; Archimedes 
Pharma).   
 
2.6.2 Tracheotomy and carotid artery cannulation 
The trachea was exposed through a midline cervical incision and supported by a 
2.5cm long piece of polythene tubing, 0.58mm internal diameter, 0.96mm outer 
diameter (P90; Smiths Medical International Ltd.), inserted under its dorsal aspect.  
A small tracheotomy was made with electrocautery (Fig. 2.7C).   
 
The right carotid artery was exposed through careful dissection (Fig. 2.7D).  It was 
elevated with 0.17mm silk suture thread (4/0; Interfocus) and separated from the 
vagosympathetic trunk by passing DeBakey forceps between the structures and 
pulling the silk through the small gap (Fig. 2.7E).  The silk was then advanced along 
the carotid artery to its most cranial point which was then ligated.  A straight vessel 
clip (1.5 x 8mm, World Precision Instruments) was applied to the most caudal point 
of the carotid artery (Fig. 2.7F) and a loose silk ligature placed in between.  The 
carotid artery was penetrated with a bent 23 gauge needle and cannulated with 
polythene tubing (P50; Smiths Medical International Ltd) that was pre-flushed with 
heparinised saline (50IU/ml) and connected to a closed three-way tap.  Once the free 
end of the tubing had been advanced to the level of the straight vessel clip, it was 
held in place by tightening the caudal pre-placed ligature (Fig. 2.7G), and the free 
ends of the cranial ligature (Fig.2.7H).  The straight vessel clip was then released and 
























Fig. 2.7. Cannulating the jugular vein and carotid artery 
A) and B). The right jugular vein is cannulated. 
C) A tracheotomy is performed using electrocautery. 
D) and E) The right carotid artery is exposed and separated from the vagosympathetic trunk. 
F) A straight vessel clip occludes the carotid artery prior to arteriotomy 






























2.6.3 Real-time blood pressure measurement 
Following arterial cannulation, the polythene tubing was clamped, removed from its 
connection to the three-way tap and transferred via additional heparinised tubing to a 
pressure transducer (ADInstruments, Oxford, UK) that had previously been 
calibrated manually with a sphygmomanometer, bulb pump and valve.  The 
transducer was connected to a multi-channel data acquisition system (Powerlab; 
ADInstruments).  The clamp was removed and all lines flushed with heparinised 
saline.  Real-time BP was measured through this arterial line.  Signal quality was 
considered optimal when oscillations between systolic and diastolic BP were clearly 
visible.  Mean BP was recorded, post acquisition. 
 
2.6.4 Arterial blood sampling and haematocrit measurement 
Arterial blood was collected from the carotid arterial line.  The polythene tubing was 
flushed with 0.2ml heparinised saline, clamped and separated from the connection to 
the pressure transducer.  The clamp was partially released and blood allowed to flow 
slowly along to the end of the tube where five drops were blotted onto a paper towel.  
If the haematocrit was being measured, the end of the tubing was inserted into two 
haematocrit tubes which were filled by slightly releasing the clamp.  For blood 
collection, the end of the tubing was inserted into a 0.3ml heparinised collection tube 
(Microvette CB300; Sarstedt, Numbrecht, Germany) and the clamp released further 
until the tube was full.  Where appropriate, three additional collection tubes were 
filled.  Following blood collection, the tube was fully clamped, re-connected to the 
pressure transducer and then flushed with 0.2ml heparinised saline after clamp 





Blood samples were centrifuged at 1250rpm for five minutes.  Plasma was decanted 
into 0.5ml Eppendorfs.  Samples were refrigerated immediately at 4ºC and then 
stored at -80ºC.   
 
2.6.5 Tube cystotomy and urine collection 
Following coeliotomy, the bladder was identified, exteriorised and passed through a 
hole made in the centre of a small piece of paper towel.  This held the bladder in 
position.  A pre-formed loose ligature of 17mm silk (4/0; Interfocus) was placed over 
the cranial pole of the bladder (Fig. 2.8A).  Holding the cranial pole with DeBakey 
forceps, a small cystotomy was performed through the loop of the ligature using 
electrocautery.  Urine spillage was absorbed by the paper towel.  A 15cm length of 
P90 polythene tubing (Smiths Medical International Ltd), with the end pre-softened 
by the flame of a cigarette lighter, was passed into the bladder lumen.  The  
pre-placed ligature was then tightened, taking care to include bladder wall as well as 
tubing to form a tight seal (Fig. 2.8B).  The free end of the cystotomy tube was 
allowed to drip onto a paper towel so that patency could be monitored.   
 
Urine was collected from the tube cystotomy into pre-weighed 1.5ml Eppendorfs 
containing a spot of mineral oil.  Samples were refrigerated immediately at 4ºC and 









Fig. 2.8. Tube cystotomy 
A) The bladder is exteriorised and a loose silk suture is placed 
B) Following cystotomy with electrocautery, a cystotomy tube is tied in place. 
 
2.6.6 Exposure of the left kidney and renal artery 
Following coeliotomy, gentle pressure was placed on the left abdominal wall while 
simultaneously retracting the left abdominal wound margin.  This exposed the left 
kidney which was freed from its retroperitoneal site and completely exteriorised by 
blunt dissection with DeBakey forceps, while gently retracting loose fragments of 
perirenal fat (Fig. 2.9A).   
 
With gentle retraction on the kidney that was not sufficient to cause blanching, the 
left renal artery and vein were identified, the vein being dorsal and the artery ventral.  
The mesenteric fat ventral to the artery was carefully stripped away with DeBakey 
forceps.  Small 2cm x 2cm square paper towel swabs absorbed abdominal fluid and 
were inserted into the abdomen to keep intestines away from the site of interest.  The 
artery was freed from the tightly apposed vein by gentle dissection involving 
downward pressure along the dorsal border of the artery with closed DeBakey 
forceps, and then allowing the forceps to spring open (Fig. 2.9B).  The artery 




















was always started proximal to this.  Once the artery was freed, further manipulation 
ceased, to allow time for any iatrogenic vasoconstriction to resolve. 
Fig. 2.9. Exposure of the left kidney 
A) The left kidney is freed from perirenal fat and is exteriorised. 
B) The left renal artery and vein are carefully separated with forceps. 
 
2.6.7 Cannulation of the left ureter 
Following coeliotomy and exposure of the left kidney (Fig. 2.10A), the left ureter 
just cranial to the bladder was identified within the mesenteric fat by a combination 
of peristalsis and the greenish hue from inulin-coloured urine within it.  The ureter 
was undermined and a 0.17mm silk ligature (4/0; Interfocus) with long free ends was 
placed around it as close as possible to the bladder.  The ureter was then cut distal to 
this ligature.  Quickly, a second silk ligature was loosely placed around the ureter 
and advanced proximally.  An ureterotomy was performed close to the cut end, using 
the first ligature for caudal traction, and taking care not to penetrate the opposite 
luminal wall.  A 10cm length of thin polythene tubing of internal diameter 0.28mm, 
external diameter 0.61mm (P10; Smiths Medical International Ltd.) with a slightly 
sharpened tip was then inserted through the ureterotomy and advanced slowly 
proximally within the ureteral lumen (Fig. 2.10B).  Patency was confirmed by the 






did not occur until the second ligature had been tightened and the free ends of the 
first ligature had been tied around the tubing to hold it in position.  If pulsatile flow 
was still not observed, the tubing was either re-positioned or a fresh ureterotomy was 
performed.  The free end of the tubing was placed on tissue paper when urine was 








Fig. 2.10. Measurement of left renal urine output and blood flow 
A) The left kidney is exposed. 
B) The left ureter is cannulated.  Urine spillage (arrow) is stained with inulin. 
 
2.6.8 Measurement of left renal artery flow 
Renal artery flow was measured in ml/min by a Doppler ultrasound flow probe 
(Transonic, Ithaca, United States (US)) placed around the freed left renal artery  
(Fig. 2.11A).  Acoustic coupling was completed by copious application of ultrasound 
gel between and around the probe and artery using a 5ml syringe attached to a blunt 
and bent 23-gauge needle (Fig. 2.11B).  At time of placement, the probe was gently 
manipulated to give maximal flow readings, and then held in position by the 











Fig. 2.11. Measurement of left renal artery flow 
A) The ultrasonic flow probe is in place around the left renal artery. 
B) Ultrasound gel is applied through a blunt, bent needle to improve acoustic coupling. 
 
2.6.9 Measurement of intrarenal blood flow 
Renal cortical blood flow and medullary blood flow were measured separately by 
laser Doppler spectroscopy (LDS; Fig. 2.12).  This technique follows the same 
principle as Doppler ultrasonography, but instead, laser light of a set frequency is 
reflected by moving red blood cells to its source at a higher or lower frequency, 
according to whether the red blood cells are moving towards or away from it 235.  
This shift in frequency (Doppler shift) is proportional to the velocity of the red blood 
cells and the cosine of the angle of the red blood cells to the laser beam, and is 
maximised when the laser beam and the direction of the red blood cells are parallel.  
Because of the varying concentrations of red blood cells at the exact point of 
interrogation within the kidney, and because the relative contributions of small blood 
vessels at different angles to the probe are not known, an absolute flow velocity is 
not determined 236.  Instead, the laser Doppler signal is described as flux, and 
measured in a relative unitary scale (tissue perfusion units, TPU).  Therefore, 





Fig. 2.12. Schematic diagram of a laser Doppler probe and flow meter. 
Laser light is generated by a laser diode, and is split to the output cable and the photodetector.  
The photodetector compares reflected light with the incident beam through optical beating.  The 
electrical signal generated enters a digital processor which calculates the Doppler shift and the 
number of tissue perfusion units (TPUs).  The resultant analogue signal is sent to the channel 
data acquisition system.  Red arrows indicate output laser light.  Pink arrows indicate reflected 
(scattered) laser light. 
 
Renal cortical flux was measured by a surface laser Doppler flow probe 
(ADInstruments).  An adhesive patch with a central hole was placed over the 
detecting surface of the probe with the hole over the central laser beam source  
(Fig. 2.13A).  Tissue glue (Vetbond; 3M, Bracknell, UK) was applied sparingly 
around the rim of the adhesive patch, far away from the central hole so as not to 




surface closer to the table).  Gentle pressure was applied for around 30 seconds, the 






Fig. 2.13. Placement of laser Doppler probes to measure intrarenal flux 
A) The surface probe, for measuring cortical flux, adheres to the dorsal renal surface.  The 
needle probe, for measuring medullary flux, is inserted through the anti-mesenteric border of 
the kidney. 
B) The needle probe is stabilised with gauze swabs, tissue glue and a micromanipulator. 
 
Renal medullary flux was measured by a needle laser Doppler probe 
(ADInstruments).  A 25-gauge needle was inserted 5mm through the renal capsule at 
the midpoint of the anti-mesenteric border and then removed.  Following 
haemostasis, the needle probe was inserted 5mm through the hole pointing in the 
direction of the hilus (Fig. 2.13A).  The probe was stabilised with a 
micromanipulator but additional stabilisation was required in order to minimise 
movement artefact associated with respiration.  This was obtained by gluing the 
probe to the kidney without allowing glue to enter the puncture, since this could flow 
down into the kidney and occlude the tip of the probe.  The technique was as follows: 
two small squares, each with a slit on one side that formed a “V” shape (Fig. 2.13B) 
were cut from a piece of gauze swab.  Using DeBakey forceps, the “V” of one piece 








the operator.  This was followed by application of the second piece of swab with the 
arms of the “V” pointing towards the operator.  Both pieces of swab were then stuck 
to the renal capsule with tissue glue.  As the glue spread towards the probe, it dried 
and stabilised the probe, without entering the puncture site and affecting the area 
being sampled.  While the glue was setting, minor adjustments were made to the 
position of the needle probe to maximise the reading.  The combination of rigidly 
fixed cortical and medullary probes was sufficient to dampen movement artefact 
created by respiration.   
 
2.6.10 Calculation of urine flow rate 
The volume of urine in each sample was calculated by subtracting the weight of the 
Eppendorf + mineral oil from the final weight of the Eppendorf + mineral oil + urine.    
 
Urine flow rate (UV) was calculated as follows: 
UV (µl/min/gkw) =   urine volume (ml) x 1000  
   kidney weight (g) x duration of collection period (minutes) 
 
2.6.11 Calculation of urinary sodium excretion rate and fractional excretion of 
sodium 
Sodium concentrations in urine and plasma were measured by ion-selective electrode 
(9180 Electrolyte Analyzer; Roche Diagnostics Ltd.) calibrated to known 
concentrations of sodium ions, provided by the manufacturer.  Urine was diluted by a 
ratio of 1:5 in distilled water and added to 120mM sodium chloride.  The value 




to give the sodium concentration in mmol/l.  Sodium concentrations in plasma were 
measured without dilution.   
 
Urinary sodium excretion rate (UNaV) was calculated as follows: 
UNaV (µmol/min/gkw) = UV (µl/min/gkw) x sodium concentration in urine (mmol/l) 
 1000 
 
Fractional excretion of sodium (FENa), the proportion of renally filtered sodium that 
is not reabsorbed, was calculated as follows: 
FENa (%) =          UNaV (µmol/min/gkw) x 100    
  Sodium concentration in plasma (mmol/l) x GFR (ml/min/gkw) 
 
2.6.12 Calculation of glomerular filtration rate  
Using a monochromator-based microplate reader (Infinite M1000 Pro; Tecan Group 
Ltd.), diluted concentrations of FITC-inulin in urine (1:4000) and plasma (1:40) 
samples were determined by FITC-fluorescence at a wavelength of 538nm following 
excitation at 485nm.  Diluted concentrations were calculated from the equation of a 
contemporaneous standard curve of fluorescence against six standard solutions of 
known concentrations of FITC-inulin ranging from 0-1mg/ml (R2>0.9).  The original 
concentrations of FITC-inulin were calculated after multiplying by the appropriate 
dilution factor (400 for urine, 40 for plasma).  All measurements were performed in 
triplicate. 
 
GFR for every urine collection period was calculated using the equation: 
GFR =  inulin concentration in urine (mg/ml) x UV (ml/min) 




where inulin concentration in plasma was the mean of the concentrations in the 
plasma samples obtained at the beginning and end of the urine collection period.  The 
GFR was then divided by combined renal mass (tube cystotomy only) or the mass of 
the left kidney (tube ureterostomy only) to give GFR in ml/min/gkw.   
 
2.6.13 Calculation of urinary endothelin-1 excretion rate 
Urinary ET-1 excretion rate (UET-1V) was calculated for every collection period as 
follows: 
UET-1V (fg/min/gkw) = UET-1 concentration (fmol/ml) x UV (µl/min/gkw) x 2.49 
 
  
2.7 In vivo studies: radiotelemetry 
2.7.1 Housing and radiotelemetry units 
Rats were housed individually in a room dedicated to radiotelemetry studies for  
48 hours.  Every radiotelemetry unit (TA11-CA P40; Data Sciences International,  
's-Hertogenbosch, Netherlands) was re-conditioned by the manufacturer and 
contained a pressure transducer.  Differences to zero pressure were recorded for each 
unit pre- and post explantation.  Every implanted unit could be switched on and off 
by a strong magnet placed over the skin.  
 
2.7.2 Implantation of radiotelemetry units 
Strict asepsis was observed during surgical implantation. Anaesthesia was induced 
with inhalational isoflurane (IsoFlo; Zoetis Animal Health Ltd.) in an anaesthetic 
chamber, and maintained with isoflurane by mask.  10ml of warmed saline was 




rat positioned in dorsal recumbency on a thermostatically controlled heat pad (38ºC) 
with its head facing away from the operator.  Bubble wrap was placed over the 
thorax for insulation.  Following a midline coeliotomy from the umbilicus to the 
pubis, the abdominal cavity was exposed and the abdominal contents displaced to 
either side using retractors and swabs soaked in warmed, sterile saline.  The distal 
aorta was identified and, using DeBakey forceps and a cotton bud, was carefully 
dissected free from the caudal vena cava from just cranial to the aortic trifurcation 
for a length of 1-2cm, to just caudal to the left renal vein.  Straight vessel clips (1.5 x 
8mm, World Precision Instruments) were applied across the distal aorta, first 
cranially, then caudally, and a timer was started.  Following penetration of the aorta 
caudally with a 23 gauge bent needle, the sensory catheter of a radiotelemetry unit 
was inserted into the aorta using vessel cannulation forceps, and advanced to the 
cranial vessel clip.  The arteriotomy site was closed and secured around the catheter 
with two small cellulose patches (Data Sciences International) with a “V” cut on one 
free edge.  One patch was advanced between the catheter and the aorta along the “V” 
up to the point at which the catheter entered the aorta.  The other patch was 
orientated in the opposite direction and overlaid the aorta and catheter.  Each patch 
was secured separately with tissue glue (Vetbond; 3M).  The vessel clips were 
removed, ensuring that no haemorrhage occurred.  If haemorrhage did occur, the 
vessel clips were re-applied, the cellulose patches were removed and new ones 
applied.  If the final clamp removal was more than 15 minutes after aortic occlusion, 
euthanasia was performed by barbiturate overdose.  If less than 15 minutes but more 




paresis was only temporary (less than three hours).  Hind limb paresis longer than 
three hours resulted in euthanasia (Chapter 2.1, page 46).   
 
The radiotelemetry unit was secured to the peritoneal aspect of the transversus 
abdominis muscle with 2 metric polyglactin 910 (Vicryl; Ethicon, Livingston, UK).  
The abdominal wound was closed in two layers with simple interrupted and 
continuous coated 2 metric polyglactin 910 (Vicryl; Ethicon) sutures.  The skin was 
closed with staples.  Transmission from the radiotelemetry unit was confirmed, 
following activation of the unit with a strong magnet, by detection of a high 
frequency noise from an amplitude modulation (AM) transistor radio placed over the 
body wall.  Rats recovered from anaesthesia in a recovery box containing insulating 
substrate and heated by warm air flow.  Following recovery, they were transferred 
back to individual cages in the radiotelemetry room.  They received buprenorphine 
(Buprecare; Animalcare, York, UK) at 0.5mg/kg/day sc. every 12 hours for three 
days during which time they were fed a mash of standard chow.  Ten days after unit 
implantation, they were briefly anaesthetised with isoflurane (IsoFlo; Zoetis Animal 
Health Ltd.) for staple removal.  They received 10ml of warmed saline sc. to aid 
recovery in a heated chamber.   
 
Transmission from the radiotelemetry units was monitored as soon as the units were 
fitted.  Units transmitted to a receiver pad under each cage, which was connected to a 
central acquisition system (Data Sciences International) attached to a desktop 
computer.  During the immediate post-operative period, units were only switched on 





Euthanasia was performed (Chapter 2.1, page 46) if any of the following major 
complications occurred: complete wound breakdown, generalised severe wound 
infection requiring antibiosis, loss of signal due to catheter migration, damage or 
occlusion of the catheter tip with a thrombus, and failure of post-operative paresis to 
resolve. 
 
2.7.3 Measurement and calculation of blood pressure and heart rate. 
During recording, systolic and diastolic BP and heart rate were acquired continually 
at 1kHz for one minute in every hour.  However, BP and heart rate could be 
monitored at any time using a remote desktop connection.   
 
In individual rats, data acquired over one minute were averaged.  Data from every 
four hours were then combined, so that every light and dark period (12 hours) 
contained three data sets for every parameter.  Circadian variation in BP and heart 
rate was calculated using three different methods. 
 
2.7.4 Calculation of circadian variation in blood pressure: diurnal dipping  
Diurnal dipping was defined as the percentage reduction in BP as rats entered a light 
(resting) period from a dark (active) period.  The mean dip in BP in a cohort was the 
mean of every dip for every rat in that cohort.   
 
2.7.5 Calculation of circadian variation in blood pressure: 24-hour-periodicity  













where K= number of blocks that period P can be folded into, Mh= is the mean of K 
values under each time unit, and M is the mean of all N values 237.  
 
Qp represents the degree to which periodic variations in BP of duration tau hours are 
present within the data. For example, for a standard circadian rhythm, Qp is at its 
highest value when tau=24.  
 
2.7.6 Calculation of circadian variation in blood pressure: cosinor analysis 
Sinusoidal variation in heart rate and BP was determined from multiple linear 
regression, using sine function least squares regression 237.  Starting from the first 
hour of the first dark period, and assuming a 24-hourly variation, mesor values from 
every rat were calculated from the equation:  
Y= mesor + (cos coeff.cos time) – (sin coeff.sin time) 
where cos time = cos2πt  and sin time = sin2πt 
    T   T 
where t = 1- to 24-hourly and T=24 hours. 
 
Amplitude (Amp) was calculated from the equation: 
Amp = √(cos coeff.2 + sin coeff.2) 
 
Acrophase (θ) was calculated from the equation: 
θ = Arctan sin coeff. 





2.8 Statistical analysis 
All data were expressed as mean ± standard error of the mean (SEM) and analysed 
with Minitab 17 (Minitab Ltd, Coventry, UK) and GraphPad Prism 6.0 (GraphPad 
Software, La Jolla, US).  Cohort sizes for experiments were calculated to achieve a 
minimum of 80% power (Minitab 17) based on expected results.   
 
Normal distribution of data within cohorts was determined by the Anderson-Darling 
test.  If data were not distributed normally, they were transformed to permit the use 
of parametric tests.  If transformation was not possible, appropriate non-parametric 
tests were used.   
 
Independent and dependent variables were compared between two cohorts by  
two-sample Student’s t tests (normal) or Mann-Whitney U tests (non-normal).  If 
experiments included more than two cohorts, one-way or two-way analysis of 
variance (ANOVA) or Kruskal-Wallis tests were used, according to normality and 
equality of variance of residuals, with Tukey’s (normal) or Dunn’s (non-normal) post 
hoc tests.   
 
Correlations were calculated by Pearson’s (normal) or Spearman’s rank (non-normal) 
tests.  Where dependent variables were plotted against an independent variable, 
regression lines were compared by analysis of covariance (ANCOVA) with Tukey’s 
post hoc tests (linear) and extra sum of squares F-tests (non-linear).   
 




2.9 Reagents and solutions 
The following reagents were prepared: 
Balanced electrolyte solution for in vivo studies 
0.25g FITC-inulin (Sigma-Aldrich Company Ltd), 0.58g sodium chloride,  
0.13g sodium hydrogen carbonate, 0.04g potassium chloride, in 100ml distilled water;  
pH to 7.4 at room temperature. 
 
0.5M ethylenediaminetetraacetic acid  
186.1g disodium EDTA.2H2O, in 800ml distilled water (vigorous stirring);  
pH to 8.0 with 10M sodium hydroxide 
 
4% paraformaldehyde  
40g PFA powder, in 500ml distilled water (fume cupboard, stirred on a hot plate at 
60-65ºC), 10ml 1M sodium hydroxide to clear solution, 100ml 10 x phosphate 
buffered saline (PBS); 
pH to 7.4 at room temperature, adjust volume to 1 litre with distilled water 
 
Phosphate buffered saline  
80g sodium chloride, 2.0g potassium chloride, 14.4g disodiumhydrogenphosphate, 
2.4g potassiumdihydrogenphosphate, in 800ml distilled water; 





0.9% saline solution 
9g sodium chloride, in 1l distilled water; 
pH to 7.4 
 
Sodium citrate buffer 
1.47g sodium citrate (enzyme grade), in 50ml distilled water; 
pH to 4.5 with citric acid solution 
 
10 x Tris borate ethylenediaminetetraacetic acid  
56g tris base, 57.5g boric acid, in 20ml 0.5M EDTA pH8.0 and 500ml distilled water 
 
Tris borate ethylenediaminetetraacetic acid running buffer and gel 
Dilute 10 x tris borate EDTA (TBE) diluted 1:20 with distilled water (0.5xTBE), for 
running buffer 
1.20g agarose (Seakem LE Agarose; Lonza, Rockland, US) in 100ml 0.5xTBE; 








3 Method development: optimisation of 





Acute pressure natriuresis is the process by which increases in arterial blood pressure 
(BP) lead to corresponding increases in urinary sodium and water excretion while 
glomerular filtration rate (GFR) is autoregulated 89,112.  To investigate the hypothesis, 
acute pressure natriuresis will be induced by arterial ligation in a rat model of early 
Type 1 diabetes mellitus (T1DM).  In healthy rats, this technique produces consistent, 
marked step-ups in BP and urinary sodium and water excretion 112 that allow 
deficiencies in acute pressure natriuresis to be identified.  Unfortunately, it is also 
surgically invasive, and requires prolonged general anaesthesia, so the protocol has 
to be adapted to meet the experimental requirements of unhealthy animal models.  In 
this chapter, experiments investigated cardiovascular and renal stability during 
prolonged general anaesthesia in a rat model of early T1DM.  They also determined 
the adaptations to the protocol for inducing acute pressure natriuresis that will suit 
the needs of the model and optimise increases in BP and urinary sodium and water 
excretion.  
 
There are several different techniques for inducing acute pressure natriuresis.  Of 
these, expansion of the vascular compartment through water immersion, and rapid 
intravenous (iv.) infusion of isotonic fluids have been applied previously to diabetic 
patients 107 and models of T1DM 108,109.  While these techniques successfully induce 
diuresis/natriuresis, the increases in BP, urinary sodium excretion rate (UNaV) and 
urine flow rate (UV) are gradual and variable 108,109, making it difficult to establish 





Ligature-induced acute pressure natriuresis is the technique that has been selected for 
this thesis because it is the current “gold standard”.  Sequential ligation of major 
arteries generates marked stepwise increases in BP at fixed time points.  These do not 
prevent maintenance of glomerular filtration rate (GFR) but still induce 
corresponding rapid rises in sodium and water excretion 112.  This permits generation 
and comparison of pressure diuresis/natriuresis curves 112,116.  Ligature-induced acute 
pressure natriuresis has never been applied to a rodent model of T1DM, and so it is 
not known whether the model can tolerate the procedure.  If the model cannot 
maintain BP and GFRs during prolonged general anaesthesia and surgical 
intervention, and if glycosuria increases baseline urinary sodium and water  
excretion 238, comparisons between T1DM rats and healthy controls during acute 
pressure natriuresis will not be possible.   
 
One method of adapting the protocol to meet the needs of early T1DM rats is to 
shorten the duration of the experiment.  Surgical preparation time and surgical 
trauma can be reduced if the operator is sufficiently skilled and experienced.  Shorter 
urine collection periods after arterial ligation (clearance periods) reduce the risk of 
avascular necrosis of abdominal viscera supplied by ligated arteries, and allow  
step-ups in BP despite rapid onset compensatory diuretic/natriuretic responses 112.  
However, if clearance periods are too short, time, rather than a treatment or disease 
effect, becomes the major limiting factor for diuresis/natriuresis, and a larger number 
of animals is required to demonstrate differences between cohorts.  Therefore, 
optimising the duration of clearance periods maximises rises in BP, UV and UNaV 




time and resource, and the generation of incomplete data sets of questionable 
reliability.   
 
In this chapter, two series of experiments were undertaken to address the proposal 
that ligature-induced acute pressure natriuresis can be successfully adapted for use in 
a sufficiently robust model of early T1DM.  In the first series, baseline renal 
clearance of early T1DM rats was compared with healthy controls.  BP, GFR, UV 
and UNaV were measured, and their stability during prolonged general anaesthesia 
determined.  In the second series, the optimal protocol for ligature-induced acute 
pressure natriuresis in healthy rats was determined.  The magnitude and duration of 
increases in BP following arterial ligation, the subsequent diuretic/natriuretic 




Experiments were performed, single-blinded, in two groups of adult male Sprague 
Dawley rats: early T1DM (blood glucose >12mmol/l induced with one or two 
intraperitoneal (ip.) injections of streptozotocin (STZ); Chapter 2.1, page 46) and 
healthy control rats (ip. citrate buffer).  Experiments were performed two-to-three 
weeks after the first ip. injection. 
 
3.2.2 Anaesthesia, preparation and vascular cannulation 
Rats were anaesthetised with ip. sodium thiopental solution (50mg/kg, 50mg/ml; 




jugular furrow were clipped and the rat placed in dorsal recumbency onto a heat pad, 
with the rat’s head pointing towards the operator.  A rectal thermometer was inserted, 
and body temperature maintained at 38-39ºC by manually adjusting the power output 
of the heat pad.   
 
Following jugular vein cannulation (Chapter 2.6, page 63), the rats were infused 
intravenously (iv.) with a balanced electrolyte solution, pH7.4, (0.01ml/gbw/hour; 
Chapter 2.6, page 63) containing 2% bovine serum albumin (BSA, Sigma-Aldrich 
Company Limited (Ltd.), Gillingham, UK) and 0.25% fluorescein isothiocyanate 
(FITC)-inulin (Sigma-Aldrich Company Ltd.) for measurement of GFR.  General 
anaesthesia was also maintained through this iv. line by small bolus injections of 
sodium thiopental solution (0.02-0.03ml of 50mg/ml; Archimedes Pharma).  
Following tracheotomy, systolic and diastolic BP were recorded continuously 
through an arterial line into the right carotid artery and mean BP was calculated post 




3.2.3 Baseline renal clearance 
Twelve healthy, control rats, and eight early T1DM rats were selected.  Following 
induction of anaesthesia and vascular cannulation, a caudal abdominal laparotomy 
was performed and urine was collected via a tube cystotomy (Chapter 2.6, page 67). 
 
Following a 60-minute equilibration period, 0.3ml of blood was collected through the 
arterial line (Chapter 2.6, page 66) at the beginning and end of three consecutive  
60-minute clearance periods (Clearance 1, Clearance 2, Clearance 3; Fig. 3.1).  Every 
clearance period was subdivided into two urine collection periods, each lasting  
30 minutes.  Mean BP was recorded continuously (Chapter 2.6, page 66) and the 
average value for every 30 minutes was calculated.  After the final blood collection, 
every rat was euthanased by an iv. overdose of sodium thiopental.  The kidneys were 
removed and weighed.  The rat carcase was incinerated as clinical waste.   
 
Urinary sodium concentrations were measured.  GFR, UV, UNaV and FENa for 
every 30 minutes were calculated (Chapter 2.6, pages 74-76).   
 
Fig. 3.1. Timeline for determining baseline renal clearance 





3.2.4 Acute pressure natriuresis: ligature placement and tube cystotomy 
The protocol proposed by Roman and Cowley 112 was adapted and applied to  
12 healthy rats, without controlling neural and hormonal influences on the  
kidney (Fig. 3.2).   
 
A midline coeliotomy was performed from the costal arch to the pubis, taking care 
not to cut through large subcutaneous blood vessels or lacerate the liver and bladder.  
Mean BP was monitored closely during this process.  If mean BP fell acutely, 
surgery was stopped for two-to-three minutes to allow mean BP to recover.   
 
The omentum and intestines were displaced to the left hemiabdomen, exposing the 
coeliac and cranial mesenteric arteries.  Following blunt dissection with DeBakey 
forceps through the mesentery, ligatures of 0.17mm silk (4/0; Interfocus, Linton, UK) 
with long free ends were pre-placed around each of these vessels but not tightened.  
The free ends of each ligature were then labelled with tape and placed to the right of 
the rat, out of the surgical field (Figs. 3.3A-C).  Fluctuations in BP, associated with 
manipulation of the arteries, were then allowed two-to-three minutes to stabilise.   
 
The aorta distal to the left kidney was identified.  Using DeBakey forceps and cotton 
buds, it was carefully dissected away from the caudal vena cava as close to the left 
kidney as possible.  There was frequent variation in the branching of the aorta and 
caudal vena cava into the left hemi-abdomen, and in the degree of mesenteric fat, so 
care had to be taken not to rupture concealed large blood vessels.  Once freed, a 




tape (Figs. 3.3D,E).  Again, there was a pause of two-to-three minutes to allow BP to 
stabilise. 
 
A tube cystotomy was performed, allowing the free end of the cystotomy tube to drip 
onto a paper towel, so that patency could be monitored (Chapter 2.5, page 67;  
Fig. 3.3F).  The iv. infusion rate was increased to (0.02ml/gbw/hour).  The surgical 
preparation time (approximately 60 minutes) was noted and an equilibration period 




































Fig. 3.3. Pre-placement of arterial ligatures and cystotomy 
A) The coeliac artery is isolated.  
B) A loose ligature is placed around the coeliac artery and labelled C. 
C) A loose, labelled ligature (M) is placed around the cranial mesenteric artery. 
D) A loose, labelled ligature (A) is placed around the distal aorta. 
E) Cystotomy is performed by electrocautery.   






















Fig. 3.4. Timeline for ligature-induced acute pressure natriuresis 
mins=minutes 
 
3.2.5 Acute pressure natriuresis: arterial ligation and urine and plasma collection 
Following equilibration, 0.3ml of blood was collected through the arterial line at the 
beginning and end of three consecutive 60-minute clearance periods (Baseline, 
Clearance 1, Clearance 2; Fig. 3.4).  Every clearance period was divided into two 
urine collection periods, each lasting 30 minutes.  Mean BP was recorded 
continuously, and the average value for every five minutes after arterial ligation was 
calculated.  After the final blood collection, every rat was euthanased by iv. overdose 
of sodium thiopental (Archimedes Pharma).  The kidneys were removed and 
weighed.  The rat carcase was incinerated as clinical waste.   
 
Urinary sodium concentrations were measured.  GFR, UV, UNaV and FENa for 





3.2.6 Statistical analysis 
Data were expressed as mean ± standard error of the mean (SEM) and analysed with 
Minitab 17 (Minitab Ltd, Coventry, UK) and GraphPad Prism 6.0 (GraphPad 
Software, La Jolla, US).   
 
For baseline renal clearance, two-way analysis of variance (ANOVA) with Sidak’s 
post hoc tests were used for between-cohort comparisons of independent (mean BP) 
and dependent variables (GFR, UV and UNaV) during individual urine collection 
periods, and to compare every urine collection period with the same-cohort first urine 
collection period.  Data were subjected to log or square-root transformation 
according to normality and equality of variance of residuals.  Interaction between 
diabetic status and clearance period was calculated.   
 
For the acute pressure natriuresis studies, independent (mean BP) and dependent 
variables (UV, UNaV and FENa) during Clearances 1 and 2 were compared to 
Baseline values by one-way ANOVA with Tukey’s post hoc tests. 
 





3.3.1 Baseline renal clearance and mortality 
Three control and three early T1DM rats did not complete the study (30% mortality 
rate).  Of these, two early T1DM rats were euthanased because of excessive weight 
loss (>20% starting bodyweight).  The other rats developed severe hypotension 
during baseline renal clearance and died or were euthanased. 
 
Mean BP did not vary during the study and was similar in control (126.9±4.7mmHg) 
and early T1DM (132.0±3.8mmHg) rats (Fig. 3.5A; Table 3.1).  Overall, GFR rose 
(P=0.04, interaction P=0.32) and had doubled in controls by the end of Clearance 2 
(P=0.03; Fig. 3.5B; Table 3.1).  Though the effect was less in early T1DM rats (mean 
GFR 0.8±0.1ml/min/gkw) than in controls (1.3±0.1ml/min/gkw, P<0.01), GFR did 
not differ between cohorts during individual clearance or urine collection periods 
(Fig. 3.5B).   
 
Overall, fluid perfusion induced a mild diuresis (P=0.02, interaction P=0.25) and 
mild natriuresis (P<0.01, interaction P=0.96).  The increases in UV in control rats 
during Clearances 2 (P=0.02) and 3 (P=0.04; Fig. 3.6A; Table 3.1) were not observed 
in early T1DM rats.  By contrast, UNaV (P<0.01) and FENa (P<0.01, interaction 
P=0.85) increased overall in only early T1DM rats (Figs. 3.6B,C; Table 3.1).  
Despite these small differences, UV, UNaV and FENa remained unaffected by early 




Fig. 3.5. Mean blood pressure (BP) and glomerular filtration rate (GFR) during baseline 
renal clearance in control and diabetic rats 
A) Similar values for mean BP were maintained in controls and diabetic rats. 
B) An increase in GFR during Clearance 2 was not observed in diabetic rats.  The dashed lines 
represent mean values of GFR in male Sprague Dawley rats during general anaesthesia, prior to 
intervention 225,239. 
Columns show mean ± standard error of the mean (SEM), *=P<0.05 compared with first  
30-minute urine collection period in same cohort.  All comparisons made with two-way analysis 











Fig. 3.6. Urine flow rate (UV), urinary sodium excretion rate (UNaV) and fractional 
excretion of sodium (FENa) during baseline renal clearance in control and diabetic rats 
A) A small diuretic effect during Clearances 2 and 3 was not observed in diabetic rats. 
B) Sodium excretion during individual clearance periods did not vary between cohorts. 
C) FENa during individual clearance periods did not vary between cohorts. 
Columns show mean ± standard error of the mean (SEM), *=P<0.05 compared with first  
30-minute urine collection period in same cohort.  All comparisons made with two-way analysis 










 Clearance 1 Clearance 2 Clearance 3 
Minutes 30 60 30 60 30 60 
 Control Diabetic Control Diabetic Control Diabetic Control Diabetic Control Diabetic Control Diabetic 
Weight 
(g) 
367.0±18.1 353.4±7.4           
Mean BP 
(mmHg) 
126.4±4.7 133.2±12.7 129.6±4.5 134.1±9.7 130.8±5.5 130.9±11.1 127.5±5.4 135.2±10.9 125.3±5.3 130.9±8.9 122.1±5.5 127.9±7.1 
GFR 
(ml/min/gkw) 
0.7±0.1    0.8±0.2   1.20±0.1     0.7±0.1 1.4±0.2  0.8±0.2   1.5±0.2*  1.0±0.4 1.5±0.2   0.8±0.2 1.4±0.2    1.0±0.3 
UV 
(µl/min/gkw) 
2.5±0.4   8.6±3.8   7.2±1.5    5.6±0.6 14.3±4.5  9.2±2.8 18.0±3.5* 12.0±4.9 18.1±2.9*   9.2±3.4 16.7±2.3  10.7±3.7 
UNaV 
(µmol/min/gkw) 
   0.18±0.1   0.6±0.5  0.2±0.1   0.7±0.2 0.4±0.1  1.2±0.5 1.1±0.5 2.1±0.9 1.0±0.3  1.9±0.7 1.4±0.3   2.4±0.7 
FENa 
(%) 
     1.8±0.1   3.1±0.2  1.2±0.1   4.9±1.5 1.9±0.5  7.4±4.1  4.2±1.5 10.5±5.5 4.6±1.9 11.5±3.2 6.6±1.6  13.2±3.4 
Table 3.1. Weight, urine flow rate (UV), urinary sodium excretion rate (UNaV), fractional excretion of sodium (FENa), glomerular filtration rate (GFR) and 
blood glucose (BG) in control and diabetic rats during baseline renal clearance  
*=P<0.05 compared with first 30-minute urine collection period in same cohort.  All comparisons made with two-way analysis of variance (ANOVA) with 




3.3.2 Acute pressure natriuresis  
Six rats completed the study (50% mortality rate). Two rats died prematurely due to 
haemorrhage caused by laceration of one of the major abdominal arteries.  A severe 
abdominal effusion developed during Clearance 2 in three rats, accompanied by 
pallor and odour from the jejunal loops, and hypotension.  This was consistent with 
avascular necrosis and endotoxaemic shock that necessitated immediate euthanasia.  
One rat developed severe bradycardia and hypotension degenerating into death, 
immediately following cystotomy.   
 
Following sequential arterial ligation, Baseline mean BP rose overall by ~10mmHg 
from 142.5±3.3mmHg to 152.8±1.4mmHg but there was marked variation in mean 
BP during Clearances 1 and 2 (Fig. 3.7A; Table 3.2).  Following an initial rise of 
~20mmHg, mean BP decreased during the second half of Clearance 1 to Baseline 
levels.  Although mean BP increased again following the second arterial ligation, it 
did not exceed the maximum mean BP obtained during Clearance 1.  Variance in 
mean BP increased during Clearance 2 after ~25 minutes. 
 
GFR (1.20 ml/min/gkw) was maintained within values obtained during the previous 
experiment on baseline renal clearance (Fig. 3.7B; Table 3.2).  There was a 
significant pressure diuresis and natriuresis.  UV rose during Clearance 1 from 
1.48±0.21 to 2.54±0.34 µl/min/gkw (P=0.02; Fig. 3.7C; Table 3.2), and was 
maintained during Clearance 2 (P=0.04).  However, although UNaV rose from 
4.07±1.22 to 9.43±2.47µmol/min/gkw (P=0.045; Fig. 3.4D; Table 3.2) during 




FENa increased from 4.7±1.1% to 8.7±1.1% (P=0.03) during Clearance 1 but 












Fig. 3.7. (page opposite) Ligature-induced acute pressure natriuresis in healthy rats 
A) Rises in mean blood pressure (BP) following arterial ligation, the dashed circles show where 
BP falls during Clearance 1 and where variance in BP is increased during Clearance 2. 
B) Mean glomerular filtration rates (GFR) remained within the range of maximum and 
minimum mean values obtained during baseline renal clearance, represented by the dashed 
lines. 
C) Urine flow rate (UV) increased during Clearance 1 and was maintained during Clearance 2. 
D) Urinary sodium excretion rate (UNaV) increased during Clearance 1 but fell to Baseline 
levels during Clearance 2. 
E) Fractional excretion of sodium (FENa) also increased during Clearance 1 and fell to Baseline 
levels during Clearance 2. 
Columns show mean ± standard error of the mean (SEM), *=P<0.05 compared with 60-minute 
Baseline values.  All comparisons made with one-way analysis of variance (ANOVA) with 








 Baseline Clearance 1 Clearance 2 
Minutes 30 60 30 60 30 60 












1.3±0.1 1.7±0.4   2.4±0.4*   2.7±0.6*   2.3±0.5* 2.6±0.6* 
UNaV 
(µmol/min/gkw) 
3.0±1.3 3.2±1.1 10.0±4.1* 5.9±1.7 5.9±1.2 6.5±2.6 
       
FENa 
(%) 
3.6±1.3 5.3±2.1  8.5±1.6 8.9±1.3 7.9±1.3 7.5±0.7 
Table 3.2. Weight, mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate (UNaV) and fractional 
excretion of sodium (FENa) in healthy rats during Baseline and Clearances 1 and 2 







The experiments in this chapter investigated the suitability of a rat model for 
studying the effects of early T1DM on renal sodium handling, and then modified a 
protocol for inducing acute pressure natriuresis.   
 
For an early T1DM rat model to be suitable, it must be sufficiently robust to survive 
general anaesthesia and surgery, and baseline determinants of renal sodium and 
water excretion must be similar to those in healthy controls.  This can be facilitated 
by adapting experimental procedures so that they suit the model’s needs.  In the first 
series of experiments, general anaesthesia was as well tolerated in the model as in 
healthy controls, and early T1DM exerted only minor influences on BP, GFR and 
sodium and water excretion.  In the second series of experiments, a protocol for 
inducing acute pressure natriuresis, based on the work of Roman and Cowley 112, 
successfully increased diuresis and natriuresis in healthy rats.  However, elevated 
BPs and levels of sodium and water excretion were not sustained for more than  
30 minutes, and experimental mortality, to which avascular necrosis contributed the 
most, was too high.  This suggests that the experimental timeline should be shortened 
not only to suit the requirements of early T1DM rats, but also to maximise the degree 
of diuresis/natriuresis while minimising experimental mortality.   
 
From these experiments, it is concluded that, following arterial ligation, clearance 
periods limited to 30 minutes will be sufficient to demonstrate impairment to acute 





3.4.1 Baseline renal clearance was similar between healthy control and diabetic 
rats. 
Uncontrolled T1DM causes glycosuria that can increase urinary sodium and water 
excretion and modify the stability of BP and GFR 238.  Variations in BP and GFR 
confound comparisons with healthy controls because acute pressure natriuresis is 
induced by increased BP while GFR is autoregulated 89,112.  Therefore, before 
proceeding to experiments on acute pressure natriuresis, baseline BP, GFR and 
urinary sodium and water excretion were measured in healthy and early T1DM rats 
during prolonged general anaesthesia.   
 
Following induction of anaesthesia, mean BP remained stable and was unaffected by 
early T1DM.  Despite a lower overall GFR in early T1DM rats, and increases in BP 
that were only observed in controls, GFR in both cohorts remained within ranges 
previously published for this rat strain during general anaesthesia 225,239.  This 
suggested that autoregulation of GFR was maintained in both healthy and diabetic 
states.  There was a small influence of early T1DM on UV, UNaV and FENa, but 
none of these parameters differed from control values during individual clearance 
periods.  These results are significant.  The similarity and stability in baseline BP 
mean that subsequent acute pressure natriuresis studies will not require placement of 
a cuff around the proximal aorta in order to equalise renal perfusion pressures 112.  
The similar baseline levels of sodium and water excretion will permit comparisons 
between cohorts in response to changes in BP.  Together, the data demonstrate that 





These studies on baseline renal clearance were not performed single-blind.  This was 
so that requirements specific to early T1DM rats could be determined and 
incorporated into the protocols of subsequent studies that require general anaesthesia 
and surgery.  These adaptations concerned anaesthetic dosing and frequency of 
dosing to minimise the effect on BP, and included pauses during laparotomy and 
manipulation of viscera to allow BP sufficient time to recover.  Identifying these 
requirements may have contributed to maintaining an acceptably low mortality rate.  
There was a subjective increase in surgical skill over the months that these studies 
were conducted.  The effect this had on outcome was minimised by use of 
contemporaneous controls and random selection of rats.  
 
3.4.2 Acute pressure natriuresis was successfully induced in healthy rats. 
The second series of experiments optimised a technique for inducing acute pressure 
natriuresis through ligation of abdominal arteries 112.  In acute pressure natriuresis, 
rises in BP increase urinary sodium and water excretion because of reduced tubular 
sodium reabsorption and not because of increased GFR, which is autoregulated 89,112.  
Therefore, to induce acute pressure natriuresis experimentally, step-ups in BP must 
be of sufficient magnitude and duration to induce diuresis and natriuresis, and a 
stable GFR must be maintained 112.  In Roman and Cowley’s original protocol in 
healthy rats, clearance periods of 40 minutes followed a five-minute equilibration 
period 112, whereas in their follow-up study in unhealthy, hypertensive rats, shorter 
clearance periods of 15 and 30 minutes were employed 116.  Several published studies 
have also adapted the original protocol 114,115,120,240-246, using clearance periods as 




and arterial ligation ranging from five minutes to one hour.  The reasons for these 
adaptations are not clear.  One could speculate that as well as reflecting variable 
susceptibility of unhealthy animal models to prolonged general anaesthesia and 
surgical manipulation, they might also have been modified according to operators’ 
skill, and the differences in UV and UNaV required between cohorts to achieve 
adequate power.   
 
To determine whether similar adaptations in experimental time could be applied in 
this thesis, dependent and independent variables were sampled frequently during 
prolonged periods of renal clearance after arterial ligation.  An equilibration period 
of 30 minutes was sufficient for BP, UV and UNaV to recover after surgery, and to 
exceed levels recorded during the preceding baseline renal clearance studies.  These 
elevated levels may have been a consequence of the higher rate of iv. fluid infusion 
that was used, and could also be attributed to adequate surgical skill, and the shorter 
surgical preparation time afforded by not having to place a cuff around the proximal 
aorta.   
 
Following arterial ligation, increments in BP stabilised within two-to-three minutes, 
and diuresis and natriuresis were rapidly induced, suggesting longer post-ligation 
equilibration periods were unnecessary.  Rises in BP were sufficient to double UV 
and UNaV during clearance periods of one hour.  This diuretic/natriuretic response 
could not be explained by increases in GFR, which remained within the range of 
GFRs recorded during the previous baseline renal clearance studies.  By contrast, 




demonstrated that sodium and water excretion had increased because of decreased 
tubular sodium reabsorption.  Together, these data show that acute pressure 
diuresis/natriuresis can be induced in the healthy Sprague Dawley rat.   
 
3.4.3 Thirty-minute clearance periods are sufficient and suitable for inducing acute 
pressure natriuresis. 
Following the first of two arterial ligations, the compensatory diuretic/natriuretic 
response was so marked, that it rapidly offset the rise in BP.  As a consequence, after 
one hour of clearance time, the second arterial ligation did not achieve an additional 
step-up in BP even higher than the first, and additional increases in UV and UNaV 
were limited.  This contributed to an overall diuretic/natriuretic effect that was less 
than that achieved in healthy rats following rapid expansion of circulatory volume 
with iv. saline 109.  However, the data also identified how this deficit could be 
corrected.  Limiting clearance periods in future experiments to 30 minutes, will lead 
to further increases in BP, UV and UNaV because they will not have had adequate 
time to return to Baseline levels.  The data also suggest an additional benefit of using 
30-minute clearance periods.  One of the advantages of ligature-induced acute 
pressure natriuresis over natriuresis through volume expansion is that variance in BP 
is reduced within cohorts 112.  With acute volume expansion, there is variability in 
distribution of fluid within the vascular compartment, and the resulting increases in 
BP are less reproducible.  It was therefore important to demonstrate in these studies 
that there was a low level of variance in BP following arterial ligation.  Variance was 
low throughout Clearance 1, but after 30 minutes of Clearance 2, the BP decreased in 




will minimise this potentially confounding effect and facilitate inter-cohort 
comparisons.   
 
3.5 Conclusions 
The experiments in this chapter demonstrated that the rat model of early T1DM will 
meet the requirements of future experiments on acute pressure natriuresis and allow 
the hypothesis of this thesis to be explored.  The model is sufficiently robust to 
maintain BPs and GFRs similar to those in healthy controls rats, over prolonged 
periods of general anaesthesia.  Baseline UV and UNaV are also similar to control 
values, facilitating future comparisons between cohorts.  A suitable protocol for 
ligature-induced acute pressure natriuresis has also been determined.  Shorter 
equilibration and clearance periods than originally described for this technique will 
provide predictable and reproducible increases in BP.  These will be adequate for 
studying differences in UV and UNaV that are independent of GFR, while also 
reducing the risk of experimental mortality.  It is intended to test the new protocol for 
the first time in early T1DM rats in the following chapter, when investigating the 





4 The effects of early Type 1 diabetes mellitus 





Hypertension and nephropathy are major risk factors for cardiovascular disease 
(CVD) in Type 1 diabetes mellitus (T1DM) 247-250.  Hypertension and 
hyperglycaemia are key to the development of diabetic nephropathy 72 and when 
either blood pressure (BP) or blood glucose is tightly controlled in early T1DM, the 
risk of nephropathy and CVD is much reduced 31,251.  However, lowering blood 
glucose increases the risk of potentially life-threatening hypoglycemia 29.  Thus, BP 
and its regulation in early T1DM are attractive therapeutic targets to complement 
control of blood glucose. 
 
The kidneys are central to regulation of BP.  As BP rises, there is a corresponding 
increase in renal medullary blood flow 138 that induces a compensatory diuresis and 
natriuresis in a process called acute pressure natriuresis 89.  Excretion of sodium and 
water is reduced when BP subsequently falls.  Hyperglycaemic T1DM patients and 
animal models are unable to excrete an acute sodium and water load rapidly 109,110,252, 
suggesting that they have impaired acute pressure natriuresis, although this has not 
been confirmed experimentally.  Such dysfunction in renal sodium handling is 
important because it has been implicated in the rise in nocturnal BP that predicts 
hypertension and nephropathy in T1DM patients 74,124.  Increased nocturnal BP has 
now become a therapeutic target for reducing cardiovascular risk 106, and  
night-time dosing of anti-hypertensive medication is recommended by the American 
Diabetes Association to reduce cardiovascular risk 253.  However, conventional  




an alternative strategy to restore the dip in BP at night, and reduce cardiovascular 
risk, might be to manipulate acute pressure natriuresis directly.   
 
The paracrine peptide endothelin-1 (ET-1) may be a suitable therapeutic target for 
three reasons.  First, it regulates vascular and tubular components of acute pressure 
natriuresis 89 via its two receptor subtypes.  ETA receptor-mediated vasoconstriction 
can reduce renal medullary blood flow 182,184 and suppress acute pressure natriuresis, 
whereas ETB receptor-mediated vasodilation 
77 and suppression of tubular sodium 
reabsorption through the epithelial sodium channel (ENaC) 181 have the opposite 
effect.  Second, T1DM is known to have profound effects on ET-1 signalling that are 
implicated in impaired regulation of BP.  Hyperglycaemia increases transcription and 
release of ET-1 from endothelial cells 205,254, and plasma levels of ET-1 are elevated 
in STZ-induced T1DM rats 255 and in patients with T1DM and hypertension 256.  
There is a shift towards increased vasoconstriction from enhanced ETA receptor  
signalling 257,258 and impaired vasodilation via nitric oxide (NO) 259, the mediator of 
both ETB receptor-mediated vasodilation and inhibition of ENaC 
122,260.  Third, and 
finally, selective ETA receptor antagonists are already at an advanced stage of 
clinical development.  They reduce BP and proteinuria in clinical diabetic 
nephropathy 217, and re-establish nocturnal dipping in non-diabetic chronic kidney 






1) Acute pressure natriuresis is impaired in early T1DM before the development 
of established nephropathy.   
2) This impairment is reversed by insulin and mediated by renal ET-1.   
 
4.1.2 Aims 
To investigate these hypotheses, a rat model of early T1DM was used to answer the 
following questions: 
1) Does early T1DM impair acute pressure natriuresis prior to overt 
nephropathy? 
2) Is this reversed by lowering blood glucose with insulin? 
3) Does urinary ET-1 (UET-1) excretion correlate with urinary sodium and 
water excretion during acute pressure natriuresis? 






Experiments were performed, single-blinded, in two groups of adult male Sprague 
Dawley rats: early T1DM (blood glucose >12mmol/l induced with one or two 
intraperitoneal (ip.) injections of streptozotocin (STZ); Chapter 2.1, page 46) and 
healthy control rats (ip. citrate buffer).  Experiments were performed two-to-three 
weeks after the first ip. injection. 
 
Selected experiments included a third cohort of early T1DM rats that had received a 
subcutaneous (sc.) insulin implant (T1DM+insulin) seven days after the first 
injection of STZ (Chapter 2.1, page 47).   
 
4.2.2 Effects of Type 1 diabetes mellitus on acute pressure natriuresis  
Acute pressure natriuresis was induced by arterial ligation in anaesthetised control 
and early T1DM rats (Table 4.1), using a protocol developed by Roman and  
Cowley 112, and modified in Chapter 3 (Fig. 4.1).  Briefly, after a 30-minute baseline 
clearance period (Baseline), urine was collected, at higher mean BPs, during two 
subsequent 30-minute clearance periods (Clearance 1 and 2) that followed sequential 
arterial ligation.  Systolic and diastolic BP were recorded continuously and mean BP 
was calculated post acquisition (Chapter 2.6, page 66).  Arterial blood samples 
(0.3µl) were obtained at the beginning and end of every clearance period.  Urinary 
sodium concentrations were measured (Chapter 2.6, page 74).  Urine flow rate (UV), 




fractional excretion of sodium (FENa) were calculated (Chapter 2.6, pages 74-76).  
Where appropriate, measurements were indexed to kidney weight (gkw). 
 
 Control  Diabetic 
Number 8        7 
Weight 
(g) 





Table 4.1 Number, weight and blood glucose (BG) of control and diabetic rats, immediately 
prior to general anaesthesia for ligature-induced acute pressure natriuresis 
Data are mean ± standard error of the mean (SEM), **=P<0.05 compared with diabetics.  All 
comparisons made with two-sample Student’s t-tests. 
 
Fig. 4.1 Timeline for ligature-induced acute pressure natriuresis  




4.2.3 Effect of insulin treatment on acute pressure natriuresis in diabetic rats 
In a second series of experiments, ligature-induced acute pressure natriuresis was 
repeated but with an additional cohort of T1DM+insulin rats (Table 4.2).  
Concentrations of UET-1, a marker of renal ET-1 activity 209, were also measured by 
commercial enzyme-linked immunosorbent assay (ELISA; Chapter 2.3, page 56).  
UET-1 excretion rate (UET-1V) was calculated (Chapter 2.6, page 76). 
 
 
   Control   Diabetic       Insulin 
Number          9          7          8 
Weight 
(g) 
399.5±12.9 338.3±18.5** 362.7±9.1 
BG 
(mmol/l) 
    4.8±0.2   16.8±1.8**     9.3±0.6* 
 
Table 4.2 Number, weight, and blood glucose (BG) in control, diabetic and insulin-treated 
diabetic rats, immediately prior to general anaesthesia for ligature-induced acute pressure 
natriuresis 
Data are mean ± standard error of the mean (SEM),*=P<0.05 compared with diabetics, 
**=P<0.05 compared with controls.  All comparisons made with one-way analysis of variance 
(ANOVA) with Tukey’s post hoc tests.  
 
4.2.4 Biochemical and molecular assessment of renal injury and activation of the 
renin-angiotensin-aldosterone system 
Urine was collected for 24 hours from eight control, eight early T1DM and eight 
T1DM+insulin rats placed in metabolic cages (Chapter 2.2, page 48; Table 4.3).  To 




concentrations were measured with adapted commercial kits (Chapter 2.3, page 56).  
Activity of the renin-angiotensin-aldosterone system (RAAS) was determined from 
urinary aldosterone concentrations measured by an in-house ELISA (Chapter 2.3, 
page 56).  Albumin and aldosterone were both indexed to creatinine.  Twenty-four-
hourly UET-1 excretion, a marker of diabetic renal injury 261, was calculated by 
multiplying 24-hourly urinary volume by urinary ET-1 concentration as determined 
by commercial ELISA.  The value was indexed to kidney weight.   
 
 Control Diabetic Insulin 
Number          8          8   8 
Weight 
(g) 
383.8±7.7 359.5±12.4 372.7±13.0 
BG 
(mmol/l) 
  6.8±0.3   22.0±3.0**   10.5±0.9* 
Table 4.3 Number, weight and blood glucose (BG) in control, diabetic and insulin-treated 
diabetic rats during a metabolic cage study, prior to tissue collection 
Data are mean ± standard error of the mean (SEM), *=P<0.05 compared with diabetics, 
**=P<0.05 compared with controls.  All comparisons made with one-way analysis of variance 
(ANOVA) with Tukey’s post hoc tests.  
 
Following removal from the metabolic cages, rats were anaesthetised for tissue 
collection (Chapter 2.2, pages 49-55).  The left kidney was removed, and sections of 
cortex and medulla were snap-frozen separately on dry ice for subsequent extraction 
of messenger ribonucleic acid (mRNA).  Tissues were then perfusion-fixed with 4% 
paraformaldehyde (PFA) 229, the right kidney was removed, paraffin-embedded, and 





Semi-quantitative polymerase chain reaction (qPCR) of renal tissue (Chapter 2.4, 
pages 57-60) measured expression of markers of renal injury, inflammation and 
fibrosis.  Total RNA was extracted from pulverised snap-frozen renal cortex and 
medulla from control, early T1DM and T1DM+insulin rats.  First-strand 
complementary deoxyribonucleic acid (cDNA) was reverse transcribed and 
amplified (qPCR) with exon-spanning, unlabelled, rat-specific primers for renal 
injury and fibrosis (kidney injury molecule-1 (KIM-1), collagen (Col) 1a1, Col3a1 
and cluster of differentiation 68 (CD68)) mixed with a fluorescein amidite (FAM) 
dye-labelled Taqman probe (ThermoFisher Scientific Inc, Glasgow, UK; Table 4.4).  
Using the change in cycle threshold (ΔCT) method, fluorescence of the FAM probes 
was compared to reference genes 3-phophate dehydrogenase (GAPDH) and thymine-
adenine-thymine-adenine (TATA) box binding protein (TBP) 232, which had been 
previously compared between cohorts to confirm they were unchanged by diabetic 
status.  Where differences were identified, the fold-difference was calculated using 
the ΔΔCT method 
233. 
 
Glomerulosclerosis and renal fibrosis were assessed histologically.  Fixed, sectioned 
renal tissue, from control and early T1DM rats only, was stained with haematoxylin 
and eosin (H&E), and the pancollagen marker picrosirius red, using standard 
protocols (Chapter 2.5, pages 61-62).  For each rat, the glomerulosclerosis index was 
calculated from all glomeruli in one sagittal section of kidney stained with H&E, and 
viewed, single-blind, under a 20x objective lens (Chapter 2.5, pages 62-63).  The 




(10 cortical, 10 medullary) was determined using Photoshop software (Adobe 












Exon boundary Location Length Approximate probe sequence 
KIM-1 Renal injury Rn00597703_m1 5-6 1264 60 5'TAATCACACTGTAAGAATCCCTTTGAG3' 
Col1a1 Renal fibrosis Rn01463848_m1 1-2 189 115 5'GCCAAGAAGACATCCCTGAAGTCAGCT3' 
Col3a1 Renal fibrosis Rn01437681_m1 48-490 3921 71 5'ACTCAAGAGCGGAGAATACTGGGTTGA3' 
CD68 Macrophage Rn01495634_g1 5-6 911 62 5'TTCGGGCCATGCTTCTCTTGCGCCAGT3' 
GAPDH Reference gene Rn01775763_g1 8-8 1153 174 5'GAGGAGTCCCCATCCCAACTCAGCCCC3' 
TBP Reference gene Rn01455646_m1 4-5 791 75 5'TAATCCCAAGCGGTTTGCTGCAGTCAT3' 
Table 4.4 Semi-quantitative polymerase chain reaction (qPCR) probes selected for determining renal injury 
The probe sequence is not released by the manufacturer (ThermoFisher Scientific).  The approximate probe sequence within the amplicon is derived from 
adding 13 nucleotides upstream and downstream of the assay location, using the Reference Sequence Database of the National Center for Biotechnology 
Information (NCBI, Bethesda, United States (US)), KIM-1=kidney injury molecule-1, Col=collagen, CD=cluster of differentiation, GAPDH= glyceraldehyde 




4.2.5 Statistical analysis 
Studies were designed to obtain a power >80% if cohort sizes were six rats and 
UNaV in diabetic rats was 50±25% 262 of the expected value in controls 112.  
Additional rats were included to account for an expected dropout rate of 25% based 
on experimental mortality in Chapter 3, and to ensure controls were 
contemporaneous.  
 
Data were expressed as mean ± standard error of the mean (SEM) and analysed with 
Minitab 17 (Minitab Ltd, Coventry, UK) and GraphPad Prism 6.0 (GraphPad 
Software, La Jolla, US).   
 
Single comparisons (weight, blood glucose and renal injury) between two cohorts 
were made with two-sample Student’s t-tests (normal) or Mann Whitney U-tests 
(non-normal) according to normality (Anderson-Darling test), while multiple 
comparisons between three cohorts employed one-way analysis of variance 
(ANOVA) with Tukey’s post hoc tests (normal) or Kruskal Wallis with Dunn’s post 
hoc tests (non-normal).  Data for all ANOVAs were transformed by log or  
square-root transformation according to normality and equality of variance of 
residuals.   
 
For acute pressure natriuresis, two-way ANOVA with Sidak’s (two cohorts) or 
Tukey’s (three cohorts) post hoc tests confirmed similar Baseline mean BP and 




similarly compared, and interaction between diabetic status and clearance period was 
calculated.   
 
As additional analyses, dependent variables were plotted against BP and regression 
lines compared by analysis of covariance (ANCOVA) with Tukey’s post hoc tests 
(linear) and extra sum of squares F-tests (non-linear).  Correlations between 
dependent variables used Pearson’s (normal) or Spearman’s rank (non-normal) tests.   
 
For all tests, statistical significance was set at P<0.05.  
 
4.3 Results 
4.3.1 Effects of Type 1 diabetes mellitus on acute pressure natriuresis 
Two control rats died prior to inducing acute pressure natriuresis- one died 
immediately after induction of anaesthesia, and the other developed severe 
hypotension following cystotomy.  One early T1DM rat was euthanased (Chapter 2.1, 
page 46) because of excessive weight loss.  None of these rats is included in the data 
presented.   
 
Baseline mean BP (aggregated mean 136±3mmHg) and the increase in mean BP 
following sequential arterial ligation (~25mmHg) did not differ between early T1DM 
and control rats (Fig. 4.2A, Table 4.5).  GFR rose as mean BP rose (P<0.01;  
Figs. 4.2B,C; Table 4.5), independently of diabetic status (interaction P=0.13).  




versus 1.6±0.1ml/min/gkw, P=0.011) but did not differ from controls during 
individual clearance periods (Table 4.5). 
 
There were a significant pressure diuresis (P<0.01; Figs. 4.3A,B) and natriuresis 
(P<0.01; Fig. 4.3C,D), largely reflecting inhibition of tubular sodium reabsorption, 
since FENa also increased as mean BP rose (P<0.01; Figs. 4.3E,F; Table 4.5).  Early 
T1DM substantially suppressed both the pressure diuresis and natriuresis 
relationships (both P<0.01, interactions P<0.01 (UV) and P=0.05 (UNaV)).  During 
Clearance 2, UV reached only 24% (P<0.01; Figs. 4.3A,B; Table 4.5) and UNaV 
only 14% (P<0.01; Figs. 4.3C,D; Table 4.5) of the values obtained in controls, 
despite similar increases in mean BP.  There was a linear relationship between UV 
and mean BP in both cohorts (both P<0.01; Fig. 4.3B) but the slope of the pressure 
diuresis response was markedly reduced in early T1DM (P<0.01).  UNaV and FENa 
increased in a nonlinear manner in both cohorts (Figs. 4.3D,F) but the rate of 




















Fig. 4.2. Mean blood pressure (BP) and glomerular filtration rate (GFR) during  
ligature-induced acute pressure natriuresis in control and diabetic rats 
A) Baseline mean BP and increments were not significantly different between cohorts, columns 
show mean ± standard error of the mean (SEM), *=P<0.05 compared with mean BP in previous 
period, NS=not significant.  All comparisons made with two-way analysis of variance (ANOVA) 
with Sidak’s post hoc tests. 
B) GFRs were similar between cohorts during every clearance period.  Every data point is the 
mean value of the dependent variable plotted against mean BP±SEM of both variables, and 
corresponds to one of three clearance periods.   

































Fig. 4.3. (page opposite) Ligature-induced acute pressure natriuresis in control and diabetic 
rats 
A) Pressure diuresis responses, with reduced urine flow rate (UV) in diabetic rats during 
Clearance 2   
B) Pressure diuresis responses, with reduced gradient of the regression line for UV in diabetic 
rats (0.11-0.49, 95% confidence) compared with controls (0.9-2.9)   
C) Pressure natriuresis responses, with reduced urinary sodium excretion rate (UNaV) in 
diabetic rats during Clearance 2   
D) Pressure natriuresis responses, with reduced nonlinear rise in UNaV in diabetic rats (growth 
constant (k) =0.01) compared with controls (k=0.05)   
E) Reduced fractional excretion of sodium (FENa) in diabetic rats during all three clearance 
periods    
F) Reduced nonlinear rise in FENa in diabetic rats (k=0.01) compared with controls (k=0.04)    
For A), C) and E), every data point is the mean value of the dependent variable plotted against 
mean blood pressure (BP) ± standard error of the mean (SEM) of both variables, and 
corresponds to one of three clearance periods, **=P<0.05 compared with controls.  All 
comparisons made with two-way analysis of variance (ANOVA) with Sidak’s post hoc tests.   





 Baseline Clearance 1 Clearance 2 
   Control   Diabetic   Control   Diabetic  Control    Diabetic 
BP 
(mmHg) 
136.6±2.9 135.6±6.0 152.7±4.2 154.4±5.3 162.8±3.6 162.4±3.8 
GFR 
(ml/min/gkw) 
    1.2±0.1    1.2±0.1   1.7±0.2    1.4±0.1 2.0±0.1     1.5±0.1 
UV  
(µl/min/gkw) 
    7.6±0.9     8.3±1.1   27.6±8.5   18.4±2.6 93.7±11.1 22.9±2.9** 
UNaV 
(µmol/min/gkw) 
   1.4±0.2     0.9±0.1    7.0±2.1     2.0±0.3 22.7±3.3   3.2±0.7** 
FENa 
(%) 
   2.7±0.4 0.5±0.1**   8.1±2.2    1.0±0.2** 25.4±3.9   1.4±0.3** 
Table 4.5 Mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), 
urinary sodium excretion rate (UNaV) and fractional excretion of sodium (FENa) in control and 
diabetic rats during Baseline and Clearances 1 and 2 
**=P<0.05 compared with controls.  All comparisons made with two-way analysis of variance 
(ANOVA) with Sidak’s post hoc tests.  
 
4.3.2 Effects of insulin treatment of Type 1 diabetes mellitus on acute pressure 
natriuresis 
One early T1DM rat was euthanased (Chapter 2.1, page 46) because of excessive 
weight loss.  This rat is not included in the data presented.   
 
Baseline mean BP (aggregated mean 110±2mmHg) and GFR (aggregated mean 
0.4±0.1ml/min/gkw) did not differ between the three cohorts (Table 4.6). Sequential 
arterial ligation induced significant increases in mean BP of ~35mmHg (P<0.01;  
Fig. 4.4A) that did not differ between cohorts.  GFR (Figs. 4.4B,C) rose as mean BP 
rose (P<0.01), in a linear manner (P<0.01), and independently of diabetic status 




Clearance 2, by~0.7±0.2ml/min/gkw (P=0.01; Fig. 4.4B; Table 4.6) but did not differ 















Fig. 4.4. Mean blood pressure (BP) and glomerular filtration rate (GFR) during  
ligature-induced acute pressure natriuresis in control, diabetic and insulin-treated diabetic rats 
A) There were similar Baseline mean BP and increments after ligation in all three cohorts.  
Columns show mean ± standard error of the mean (SEM), *=P<0.05 compared with mean BP in 
previous period, NS=not significant. 
B) GFR was lower in diabetic rats than in controls during Clearance 2.  Every data point is the 
mean value of the dependent variable plotted against mean BP±SEM of both variables, and 
corresponds to one of three clearance periods, **=P<0.05 compared with controls. 
C) GFR increased in the same linear manner in all three cohorts, R2=coefficient of 
determination.   
For A) and B), all comparisons made with two-way analysis of variance (ANOVA) with Tukey’s 






Pressure diuresis (Figs. 4.5A,B) and natriuresis (Figs. 4.5C,D) were again induced by 
increasing mean BP (both P<0.01) and suppressed overall by early T1DM (both 
P<0.01, interactions P<0.01 (UV) and P=0.03 (UNaV)), particularly during 
Clearance 2 (P<0.01 (UV) and P=0.02 (UNaV); Table 4.6).  This effect was 
associated with a reduction in FENa (P<0.01, interaction P=0.02; Figs. 4.5E,F), most 
noticeable during Clearance 2 (P=0.02; Table 4.6), that suggested differences in UV 
and UNaV could not be ascribed to differences in GFR.  By contrast, suppression of 
UV (P<0.01 versus early T1DM), UNaV and FENa (P=0.02 versus early T1DM; 
Table 4.6) was not observed in insulin-treated diabetic rats: the slopes of these linear 
relationships were comparable to controls (Figs. 4.5B,D and F); both were 

















Fig. 4.5. (page opposite) Ligature-induced acute pressure natriuresis in control, diabetic and 
insulin-treated diabetic rats 
A) Pressure diuresis responses, with lower urine flow rate (UV) in diabetic rats than  
insulin-treated diabetic rats and controls during Clearance 2   
B) Pressure diuresis responses, with reduced gradient of the regression line for UV in diabetic 
rats (0.6-1.4, 95% confidence) compared with insulin-treated diabetic rats (1.2-2.2) and controls 
(0.9-2.9) 
C) Pressure natriuresis responses, with lower urinary sodium excretion rate (UNaV) in diabetic 
rats than insulin-treated diabetic rats during Clearances 1 and 2, and compared with controls 
during Clearance 2   
D) Pressure natriuresis responses, with reduced gradient of the regression line for UNaV in 
diabetic rats (0.2-0.6, 95% confidence) compared with insulin-treated diabetic rats (0.4-1.0) and 
controls (0.6-1.1) 
E) Lower fractional excretion of sodium (FENa) in diabetic rats compared with insulin-treated 
diabetic rats during Clearances 1 and 2, and compared with controls during Clearance 2    
F) FENa responses, with reduced gradient of the regression line in diabetic rats (0.1-0.3, 95% 
confidence) compared with insulin-treated diabetic rats (0.3-0.7) and controls (0.4-0.6) 
 
For A, C) and E), every data point is the mean value of the dependent variable plotted against 
mean blood pressure (BP) ± standard error of the mean (SEM) of both variables, and 
corresponds to one of three clearance periods, **=P<0.05 compared with controls, *=P<0.05 
compared with diabetics.  All comparisons made with two-way analysis of variance (ANOVA) 









 Baseline Clearance 1 Clearance 2 
 Control    Diabetic  Insulin   Control Diabetic Insulin Control    Diabetic   Insulin 
BP 
(mmHg) 
111.0±2.4 107.7±3.8 110.2±3.6 123.4±4.0 118.9±4.2 119.0±2.5 146.6±5.6 141.9±4.5 152.1±2.4 
GFR 
(ml/min/gkw) 
    0.4±0.0     0.3±0.0     0.4±0.1     0.5±0.0   0.4±0.1  0.7±0.1     1.4±0.2     0.7±0.2** 1.0±0.1 
UV  
(µl/min/gkw) 
    4.0±1.1     2.9±0.5     8.4±2.9   13.6±2.8  7.0±1.5  27.9±9.0   99.7±11.2   42.1±10.6**  90.6±9.8* 
UNaV 
(µmol/min/gkw) 
    0.3±0.2     0.3±0.0     1.3±0.5     3.3±1.5  0.8±0.4  16.7±6.7*   36.1±5.4   14.6±4.8** 35.8±4.9* 
FENa 
(%) 
    0.5±0.2     0.8±0.6    2.0±0.6*    5.0±2.3  1.3±0.7 13.5±4.6*   20.9±3.9   13.0±2.2** 27.7±3.5* 
UET-1V 
(fg/min/gkw) 
    3.8±0.8 4.3±1.0 6.3±2.5    7.6±1.6  4.8±1.1  10.6±4.1  37.6±6.4   13.4±3.9** 28.9±7.1 
Table 4.6 Mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate (UNaV), fractional excretion of 
sodium (FENa) and urinary endothelin-1 excretion rate (UET-1V) in control, diabetic and insulin-treated diabetic rats during Baseline and Clearances 1  
and 2 
*=P<0.05 compared with diabetics, **=P<0.05 compared with controls.  All comparisons made with two-way analysis of variance (ANOVA) with Tukey’s 
post hoc tests 





4.3.3 Relationships of renal endothelin-1 with mean blood pressure, urinary 
sodium and water excretion and diabetic status 
UET-1V increased with mean BP (P=0.02, interaction P=0.05; Figs. 4.6A,B;  
Table 4.5).  By the end of Clearance 2, the increase in UET-1V by ~30fg/min/gkw 
was suppressed by early T1DM by ~25fg/min/gkw (P<0.01; Fig. 4.6A; Table 4.6) 
but recovered with insulin (P=1.0 and 0.05 versus control and early T1DM rats 
respectively).  The rise in UET-1V was linear in all three cohorts (control P<0.01; 
diabetic P<0.01; insulin-treated diabetic P<0.01; Fig. 4.6B) and correlated strongly 




Fig. 4.6. Relationships of urinary endothelin-1 excretion rate (UET-1V) with mean blood 
pressure (BP), urine flow rate (UV) and urinary sodium excretion rate (UNaV) in control, 
diabetic and insulin-treated diabetic rats 
A) Lower UET-1V in diabetic rats than controls during Clearance 2, every data point is the mean 
value of the dependent variable plotted against mean BP ± standard error of the mean (SEM) of both 
variables, and corresponds to one of three clearance periods, **=P<0.05 compared with controls, all 
comparisons made with two-way analysis of variance (ANOVA) with Tukey’s post hoc tests.   
B) Changes in UET-1 V with mean BP, with reduced gradient of the regression line in diabetic rats 
(0.07-0.40, 95% confidence) compared with insulin-treated diabetics (0.23-0.81) and controls  
(0.44-0.99), **=P<0.05 compared with controls, R2=coefficient of determination 
C) Strong correlations between UET-1V and UV regardless of diabetic status 
D) Strong correlations between UET-1V and UNaV regardless of diabetic status 













4.3.4 Biochemical, histological and molecular assessment of renal injury 
All of the rats that entered these experiments, completed them.  The urinary 
albumin:creatinine ratio was slightly higher in early T1DM rats than controls by 
~0.17mg/mg (P=0.02; Fig. 4.7A; Table 4.7) but no different in T1DM+insulin rats.   
 
Aldosterone:creatinine ratios (aggregated mean 0.76±0.32ng/mg) and 24-hourly 
UET-1 excretion (aggregated mean 39.4±10.6pg/day) were not different between 
cohorts (Figs. 4.7B,C).  Similarly, the cortical (Fig. 4.8A) and medullary (Fig. 4.8B) 
expressions of mRNA of all the renal injury markers tested were unchanged in early 
T1DM and T1DM+insulin rats (Table 4.7).   
 
Glomerulosclerosis was not observed on any H&E stained sections (Figs. 4.9A,B).  
Cortical (Figs. 4.9C,D) and medullary staining (Figs. 4.9E,F) with picrosirius red did 
not differ over 160  fields (x20 objective) in control and early T1DM cohorts  
























Fig. 4.7. Urinary markers of renal injury and activation of the renin-angiotensin-aldosterone 
system (RAAS) in control, diabetic and insulin-treated diabetic rats  
A) Urinary albumin:creatinine was higher in diabetic rats than controls.  Although statistically 
significant, the difference was not physiologically significant. 
B) Urinary aldosterone:creatinine did not differ between cohorts. 
C) Twenty-four-hourly urinary endothelin-1 (ET-1) excretion did not differ between cohorts. 
Columns show mean ± standard error of the mean (SEM), **=P<0.05 compared with controls.  All 
comparisons made with one-way analysis of variance (ANOVA) or Kruskal Wallis with Tukey’s or 























Fig. 4.8. Expression of markers of renal injury in control, diabetic and insulin-treated 
diabetic rats 
A) Expression of kidney injury molecule-1 (KIM-1), collagen (Col) 1a1, Col3a1, and cluster of 
differentiation (CD) 68 in the renal cortex did not differ between cohorts.  
B) Expression of KIM-1, Col1a1, Col3a1, and CD68 in the renal medulla did not differ between 
cohorts. 
ΔCT refers to the cycle threshold referenced to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH).  Columns show mean ± standard error of the mean (SEM).  All comparisons made 
with one-way analysis of variance (ANOVA) or Kruskal Wallis with Tukey’s or Dunn’s post hoc 







Fig. 4.9. Renal histopathology in control and diabetic rats   
A) and B) Glomerulosclerosis was absent on haematoxylin and eosin staining, as demonstrated 
in the central glomerulus.   
C) and D) Picrosirius red staining for collagen in the cortex (arrows indicate glomeruli) did not 
identify fibrosis. 
E) and F) Picrosirius red staining for collagen in the medulla did not identify fibrosis.  Positive 








 Control Diabetic Insulin 
Albumin:creatinine (mg/mg) 0.28±0.03     0.45±0.04** 0.43±0.08 
Aldosterone:creatinine (ng/mg) 0.83±0.78 0.37±0.15 0.83±0.50 
ET-1 excretion (pg/day) 30.25±12.01 47.38±10.32 36.26±24.93 
 Cortex Medulla Cortex Medulla Cortex Medulla 
CT GAPDH   25.2±1.5 23.1±0.4 22.6±0.2 22.9±0.2 23.2±0.2 22.9±0.5 
CT TBP   32.2±0.3 31.2±0.4 31.7±0.2 31.7±0.2 32.2±0.2 31.8±0.5 
ΔCT KIM-1 8.3±1.2   9.7±0.7    9.9±0.6   8.4±0.7   9.8±0.3 10.1±0.9 
ΔCT Col1a1 8.7±1.4 10.3±0.5  10.4±0.4 10.4±0.3 10.1±0.3 10.2±0.6 
ΔCT Col3a1 5.1±1.4   5.4±0.7    6.4±0.5   5.8±0.3   6.3±0.2   5.7±0.7 
ΔCT CD68 5.5±1.5   6.8±0.2    7.0±0.2   6.8±0.3   6.6±0.3   6.0±0.6 
Picrosirius staining 0.41±0.02   0.52±0.08    0.36±0.03   0.29±0.03 - - 
Table 4.7 Markers of renal injury 
All data are mean ± standard error of the mean (SEM), **=P<0.05 compared with controls.  All comparisons made with one-way analysis of variance 
(ANOVA) or Kruskal Wallis with Tukey’s or Dunn’s post hoc tests, ΔCT refers to the threshold cycle referenced to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH).  ET-1=endothelin-1, TBP= thymine-adenine-thymine-adenine (TATA) box binding protein, KIM-1=kidney injury molecule-1,  





This chapter describes the first direct assessment of acute pressure natriuresis in early 
T1DM rats.  It demonstrates that acute pressure natriuresis is severely impaired 
within three weeks of inducing T1DM, before clear evidence of renal injury and 
fibrosis has developed.  The effect can be reversed with insulin, and is associated 
with changes in UET-1 excretion.  Acute pressure natriuresis stabilises BP, so it is 
concluded that functional changes that may contribute to cardiovascular risk are 
present at an early stage of T1DM, prior to the onset of nephropathy.   
 
4.4.1 Type 1 diabetes mellitus severely blunts acute pressure natriuresis by 
increasing tubular sodium reabsorption. 
After adopting renal clearance times derived from Chapter 3, sequential arterial 
ligation gave predictable rises in BP, generating a robust and controllable 
experimental protocol.  This permitted statistically rigorous comparisons between 
cohorts, and investigation of a potential causative mechanism.  Attenuation of UV 
and UNaV at higher BPs in the early T1DM rats was accompanied by a striking 
reduction in FENa, showing that excessive sodium reabsorption made a greater 
contribution than a slightly lowered GFR to reduced sodium excretion.   
 
A smaller FENa might have been expected in the early T1DM rats because T1DM 
increases sodium reabsorption in the proximal convoluted tubule (PCT) 263.  
However, this would have increased rather than decreased GFR by reducing 
tubuloglomerular feedback (TGF) and increasing afferent arteriolar flow 263.  The 




and, importantly, increased GFR and renal blood flow would have been confounding 
variables in this study.  A rat model of early T1DM, only two-to-three weeks after 
STZ injection, was deliberately selected because STZ-induced T1DM rats take 
several weeks to develop hyperfiltration 72, and even Dahl salt-sensitive rats take 
nine weeks to demonstrate increased GFR and increased renal blood flow 264.  The 
GFR of the model had already been shown to match GFR in healthy controls under 
prolonged anaesthesia (Chapter 3), and there was no biochemical, histological or 
molecular evidence of renal pathology or RAAS activation.  Although urinary 
albumin levels were slightly higher in the earlyT1DM rats, the levels were not 
consistent with significantly increased glomerular permeability 72.  Therefore, it was 
concluded that impaired acute pressure natriuresis precedes hyperfiltration in early 
T1DM rats and cannot be explained by reduced TGF, RAAS activation or structural 
nephropathy. 
 
Acute pressure natriuresis is a renal vasculotubular response to increases in BP.  
Medullary blood flow, which, unlike cortical flow and GFR, is not autoregulated, 
rises in line with BP 138.  Medullary hydrostatic pressures also rise, and there is a 
reduction in sodium reabsorption, principally from the PCT 91, although the overall 
natriuretic effect is also dependent on sodium transport activity in the more distal 
nephron 186,265.  Impaired excretion of sodium and water has been identified 
previously in T1DM rats 108,109,266 but this study shows that it results from either 





4.4.2 Impairment of acute pressure natriuresis is reversed with insulin. 
In these experiments, impairment of acute pressure natriuresis by early T1DM was 
reversed when blood glucose was reduced with insulin.  Whether this was a 
consequence of lowering blood glucose or a direct effect of insulin was not 
determined, but the latter is a possibility since the effects of insulin on sodium 
reabsorption are well documented 238.  Insulin stimulates ENaC as well as other renal 
transporters 267, and in hyperinsulinaemia due to Type 2 diabetes mellitus (T2DM), 
sodium-glucose transporter-2 (SGLT2) inhibitors combat hypertension from 
enhanced sodium reabsorption 268.  However, insulin also promotes sodium excretion, 
which is more consistent with the recovery of acute pressure natriuresis in this study.  
This occurs through the actions of the vasodilator, NO 146,269, which also mediates the 
vasodilatory effects of ET-1, and its pro-natriuretic effects at ENaC 122, raising the 
possibility that insulin could modify acute pressure natriuresis via vascular or tubular 
renal ET-1.   
 
4.4.3 Urinary endothelin-1 excretion rate varies with urine flow rate and urinary 
sodium excretion rate, regardless of diabetic status. 
All ET-1 in urine is renally derived 77 so UET-1 excretion was used in these 
experiments as a surrogate marker of renal ET-1 activity 209.  Twenty-four-hourly 
UET-1 excretion failed to demonstrate increased chronic renal ET-1 signalling in the 
early T1DM model, but this probably reflected the absence of overt glomerular 
remodelling 261.  By contrast, during acute pressure natriuresis, UET-1V increased 
abruptly, and matched marked increases in UV and UNaV in control and 




T1DM rats.  UET-1V and UNaV are both a function of flow rate, and so the data 
demonstrate that the urinary concentrations of ET-1 and sodium were maintained, 
even at higher urine flow rates.  This is consistent with release of ET-1 from the 
collecting duct in response to urine flow and sodium 270,271, suggesting that the 
increase in UET-1V in control and T1DM+insulin rats, and the decrease in UET-1V 
in early T1DM rats may have been more a consequence rather than a cause of 
changes to UV and UNaV.  However, although collecting duct ET-1 is a component 
of a negative feedback loop of ENaC activity that includes nitric oxide synthase 1 
(NOS1) 272, a negative feedback loop of ET-1 release has not been identified.  
Collecting duct ET-1 is an autocrine/paracrine agent that promotes natriuresis, so, in 
the absence of negative feedback, there is the potential for it to mediate a runaway 
natriuresis during pre-existing polyuria, as in glycosuria in untreated T1DM.  This 
clearly did not take place during acute pressure natriuresis in the early T1DM rats, so 
an alternative explanation for the suppression of UET-1V, UV and UNaV in T1DM 
is required.   
 
Collecting duct ET-1 expression and ETB receptor activity can be modified by many 
intrarenal regulatory mechanisms but because of their complex, conflicting 
interactions with ET-1 and ETB receptors, how these might restrict increases in 
collecting duct ET-1 in T1DM is not apparent.  For example, vasopressin and 
angiotensin II (AngII) can reduce collecting duct ETB receptor activity 
273,274.  
Equally, though, ETB receptor activity reduces collecting duct vasopressin-2 (V2) 
receptor activity 275, and, in these experiments, RAAS activation in the early T1DM 




expression in collecting duct cells 276 but activation of purinergic-2 (P2) receptors in 
the renal medulla promotes ET-dependent natriuresis 277.   
 
An alternative source of UET-1 may provide additional insight.  Studies in collecting 
duct ET-1 knockout (KO) mice 180 and with ETB receptor antagonists 
209 suggest that 
approximately half of UET-1 is an overspill from the collecting duct, and the other 
half is from the renal interstitium, the site of the medullary vasa recta where acute 
pressure natriuresis is initiated by an increase in BP.  ET-1 regulates flow through the 
vasa recta by constriction (ETA) 
182 or relaxation (ETB) 
278 of surrounding vascular 
pericytes, and endothelial ETB receptors clear locally produced ET-1 from the 
circulation 77.  T1DM is already known to increase vascular ETA receptor-mediated 
constriction 257,258, reduce endothelial ETB receptor activity 
255 and promote activity 
of ENaC 265.  This means that the reductions in UET-1, UV and UNaV observed in 
the early T1DM rats may reflect an increase in medullary vascular ETA receptor 
activity or a decrease in medullary vascular and/or collecting duct ETB receptor 
activity (Fig. 4.10).  This is an attractive theory because it links the renal vascular 
and tubular functions of ET-1 with the vascular and tubular stages of acute pressure 
natriuresis.  It also links UET-1 with BP to prevent a runaway collecting duct  
ET-1-mediated natriuresis, and offers potential mechanisms by which these might be 
modified by early T1DM.  
 
The possibility that early T1DM impairs acute pressure natriuresis through increased 
vascular ETA receptor activity is important because it could be amenable clinically to 




natriuresis and cardiovascular risk can be demonstrated in the same rat model of 
early T1DM, then further investigation of the causal role of ET-1 and its receptors in 
the suppression of acute pressure natriuresis in early T1DM, and its recovery with 
insulin would be indicated.   
 
Fig. 4.10 Algorithm proposing mechanisms by which early Type 1 diabetes mellitus (T1DM) 
and insulin modify regulation of acute pressure natriuresis by endothelin-1 (ET-1). 
Lines blocking arrows represent inhibition. 





Impairment to acute pressure natriuresis, a precursor to hypertension and 
nephropathy, occurs at a very early stage of experimental T1DM, prior to structural 
nephropathy.  The response is reversed with insulin and is associated with changes in 
renal ET-1 signalling.   
 
This study is relevant to the development of CVD risk in T1DM patients.  By 
successfully re-establishing acute pressure natriuresis in an early T1DM rat model 
with insulin, these pre-clinical data support the findings of DCCT/EDIC 24,29 that 
cardiovascular risk is tightly linked to blood glucose control.  They also suggest that 
acute pressure natriuresis may be a therapeutic target where tight blood glucose 
control cannot be achieved.  Existing drugs, such as the selective ETA receptor 
antagonists, might achieve this.     
 
4.5.1 Follow-on work 
The full implications from these data towards reducing cardiovascular risk in T1DM, 
should be determined.  The following chapter will assess the impact of such 
profound suppression of acute pressure natriuresis on BP control, and whether 




5 The effect of Type 1 diabetes mellitus on 






Acute pressure natriuresis plays a key role in regulating blood pressure (BP) by 
increasing sodium excretion when BP increases 89.  In the previous chapter, Type 1 
diabetes mellitus (T1DM) was shown to impair acute pressure natriuresis severely.  
Such impairment has clinical relevance because it would be expected to increase BP.  
However, in the previous chapter, mean BP was not increased in either of the two 
untreated early T1DM cohorts in which acute pressure natriuresis was induced.  All 
BP measurements were obtained under general anaesthesia, following laparotomy, 
and it may be that this reduced BP more in diabetic rats than controls.  This thesis is 
investigating factors that contribute to increased cardiovascular risk in early T1DM 
and, because increased BP is a major risk factor for cardiovascular disease  
(CVD) 247-250, it is necessary to determine unequivocally whether impaired acute 
pressure natriuresis in early T1DM is associated with increased BP, before 
proceeding to experiments that investigate a causative mechanism.  Consequently, 
the experiments in this chapter are designed to measure systolic and diastolic BP in 
conscious rats with early T1DM.   
 
In people, acute pressure natriuresis is more active during the day, when most salt 
intake occurs, and less active at night, when there is less salt intake.  As a result, 
sodium excretion, and hence BP, follow a circadian pattern 100.  Both vary in a 
sinusoidal manner 237 with peak levels during the day, and trough levels during the 
night 100,101.  Disruption to the circadian rhythm in BP is associated with increased 
risk of CVD 102-104, and in patients with T1DM, occurs several years in advance of 




circadian rhythm also precedes elevated BP, as recorded in the clinic (office 
hypertension) 74.  Therefore, to identify the potential full influence of impaired acute 
pressure natriuresis on BP, continuous 24-hourly BP measurements rather than single, 
daily BP measurements are performed in this chapter.  This allows the peak and 
trough levels of BP to be recorded and the sinusoidal variation between these values 
to be determined 237.    
 
Also in the previous chapter, a link between renal endothelin-1 (ET-1) and impaired 
acute pressure natriuresis was established: urinary ET-1 excretion was suppressed 
when urinary sodium excretion was suppressed.  Renal ET-1 is of interest because it 
is highly expressed within the kidney by endothelial cells, vascular smooth muscle 
cells (VSMCs) and renal tubular cells 77, all of which contribute to acute pressure 
natriuresis 89.  T1DM increases expression and secretion of ET-1 205,254, enhances 
ETA receptor signalling 
257,258 and reduces endothelial ETB receptor-mediated 
vasodilation 259.  These effects promote vasoconstriction 77, and renal injury 154 
which would be expected to impair acute pressure natriuresis 89.  This is supported by 
clinical studies with ETA receptor antagonists, which re-establish circadian variation 
in BP in non-diabetic chronic kidney disease (CKD) 226, and reduce proteinuria and 
BP in diabetic nephropathy (both T1DM and T2DM) 220.  Whether or not ETA 
receptor antagonists re-establish circadian variation in BP in pre-clinical or clinical 
T1DM has not been determined, but if demonstrated, it would implicate an inhibitory 
effect of ETA receptors on acute pressure natriuresis that can be targeted 
pharmacologically.  Therefore, to determine whether ETA receptor signalling might 




T1DM, the effect of ETA and ETB receptor antagonists on 24-hourly BP in early 
T1DM rats was also measured.    
 
5.1.1 Hypotheses 
1. Early T1DM increases BP and disrupts the circadian profile of BP. 
2. This is reversed by selective ETA but not combined ETA/ETB receptor 
antagonism.   
 
5.1.2 Aims 
To investigate these hypotheses, radiotelemetric measurement of BP in a rat model of 
early T1DM was used to answer the following questions: 
1) Does early T1DM increase BP and disrupt its circadian variation, and do the 
effects increase when salt intake increases? 
2) Does a selective ETA receptor antagonist restore normal BP in early T1DM 
and its circadian variation? 
3) Does combined ETA/ETB receptor antagonism re-establish increased BP and 






5.2.1 Implantation of radiotelemetry units and randomisation 
Experiments were performed, single-blinded, in adult male Sprague Dawley rats 
(Chapter 2.1, page 46).  After rats had been acclimatised for six days (Fig. 5.1),  
pre-calibrated radiotelemetry units (TA11-CA P40; Data Sciences International,  
's-Hertogenbosch, Netherlands) were surgically implanted (Chapter 2.7, pages 76-79) 
over a four-day period in 16 rats.  The sensory catheter of the units was implanted 
into the distal aorta and the transmitter secured to the peritoneal aspect of the body 
wall.  After a minimum of 10 days’ recovery, skin staples were removed under brief 
anaesthesia with isoflurane (IsoFlo; Zoetis Animal Health Limited (Ltd.), Sandwich, 
United Kingdom (UK)).   
 
Following a further five-to-nine-day recovery period, rats were assigned to early 
T1DM and control cohorts on Day 20 (Fig. 5.1).  Heart rate, and systolic and 
diastolic BP were acquired at 1kHz for one minute in every hour, for seven days 
(Randomisation Recording; Fig. 5.1).  The beginning of every day was defined as the 
start of the dark period at 7pm.  Data from the middle five days were analysed to 
ensure that BP and heart rate did not differ between cohorts, by chance, prior to 
induction of T1DM.   
 
5.2.2 Induction of Type 1 diabetes mellitus 
T1DM (blood glucose >12mmol/l) was induced from Day 27 with one or two 
intraperitoneal (ip.) injections of streptozotocin (STZ); Chapter 2.1, page 46) and 





5.2.3 Recording blood pressure and circadian variation in blood pressure with 
radiotelemetry 
From Day 41, two weeks after the first ip. injection of STZ/citrate, systolic and 
diastolic BP, and heart rate were measured continuously by radiotelemetry  
(Chapter 2.7, page 79) in early T1DM and control rats (Table 5.1) for five more 
weeks (Fig. 5.1).  The first of these weeks confirmed that haemodynamic parameters 
had reached stability following induction of T1DM.  Data from the second week 
(Diabetes Recording Period, Days 48-55) were analysed to determine the effect of 
early T1DM.  During the third week (Salt Recording Period, Days 55-62), after the 
6pm but before the 7pm data acquisition, rats were offered salt supplementation in 
order to exaggerate any salt-sensitive phenotype.  The salt was in the form of an ice-
cube (~10ml)-sized gelatin (Dr. Oetker UK Ltd, Leyland, UK) block containing 
soluble meat extract (80mg sodium chloride/ml; Bovril; Unilever UK Ltd, 
Leatherhead, UK).  The quantity of meat extract was measured so that, for every rat, 
daily sodium intake was 140mg of sodium/day based on 15g/day daily intake of 
pelleted food 279.  This equated to a 1% sodium diet, four times the concentration of 
sodium in the unsupplemented diet.  One gelatin block was placed in every rat’s cage 
on top of a cardboard tube used for environmental enrichment, where it could be 





5.2.4 Modification of blood pressure and heart rate with endothelin receptor 
antagonists 
During the fourth week of recording, (Days 62-69, Fig. 5.1), the gelatin block was 
supplemented with the selective ETA receptor antagonist, atrasentan (5mg/kg 
154; 
AbbVie Ltd., Maidenhead, UK).  During the fifth and final week (Days 69-76), the 
gelatin block also contained the selective ETB receptor antagonist, A-192621 
(10mg/kg 154; AbbVie Ltd.).  After the final recording period, rats were euthanased 
by a Schedule one method (Chapter 2.1, page 46) and examined post mortem, to 












Fig. 5.1. Timeline (days) for radiotelemetry study  
Radiotelemetry units were implanted following acclimatisation after purchase.  All recording periods were seven days long but only data from the middle five 






 Radiotelemetry start Radiotelemetry end 
 Control Diabetic Control Diabetic 
Number     4          4 4          4 
Weight 
(g) 
331.0±3.6 316.8±2.7** 585.5±10.5 477.3±22.8** 
BG 
(mmol/L) 
   4.4±0.3 18.7±1.8**  5.1±0.3 19.5±1.1** 
Table 5.1. Number, weight and blood glucose (BG) in control and diabetic rats that completed 
the radiotelemetry study. 
Data are mean ± standard error of the mean (SEM), **=P<0.05 compared with controls.  All 
comparisons made with two-sample Student’s t-tests. 
 
5.2.5 Statistical analysis  
Studies were designed to obtain a power >80% if cohort sizes were six rats, BP was 
3.0±1.5mmHg higher in diabetic rats than in controls, and diurnal dipping in BP was 
3.0±1.5% lower in diabetics 280.  Additional rats were included to account for an 
expected dropout rate of 25% due to experimental mortality and technological 
malfunction (n=15).  
 
The first and last days of every seven-day recording period were excluded prior to 
analysis to remove confounding stress effects associated with weekly staff changes 
and routine husbandry.   
 
Data are expressed as mean values ± standard error of the mean (SEM).  Mean 




every rat contributed 30 values in total.  To illustrate changes in BP and heart rate 
over time in each cohort, the mean value ± SEM at the same time point in every one 
of the five days was plotted against 24 individual hours.  These data differed slightly 
from the data from every four-hour period. 
 
Normality of data were determined by the Anderson-Darling test, or if n<6, by visual 
assessment of data distribution 281.  Single comparisons of BP and heart rate between 
cohorts were made with two-sample Student’s t-tests (normal) or Mann Whitney  
U-tests (non-normal) according to normality, while multiple comparisons employed 
one-way analysis of variance (ANOVA) with Tukey’s post hoc tests with or without 
transformation according to normality and equality of variance of residuals.  Kruskal 
Wallis with Dunn’s post hoc tests was employed only where transformation was 
unsuccessful.   
 
Circadian variations in BP and heart rate were determined from diurnal dipping,  
24-hour-periodicity and cosinor analysis (Chapter 2.7, pages 79-80).  Diurnal dipping 
was defined as the percentage reduction in heart rate or BP at every light-to-dark 
transition.  It was calculated for every rat for every day, from the mean of three four-
hourly light periods and three four-hourly dark periods.  Every rat contributed one 
value of dipping per day for five days to the comparisons between cohorts.   
Twenty-four-hour-periodicity in each cohort was obtained from chi-square analysis 
of hourly heart rate and BP 237 .  Every rat contributed to every mean hourly value, 
and 24 mean values per day for five days were analysed.  Tau was assumed to be 




individual rats and used hourly measurements (24 data points per rat per day) for five 
days.  Welch’s t-test was used to compare the mean values of mesor, amplitude (amp) 
and acrophase (acro) in each cohort.   
 
Seven out of 15 rats failed to complete the study.  One rat died from intra-operative 
haemorrhage, one diabetic rat was euthanased due to excessive weight loss, one rat 
failed to become diabetic, and device malfunction occurred in four rats due to lead 
migration or thrombus formation over the lead tip.  Where applicable, these rats were 
euthanased.  None of the data from these rats is presented.   
 





5.3.1 Haemodynamic parameters prior to induction of Type 1 diabetes mellitus 
(Randomisation Recording Period) 
There was no difference in systolic and diastolic BP and heart rate between rats 
assigned to control and early T1DM cohorts prior to induction of T1DM (Table 5.2;  
Fig. 5.2). 
 
     RRP        Systolic BP        Diastolic BP       Heart rate 
 
Control Diabetic Control  Diabetic Control Diabetic 
Mean 
(mmHg/bpm) 
 124.1±0.5 124.2±0.4 93.8±0.4 91.9±0.3 405.1±2.5 406.1±2.4 
Dip 
(%) 
  4±1     3±1   5±0      5±0 12±1        13±1 
Mesor 
(mmHg/bpm) 
123.5±4.5 124.9±3.8 93.8±2.7 91.5±3.2 402.4±13.5 406.6±12.1 
Amp 
(mmHg/bpm) 
    3.9±0.3     3.2±0.3   3.7±0.9   2.8±0.9 39.9±4.5 42.0±4.7 
Acro 
(radians) 
26.7±16.1    20.5±17.0  27.1±11.2 41.7±13.1 11.9±5.7   5.0±4.8 
Table 5.2. Means, dips and cosinor analysis values for systolic and diastolic blood pressure (BP) 
and heart rate in rats assigned to control and diabetic cohorts rats during the Randomisation 
Recording Period (RRP) 
Data are mean ± standard error of the mean (SEM).  Comparisons made with two-sample 
Student’s t-tests for means and dips, and Welch’s t-test for cosinor analysis. 








Fig. 5.2. Twenty-four-hourly blood pressure (BP) and heart rate (beats per minute) with dips 
in rats assigned to control and diabetic cohorts during the Randomisation Recording Period 
A) Systolic BP did not differ between cohorts. 
B) Diastolic BP did not differ between cohorts. 
C) Heart rate did not differ between cohorts.   
D) Dipping in BP and heart rate did not differ between cohorts, bars=mean ± standard error of the 
mean (SEM). 
For A), B) and C), every data point is the mean ± SEM of every reading in every rat at that time point 










5.3.2 Stability of haemodynamic parameters two weeks after induction of Type 1 
diabetes mellitus (Stability Recording Period) 
Subjective assessment of graphs of systolic and diastolic BP and heart rate (Fig. 5.3), 
showed that dark-to-light dipping in all these parameters was established in both 
cohorts by the second dark-to-light transition of the five-day Stability Recording 
Period.  Differences between cohorts reached stability by the third dark-to-light 










 Fig. 5.3. Twelve-hourly blood pressure (BP) and heart rate (beats per minute) in control and diabetic rats during the Stability Recording Period 
A) Variation in systolic BP was established in control rats by the second dark-to-light period.  The difference between cohorts had narrowed by the end of the 
recording period.   
B) Variation in diastolic BP was established in diabetic rats by the second dark-to-light period.  Differences between cohorts were subsequently maintained.   
C) Variation in heart rate (beats per minute) was well established in both cohorts throughout the recording period.  There was a trend towards a lower heart 
rate in both cohorts during the final two dark-to-light periods. 









5.3.3 Effects of Type 1 diabetes mellitus on blood pressure (Diabetes Recording 
Period) 
Twenty-four-hourly systolic BP (Fig. 5.4A) was not different between cohorts 
(~126mmHg) but 24-hourly diastolic BP (Fig. 5.4B) was 5mmHg higher in early 
T1DM rats (P<0.01; Table 5.3).  Mean heart rate was lower in early T1DM rats by 
~20 beats/min (P<0.01; Table 5.3; Fig. 5.4C).  
 
5.3.4 Effects of Type 1 diabetes mellitus on circadian variation (Diabetes 
Recording Period)  
Circadian variation in systolic BP (dipping ~3%, mesor ~127mmHg, amplitude 
~3mmHg and acrophase ~70 radians) and heart rate (dipping ~14%, mesor  
350 beats/min, amplitude ~40 beats/min and acrophase ~74 radians) were similar 
between cohorts (Table 5.3; Figs. 5.4A,C).  By contrast, there were abnormalities in 
the circadian variation in diastolic BP in early T1DM rats.  Diastolic dipping was 4% 
less compared to controls (P<0.01; Figs. 5.4B,D) and in agreement with this, early 
T1DM reduced diastolic amplitude by ~2mmHg.  Diastolic mesor and acrophase 
were unaffected (Table 5.3).  Twenty-four-hour-periodicity in systolic and diastolic 
BP were unaffected by diabetic status (Figs. 5.5A,B).  Heart rate in diabetics varied 






DRP Systolic BP Diastolic BP Heart rate 
 
Control Diabetic Control Diabetic Control   Diabetic 
Mean 
(mmHg/bpm) 
126.2±0.5 126.5±0.4 92.2±0.4 97.1±0.4** 361.7±2.5 341.5±2.3** 
Dip 
(%) 
    3±1     3±1   6±1   2±1** 15±1       12±1 
Mesor 
(mmHg/bpm) 
127.4±2.9 126.5±1.1 91.4±1.2 94.0±2.7 362.3±11.1 336.7±17.5 
Amp 
(mmHg/bpm) 
    2.9±0.5     3.1±0.3   4.1±0.4 1.8±0.7** 45.8±4.5 35.4±3.8 
Acro 
(radians) 
  69.3±4.4   71.3±1.7 81.6±2.9 46.2±15.8 71.1±2.6 76.6±6.8 
Table 5.3. Means, dips and cosinor analysis values for systolic and diastolic blood pressure (BP) 
and heart rate (beats per minute) in control and diabetic rats during the Diabetes Recording 
Period (DRP) 
Data expressed as mean ± standard error of the mean (SEM), **=P<0.05 compared with 
controls.  Comparisons made with two-sample Student’s t-tests for means and dips, and Welch’s 
t-test for cosinor analysis.  









Fig. 5.4. Twenty-four-hourly blood pressure (BP) and heart rate with dips in control and 
diabetic rats during the Diabetes Recording Period 
A) Systolic BP and systolic dipping did not differ between cohorts. 
B) Diastolic BP was higher in diabetic rats while the dip in diastolic BP was lower. 
C) Heart rate was lower in diabetic rats but there was no difference in dipping. 
D) Diastolic dipping was lower in diabetic rats, bars=mean±standard error of the mean (SEM), 
**=P<0.05 compared with controls. 
For A), B) and C), every data point is the mean ± SEM of every reading in every rat at that time point 
every day over five days, **=P<0.05 for average value over 24 hours in diabetic rats compared with 













Fig. 5.5. Twenty-four-hour-periodicity (Qp) in blood pressure (BP) in control and diabetic rats during the Diabetes Recording Period 
A) Twenty-four-hour-periodicity in systolic BP was present in control and diabetic rats.  
B) Twenty-four-hour-periodicity in diastolic BP was present in control and diabetic rats. 
C) Heart rate varied around a period of 25 hours in control rats and 22 hours in diabetic rats. 









5.3.5  Effects of salt supplementation (Salt Recording Period) 
Salt supplementation eliminated the differences in diastolic BP and dipping observed 
during the Diabetes Recording Period.  In control rats, systolic (Fig. 5.6A) and 
diastolic BP (Fig. 5.6B) increased by ~3-5mmHg (both P<0.01; Table 5.4), and 
diurnal diastolic dipping decreased from 6 to 3% (P=0.03; Fig. 5.6D).  Sinusoidal 
variation and 24-hour periodicity in systolic BP were also both lost in controls  
(Table 5.4; Fig. 5.7A;).  By contrast, BP in the early T1DM rats was relatively 
unaffected with only a rise of ~2mmHg in systolic BP (Table 5.4; Fig. 5.6A), and 
sinusoidal variation in systolic and diastolic BP and their 24-hour-periodicity were 
also maintained (Table 5.4; Figs. 5.7A,B).  Heart rate decreased in both cohorts by 
~8-15 beats/min but remained lower in the early T1DM rats (Table 5.4; Fig.5.6C) by 
~14 beats/min.  
SALT Systolic BP Diastolic BP Heart rate 
 Control Diabetic Control Diabetic Control    Diabetic 
Mean 
(mmHg/bpm) 
129.7±0.5*   128.2±0.4* 97.6±0.6* 96.5±05 346.9±2.6* 333.6±2.0*,** 
Dip 
(%) 
  1±1 3±1       3±1      2±1 10±3       12±3 
Mesor 
(mmHg/bpm) 
 -   127.8±2.3  94.3±1.0 96.8±6.6  347.9±7.0  328.6±7.5 
Amp 
(mmHg/bpm) 
 -  3.2±0.8    3.0±0.1   3.0±1.1 34.0±4.5    32.8±3.5 
Acro 
(radians) 
 - 7.9±9.9  71.3±0.6 74.1±6.7  62.5±9.0    81.8±5.2 
Table 5.4. Mean values, dips and cosinor analysis values for systolic and diastolic blood pressure 
(BP) and heart rate (beats per minute) in control and diabetic rats during the Salt Recording Period. 
Data are mean ± standard error of the mean (SEM).  **=P<0.05 compared with controls, *=P<0.05 
compared with Diabetes Recording Period.  Comparisons between cohorts made with two-sample 
Student’s t-tests for means and dips, and Welch’s t-test for cosinor analysis, blank boxes denote 
where sinusoidal variation was absent. Comparisons between recording periods made with one-way 








Fig. 5.6. Twenty-four-hourly blood pressure (BP) and heart rate (beats per minute) with dips 
in control and diabetic rats during the Salt Recording Period 
A) Systolic BP and systolic dipping did not differ between cohorts. 
B) Diastolic BP and diastolic dipping did not differ between cohorts. 
C) Heart rate was lower in diabetic rats. 
D) There was no difference in dipping between the cohorts, bars=mean ± standard error of the mean 
(SEM). 
For A), B) and C), every data point is the mean ± SEM of every reading in every rat at that time point 
every day over five days, **=P<0.05 for average value over 24 hours in diabetic rats compared with 













Fig. 5.7. Twenty-four-hour-periodicity (Qp) in blood pressure (BP) in control and diabetic rats during the Salt Recording Period 
A) Twenty-four-hour-periodicity in systolic BP was lost in control rats but not diabetics.  
B) Twenty-four-hour-periodicity in diastolic BP was present in control rats and diabetics. 
C) Twenty-four-hour-periodicity in heart rate was present in control rats and diabetics. 








5.3.6 Effects of selective endothelin A receptor antagonism (Salt+Atrasentan 
Recording Period) 
Atrasentan, decreased systolic BP and diastolic BP in both control and early T1DM 
rats (Table 5.5).  The effect in controls was ~8mmHg (systolic) and ~11mmHg 
(diastolic), whereas, in diabetics, the effect was much reduced (~2mmHg systolic, 
~5mmHg diastolic).  The consequence was that both systolic (Fig. 5.8A) and 
diastolic BP (Fig. 5.8B) were higher in early T1DM rats by ~5mmHg.  Heart rate 
was unaffected by atrasentan in both cohorts (Table 5.5; Fig. 5.8C).   
 
Atrasentan also induced abnormalities in circadian variation in BP, which were more 
prevalent in diabetics than controls.  In early T1DM rats, atrasentan decreased 
diastolic dipping to 2% less than in controls (Table 5.5; Fig. 5.9B) and removed  
24-hour-periodicity in systolic and diastolic BP (Figs. 5.10A,B).  In both cohorts, 
sinusoidal variation in diastolic BP was also disrupted (Table 5.5) but there was no 
effect on systolic dipping (Fig. 5.9A), sinusoidal variation in systolic BP or any 
assessment of circadian variation in heart rate (Table 5.5; Figs. 5.9C, 5.10C).   
 
5.3.7 Effects of combined endothelin receptor antagonism  
(Salt+Atrasentan+A-192621 Recording Period) 
In control rats, addition of A-192621 reversed the effects of atrasentan, by increasing 
systolic BP (Fig. 5.8A) by ~8mmHg and diastolic BP (Fig. 5.8B) by ~7mmHg.  By 
contrast, there was no effect on BP in early T1DM rats (Table 5.5; Figs. 5.8A,B) so 
that systolic and diastolic BP were ~2-3mmHg lower than control values.  Heart rate 




than in controls (Table 5.5; Fig. 5.8C).  Using all methods of assessment, circadian 
variation in systolic and diastolic BP recovered in early T1DM rats to match controls 
(Table 5.5; Figs. 5.9A,B; 5.10A,B).  In control rats, sinusoidal variation in diastolic 
BP also returned (Table 5.5).  Once again, all assessments of circadian variation in 
heart rate failed to identify an effect of ET receptor antagonism in either cohort 








Systolic BP Diastolic BP Heart rate 
 Control    Diabetic Control   Diabetic Control Diabetic 
Mean 
(mmHg/bpm) 
121.8±0.6* 126.5±0.4*,** 86.3±0.4* 91.1±0.5*,** 350.2±2.3 332.6±2.0** 
Dip 
(%) 
  2±1        1±1      3±2      1±1** 13±3        12±3 
Mesor 
(mmHg/bpm) 
120.0±2.8 122.8±0.7          -        - 340.2±19.6   332.5±22.0 
Amp 
(mmHg/bpm) 
  2.2±1.0     2.0±0.3          -        -    40.9±2.6     34.0±4.9 
Acro 
(radians) 






Systolic BP Diastolic BP Heart rate 
 Control Diabetic Control  Diabetic Control   Diabetic 
Mean 
(mmHg/bpm) 
129.1±0.5* 126.2±0.4** 93.4±0.4* 91.0±0.3** 348.1±2.7 313.1±2.2*,** 
Dip 
(%) 
  2±1 2±1      3±2      2±1 14±3       12±3 
Mesor 
(mmHg/bpm) 
128.4±4  127.9±2.6 92.3±1.9 93.0±2.0 355.3±4.9  315.5±13.1 
Amp 
(mmHg/bpm) 
 1.5±0.4      2.7±0.3   2.4±0.4   1.9±0.3 41.3±2.3    36.0±6.1 
Acro 
(radians) 
68.2±5.3    67.5±7.3 68.1±10.3 65.2±4.8  69.2±1.1    65.9±6.9 
Table 5.5. Mean values, dips and cosinor analysis values for systolic and diastolic blood 
pressure (BP) and heart rate (beats per minute) in control and diabetic rats with salt and 
endothelin (ET) receptor antagonist supplementation 
Data are mean ± standard error of the mean (SEM).  **=P<0.05 compared with controls, 
*=P<0.05 compared with previous recording period.  Comparisons between cohorts made with 
two-sample Student’s t-tests for means and dips, and Welch’s t-test for cosinor analysis, blank 
boxes denote where sinusoidal variation was absent. Comparisons between recording periods 
made with one-way analysis of variance (ANOVA) with Tukey’s post hoc tests, bpm=beats per 













Fig. 5.8. (page opposite) Twenty-four-hourly systolic and diastolic blood pressure (BP) and 
heart rate (beats per minute) in control and diabetic rats during endothelin (ET) receptor 
antagonism 
A) Atrasentan decreased systolic BP in controls and diabetics but the effect was less in diabetics.   
A-192621 increased systolic BP in control rats but not in diabetics.   
B) Atrasentan decreased diastolic BP in controls and diabetics but the effect was less in diabetics.   
A-192621 increased diastolic BP in control rats but not in diabetics.   
C) Heart rate was lower in diabetic rats than in controls during atrasentan supplementation.  
This difference increased with addition of A-192621.   
Every data point is the mean ± standard error of the mean (SEM) of every reading at that time 
point every day over five days, **=P<0.05 for average value over 24 hours in diabetic rats 
compared with controls.  †=increased average value over 24 hours in control rats on addition of 
A-192621, P<0.05. *=decreased average value over 24 hours in diabetic rats on addition of  
A-192621.  Comparisons between cohorts made with two-sample Student’s t- or Mann Whitney 
U- tests.  Comparisons between recording periods made with one-way analysis of variance 
















Fig. 5.9. Dipping in systolic and diastolic blood pressure (BP) and heart rate during 
endothelin (ET) receptor antagonism in control and diabetic rats 
A) Neither atrasentan nor A-192621 affected systolic dipping in controls and diabetics. 
B) Diastolic dipping in diabetics decreased with atrasentan but recovered with A-192621. 
C) Dipping in heart rate was similar in both cohorts during ET receptor antagonism. 
Bars=mean ± standard error of the mean (SEM), **=P<0.05 compared with controls.  All 






















Fig. 5.10. (page opposite) Twenty-four-hour-periodicity (Qp) in systolic and diastolic blood 
pressure (BP) in control and diabetic rats during endothelin (ET) receptor antagonism 
A) Atrasentan restored periodicity in systolic BP in controls.  Periodicity corresponded to cycle 
lengths of either 20 or 24 hours.  Twenty-four-hour-periodicity was lost in diabetics.  A-192621 
maintained 24-hour-periodicity in controls and restored it in diabetics. 
B) Twenty-four-hour-periodicity was lost in diabetics with atrasentan but restored with  
A-192621. 
C) Twenty-four-hour-periodicity in heart rate was maintained in both cohorts during  
ET receptor antagonism.   










Chapter 4 demonstrated that acute pressure natriuresis is suppressed in a rat model of 
early T1DM, and that this is associated with reduced urinary ET-1 excretion.  In this 
chapter, radiotelemetry demonstrated that early T1DM increases diastolic BP and 
disrupts its circadian regulation.  Therefore, impaired acute pressure natriuresis and 
UET-1 excretions are associated with increased diastolic BP and impairment to its 
circadian variation.  Attempts at exaggerating this phenotype with salt were 
unsuccessful, instead unmasking a degree of salt sensitivity in control rats.  Oral 
supplementation with selective ETA and then combined ETA/ETB receptor 
antagonists led to predictable reductions (ETA) and increments (ETB) in systolic and 
diastolic BP in controls, but these effects were small or absent in rats with early 
T1DM.   
 
Surprisingly, ETA receptor antagonism disrupted circadian variation in BP in diabetic 
rats whereas additional ETB receptor antagonism restored it.  Circadian variation in 
BP is regulated by acute pressure natriuresis, and predicts cardiovascular risk 102-104.  
It is concluded that impaired acute pressure natriuresis and reduced UET-1 excretion 
in early T1DM are associated with changes in BP that increase cardiovascular risk.  
Reduced renal ETA signalling and increased renal ETB signalling may underpin this 




5.4.1  Early Type 1 diabetes mellitus increases diastolic blood pressure, consistent 
with impaired acute pressure natriuresis. 
In these experiments, radiotelemetry recorded an increase in diastolic BP in rats with 
early T1DM.  Radiotelemetry was used because it allows real-time, direct 
measurement of BP in fully conscious, unrestrained rats.  This is advantageous 
because every rat contributes multiple data points.  This increases statistical power 
while simultaneously removing the confounding effects associated with stress from 
indirect oscillometric and Doppler-based methods of BP measurement 280, and 
associated with direct, arterial measurements during general anaesthesia.  This may 
explain the discrepancy between the increased diastolic BP measured in diabetic rats 
in these experiments and the anaesthetised diabetic rats in Chapter 4.   
 
The radiotelemetry data are novel because this is the first study to measure both 
systolic and diastolic BP continuously over several days in rats with early T1DM.  
There are only a small number of published radiotelemetric studies in T1DM rats and 
none has measured systolic and diastolic BP simultaneously for more than 24 hours.  
Two studies 282,283 measured only systolic BP and concluded that BP was unaffected 
by T1DM.  The data in this chapter show that this conclusion should not be made 
without also measuring diastolic BP, which can increase even when systolic BP is 
unchanged.  One other study, in genetically T1DM-prone rats, showed that early 
T1DM increases mean BP by ~4mmHg 280 but the relative contributions of systolic 
and diastolic BP to this increase were not determined.  Hicks et al. 284 also used 
radiotelemetry to measure diastolic BP in rats with STZ-induced T1DM but failed to 




despite the same cohort sizes and levels of hyperglycaemia.  Hicks et al. 284 sampled 
BP more frequently (every 10 minutes) than in this study, and recorded BP for 
periods lasting seven days with no intervening gaps.  Their protocol did not take into 
account the potential confounding effects of stress on BP that are associated with the 
increased husbandry needs of diabetic rats.  T1DM causes polyuria and polydipsia.  
Water bottles must be re-filled and absorbent bedding added over the day.  This must 
be controlled for by performing these tasks for all rats, including controls, at the 
same time.  During recording periods used here, BP was measured over one minute 
in every hour so that there was sufficient time for the water and bedding needs of all 
the early T1DM rats (and controls) to be met between sampling periods, leaving a 
recovery period of tens of minutes before the next BP measurement.  After every 
five-day long recording period, rats had to be transferred to clean cages with fresh 
bedding.  This coincided with staff changes during weekend periods, and gave 
rats >24 hours to recover before the first measurement of the next recording period.  
By sampling every 10 minutes with no gap between recording periods, the protocol 
used by Hicks et al. 284 contained no recovery periods and may have acquired data 
confounded by increases in BP associated with husbandry.  If control rats were less 
acclimatised to husbandry for diabetics, this could lead to an increase in BP that 
explains the discrepancy in diastolic BP between the two studies.  This possibility is 
reinforced by analysis of circadian variation in diastolic BP, which was not 




5.4.2 Early Type 1 diabetes mellitus disrupts circadian variation in diastolic blood 
pressure, consistent with impaired acute pressure natriuresis. 
As well as increasing diastolic BP, early T1DM also disrupted circadian variation in 
diastolic BP.  In mammalian species, BP is controlled by the circadian clock in the 
hypothalamus but is also highly dependent on salt balance 78,89.  BP in normotensive 
subjects is usually higher during the day, and dips by ~10-20% at night 285.   
Pre-clinical and clinical studies have shown that salt sensitivity disrupts this pattern.  
For example, a salt challenge in Dahl salt-sensitive (DSS) rats, which have an 
impaired acute pressure natriuresis response, increases their mean BP during periods 
of inactivity 286.  Similarly, people with salt sensitivity of different aetiologies 
excrete less sodium during the day at the expense of increased BP at night 101,287, but 
can restore their nocturnal dip in BP by restricting their salt intake 287.  Acute 
pressure natriuresis offsets increases in BP by increasing sodium excretion, so it is 
now believed that impairment to acute pressure natriuresis underpins the  
“non-dipper” phenotype 100.  Failure to excrete sodium during periods of peak salt 
ingestion results in elevated BP and continued acute pressure natriuresis during the 
night 100.  The “non-dipper” phenotype is clinically relevant because it is associated 
with increased cardiovascular risk 288 and predicts nephropathy in T1DM 74.  In order 
to determine the potential consequences of the impairment to acute pressure 
natriuresis in early T1DM (Chapter 4), circadian variation in systolic and diastolic 
BP were calculated in this chapter.  This analysis has not been performed previously 
in a rodent model of early T1DM, and three separate methods were used in order to 
test the consistency of large data sets: diurnal dipping (analogous to nocturnal 




sinusoidal pattern) and 24-hour-periodicity (whether cyclic variation in BP occurs 
over a 24-hour cycle) 237.   
 
A reduction in diurnal diastolic dipping and in the amplitude of sinusoidal variation 
in diastolic BP were both identified in the diabetic rats.  By contrast, circadian 
variation in systolic BP was unaffected.  BP is dependent on heart rate, stroke 
volume and peripheral vascular resistance.  Heart rate could not explain these effects 
because it was lower rather than higher in diabetic rats, and experienced minimal 
disruption to its circadian rhythm throughout the entire study.  Age-related changes 
in systolic and diastolic BP in people suggest that systolic BP is highly dependent on 
peripheral vascular resistance whereas diastolic BP is associated more with plasma 
volume 289.  Impaired acute pressure natriuresis leads to elevated plasma volume 89, 
and so in diabetic rats with impaired acute pressure natriuresis (Chapter 4), the lack 
of effect on systolic BP in this and previous radiotelemetric studies 282,283, and the 
disruption to the circadian regulation of diastolic BP, recorded only in this study, 
were predictable.  This has direct relevance to the risk of nephropathy and CVD in 
patients with T1DM.  Even before the onset of office hypertension, diastolic BP in 
young children with T1DM has a stronger correlation than systolic BP with 
microalbuminuria and morphometric abnormalities of nephropathy 74,290,291.  
Furthermore, daytime diastolic BP, and not systolic BP, increases in adults with 
T1DM, prior to development of nephropathy.  Therefore, the changes to BP in this 
chapter strongly suggest a link between impaired acute pressure natriuresis in early 





5.4.3 Salt supplementation identified salt sensitivity in the control rats. 
Both cohorts of rats received dietary salt supplementation (Salt Recording Period), 
equivalent to a moderate salt diet 292.  Since rats with early T1DM had impaired 
acute pressure natriuresis (Chapter 4), additional salt was expected to exaggerate 
their sodium retention, and increase systolic and diastolic BP by up to 10mmHg 
more than controls 292,293.  It was hoped that this would maximise the statistical 
power of the hypothesised restoration of normal BP in diabetic rats during 
subsequent selective ETA receptor antagonism.  Unexpectedly, salt supplementation 
had no effect on BP in rats with early T1DM, but, instead, it disrupted circadian 
variation in systolic BP in control rats, and increased their diastolic BP so that it 
matched diabetic levels.  This suggested that salt had unmasked a salt sensitivity in 
the control cohort rather than the diabetic cohort.  Why sensitivity to oral salt 
supplementation was not also observed in rats with early T1DM and impaired acute 
pressure natriuresis is not clear.  One possibility is that glycosuria increased sodium 
excretion through osmotic diuresis, preventing retention of excess dietary sodium, 
and increased BP 294.  Salt sensitivity increases BP and reduces circadian variation in 
BP 101,287, so if salt sensitivity was a confounder for the experiments in this chapter, it 
would at least decrease rather than increase the differences in BP and circadian 
variation in BP between control and early T1DM cohorts.  Therefore, the conclusions 
drawn from the Diabetes Recording Period that early T1DM increases diastolic BP 




5.4.4 Endothelin receptor antagonists exerted greater effects on blood pressure in 
control rats than rats with early Type 1 diabetes mellitus.  
Despite the salt sensitivity detected in control rats, addition of the selective ETA 
receptor antagonist, atrasentan, still reduced systolic and diastolic BP.  These 
reductions were predicted: atrasentan prevents calcium-dependent vasoconstriction 
and reduces mean BP by ~15mmHg in ren-2 transgenic rats that are salt sensitive 
from overexpression of the mouse renin gene 295.  Similarly, the increases in systolic 
and diastolic BP in controls, following addition of the selective ETB receptor 
antagonist, A-192621, were consistent with loss of ETB receptor-mediated 
vasodilation 77 and natriuresis 181.  By contrast, ETA and combined ETA/ETB receptor 
antagonism exerted only minor effects on systolic and diastolic BP in rats with early 
T1DM.  This was unexpected.   
 
T1DM increases endothelial secretion of ET-1 205 and shifts vascular tone towards 
increased ETA receptor-mediated vasoconstriction 
257,258 and away from ETB 
receptor-mediated vasodilation 259.  Therefore, ETA receptor antagonism was 
predicted to lower systolic and diastolic BP to a greater extent in the diabetic rats 
than the controls, and additional ETB receptor antagonism was expected to partially 
reverse these effects.  The failure of ET receptor antagonism to modify average 
systolic and diastolic BP in the diabetic state suggests that ET receptors may play a 
lesser role than predicted in the regulation of BP in early T1DM.  Further insight into 





5.4.5 Endothelin receptor antagonists exerted greater effects on circadian 
variation in blood pressure in rats with Type 1 diabetes mellitus than controls. 
There was little or no effect of atrasentan or A-192621 on circadian variation in 
either systolic or diastolic BP in controls.  However, in rats with early T1DM, ET 
receptor antagonism modified circadian variation in both systolic and diastolic BP.  
Since circadian variation in BP is a marker of acute pressure natriuresis 100, and 
urinary ET-1 excretion as well as urinary sodium excretion was suppressed in rats 
with early T1DM (Chapter 4), a greater influence of ET receptor antagonists on 
circadian variation in BP in early T1DM rats had been predicted.  It was also 
unsurprising that the effects exerted by ETA and ETB receptor antagonists were 
opposite in nature since ETA and ETB receptors generally exert opposite vascular 
effects 77.  What was not expected was that the effects on circadian variation were 
entirely at odds with the putative roles of each ET receptor subtype.   
 
ETA receptor antagonism was expected to enhance circadian variation in the rats with 
early T1DM.  This is because ETA receptor antagonists should have a greater 
vasodilatory effect in early T1DM 257,258, increasing renal blood flow and acute 
pressure natriuresis 89.  It would also be consistent with the recovery of nocturnal 
dipping in both systolic and diastolic BP observed in non-diabetic CKD patients 
treated with the selective ETA receptor antagonist, sitaxentan 
226.  Instead, atrasentan 
suppressed circadian variation in BP in the diabetic rats, removing  
24-hour-periodicity in systolic and diastolic BP, and reducing diurnal dipping in 
diastolic BP.  Addition of the ETB receptor antagonist was expected to reduce 




receptor-mediated vasodilation 259, which would reduce renal blood flow, and loss of 
inhibition of the renal epithelial sodium channel (ENaC), which would increase 
sodium reabsorption 181, should both suppress acute pressure natriuresis 89.  Instead, 
contrary to the hypothesis, addition of A-192621 restored 24-hour-periodicity in both 
systolic and diastolic BP, and diurnal dipping in diastolic BP   
 
These results would be consistent with a novel pro-natriuretic role for ETA receptors, 
and a novel anti-natriuretic role for ETB receptors that are unmasked by early T1DM.  
The mechanisms behind these roles, and how they are enhanced by early T1DM, 
should now be the focus of follow-on experiments because they have significant 
clinical implications. 
 
5.4.6  Clinical significance of results 
Decreased diurnal dipping in diastolic BP recorded in rats with early T1DM during 
ETA receptor antagonism, instead of the increased dipping recorded in clinical  
non-diabetic CKD 226, raises the possibility that clinical outcomes from ETA receptor 
antagonists that are associated with reduced cardiovascular risk may not cross over 
from CKD to diabetic nephropathy.  Further investigation of a pro-natriuretic role for 
ETA receptors may reveal a candidate mechanism for sodium and water retention, an 
important adverse effect observed clinically with even highly selective ETA receptor 





Diastolic BP is increased and circadian variation in diastolic BP is reduced in rats 
with early T1DM that also have impaired acute pressure natriuresis and suppressed 
urinary ET-1 excretion.  This is consistent with increased cardiovascular risk in early 
T1DM as a consequence of impaired acute pressure natriuresis.    
 
ET receptor antagonists modify the disruption to circadian variation in diastolic BP 
in a manner suggestive of novel pro-natriuretic and anti-natriuretic roles for ETA and 
ETB receptors respectively.  These effects are not observed in healthy control rats, 
suggesting that early T1DM may impair acute pressure natriuresis by modifying 
renal ET-1 signalling through both receptor subtypes.   
 
5.5.1 Follow-on work 
The next set of experiments in rats with early T1DM should investigate whether the 
contrasting effects of ET receptor antagonists on circadian variation in diastolic BP 
might be derived from contrasting effects on acute pressure natriuresis.  This should 
be determined by repeating ligature-induced acute pressure natriuresis studies during 
ETA and ETB receptor antagonism.  To clarify the roles of ET receptors, the effect of 
early T1DM, and provide preliminary information on their mechanistic basis, the 
renal vascular and tubular components of acute pressure natriuresis will also be 








6 The effects of Type 1 diabetes mellitus, 
insulin and endothelin receptor antagonists on 






In acute pressure natriuresis, renal vascular and tubular functions combine to 
transmit increases in blood pressure (BP) into a compensatory natriuresis 89,138.  
Previous chapters have demonstrated that early Type 1 diabetes mellitus (T1DM) 
impairs acute pressure natriuresis (Chapter 4), and disrupts regulation of diastolic BP 
(Chapter 5).  In people, hypertension and nephropathy, which are both risk factors 
for cardiovascular disease (CVD) in T1DM, are preceded by disruption of regulation 
of diastolic BP 247-249.  Therefore, Chapters 4 and 5 suggest that restoration of acute 
pressure natriuresis in early T1DM might reduce cardiovascular risk.  In order to 
identify a pharmacological target that achieves this, the mechanism to the 
impairment must first be understood. 
 
In the first phase of acute pressure natriuresis, there is an increase in blood flow 
through the medullary vasa recta 138.  Increased medullary perfusion increases 
medullary interstitial hydrostatic pressure 89,296.  The second phase of acute pressure 
natriuresis is suppression of tubular reabsorption of sodium 89,296.  The proximal 
convoluted tubule (PCT), which is responsible for ~70% of sodium reabsorption 90 is 
especially sensitive to increased interstitial hydrostatic pressure 89.  Sodium 
reabsorption is impaired through Starling’s forces 91 and pressure-sensitive paracrine 
signalling 92,297-299.  The more distal tubule has the capacity to abrogate this response 
through increased activity of multiple sodium transporters such as the  
sodium-chloride co-transporter (NCC) and the epithelial sodium channel (ENaC).  
Therefore, regulation of these transporters, by paracrine and neurohumoral  





Simultaneous measurement of intrarenal blood flow and sodium excretion during 
acute rises in BP should determine whether early T1DM impairs the vascular or 
tubular phase of acute pressure natriuresis.  Candidate mechanisms can also be tested, 
such as those regulated by insulin, which restored acute pressure natriuresis in rats 
with early T1DM in Chapter 4.  This is important because, in T2DM, insulin 
increases rather than decreases sodium reabsorption through NCC and ENaC 238 
suggesting that restoration of acute pressure natriuresis is more likely to originate 
from increased medullary perfusion.   
 
An alternative candidate mechanism is renal endothelin-1 (ET-1) signalling.  ET-1 
has potent vasoconstrictive and vasodilatory effects via vascular ETA and ETB 
receptors 77, and also promotes sodium reabsorption from the collecting duct by ETB 
receptor-mediated inhibition of ENaC 181.  Therefore, ET-1 has the potential to 
impair both vascular and tubular phases of acute pressure natriuresis.  Moreover, 
T1DM modifies ET-1 signalling in a way that could impair the acute pressure 
natriuresis response.  As well as increasing endothelial ET-1 expression 205 and 
circulatory ET-1 levels 255, T1DM also promotes vascular dysfunction through 
decreased expression of vasodilatory endothelial ETB receptors 
259 and increased 
expression of vasoconstrictive ETA and ETB receptors on vascular smooth muscle 
cells 258,300.  However, the effect of T1DM on the relative expressions of the two 
receptor subtypes may vary in individual organs, and ETA receptor expression may 
be unaffected while ETB receptor expression increases 





A link between ET-1 and impaired acute pressure natriuresis in early T1DM was 
demonstrated in Chapter 4 when suppression of urinary ET-1 excretion in diabetic 
rats matched suppression of urinary sodium excretion.  This link was reinforced in 
Chapter 5 when circadian regulation of diastolic BP, a marker of acute pressure 
natriuresis and cardiovascular risk 74,100,124, was disrupted in diabetic rats by ETA 
receptor antagonism and restored by additional ETB receptor antagonism.  However, 
these results suggest that ETA receptors promote acute pressure natriuresis in early 
T1DM, while ETB receptors impair it- novel roles which must now be confirmed 
experimentally and compared with changes in renal ETA and ETB receptor 
expression.   
 
6.1.1  Hypotheses 
1) Early T1DM impairs acute pressure natriuresis by reducing renal medullary 
blood flow.  This effect is a consequence of downregulation of renal ETA 
receptors and upregulation of renal ETB receptors. 
2) Insulin restores acute pressure natriuresis by increasing renal medullary blood 
flow and reversing the effects of early T1DM on renal ET receptor 






Ligature-induced acute pressure natriuresis was performed in rats with early T1DM 
with and without insulin treatment.  Renal blood flow was measured following 
administration of selective ET receptor antagonists.  The following questions were 
addressed: 
1) Does early T1DM reduce medullary perfusion?  
2) Is this effect reversed by insulin? 
3) Does ETA receptor antagonism suppress medullary perfusion and natriuresis? 
4) Does ETB receptor antagonism enhance medullary perfusion and natriuresis?  
5) Are the effects of ET receptor antagonism still detectable in early T1DM with 







Experiments were performed, single-blinded, in three groups of adult male Sprague 
Dawley rats: early T1DM (blood glucose >12mmol/l induced with one or two 
intraperitoneal (ip.) injections of streptozotocin (STZ); Chapter 2.1, page 46), 
T1DM+insulin (subcutaneous (sc.) insulin implant inserted into early T1DM rats 
seven days after the first injection of STZ; Chapter 2.1, page 47), and healthy control 
rats (ip. citrate buffer).   
 
6.2.2 Preparation for ligature-induced acute pressure natriuresis and measurement 
of renal blood flow 
Control, early T1DM and T1DM+insulin rats (Table 6.1) were anaesthetised 
(Chapter 3.2, page 88) and prepared for ligature-induced acute pressure natriuresis  
(Fig. 6.1; Chapter 4.2, page 115).  Tube cystotomy was not performed.  Instead, the 
left ureter was cannulated for urine collection (Chapter 2.6, page 69; Figs. 2.10A,B).  
Renal artery flow (ml/min) was measured by a Doppler ultrasound flow probe 
(Chapter 2.6, page 70; Figs. 2.11A,B).  Renal cortical and medullary blood flow were 
individually measured by laser Doppler spectroscopy (LDS; Chapter 2.6; Figs. 2.12; 
2.13A,B).  Both laser Doppler probes measured blood flow as flux in tissue perfusion 






















Fig. 6.1. Schematic diagram of measurement of renal blood flow during ligature-induced acute 
pressure natriuresis 
A) Urine is collected from the left ureter while left renal blood flow is measured at three sites.  
Stepwise increase in mean blood pressure (BP) follow simultaneous tightening of arterial 
ligatures and, later, the distal aorta.  
B) Magnified view of the three renal probes: around the left renal artery, glued to the renal 









6.2.3 Injection of endothelin receptor antagonists and ligature-induced acute 
pressure natriuresis  
On completion of surgical preparation (~80 minutes), all rats received slow (over 
five minutes) intravenous (iv.) injection of one of four treatment options: atrasentan 
(ETA receptor antagonist, 5mg/kg 
302 dissolved in 1ml of vehicle), A-192621 (ETB 
receptor antagonist, 10mg/kg 302 dissolved in 1ml of vehicle), combined atrasentan 
and A-192621, or vehicle (1ml of balanced electrolyte solution, pH 7.4 (Chapter 2.9, 
page 82), and one drop of 70% ethanol).  This created four cohorts within each group 
of control, early T1DM or T1DM+insulin rats (12 cohorts in total; Table 6.1).  All 
ET receptor antagonists were kindly supplied by AbbVie Limited (Ltd.; Maidenhead, 
United Kingdom (UK)).  Rats then entered a 30-minute equilibration period  
(Fig. 6.2).   
 
Following equilibration, urine and blood were collected as before (Chapter 4.2,  
page 115), over three 30-minute periods pre- and post arterial ligation: Baseline, 
Clearance 1 and Clearance 2.  Systolic and diastolic BP, renal artery flow, cortical 
flux and medullary flux were recorded continuously.  Mean BP was calculated post 
acquisition.   
 
After euthanasia and removal and weighing of the kidneys, the left kidney was 
sectioned sagittally to confirm correct placement of the needle laser Doppler 
medullary probe (Fig. 6.3).  Urinary sodium concentrations were measured.  
Glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate 




pages 74-76).  Changes in renal artery flow and in cortical and medullary flux after 
each arterial ligation were expressed as percentage changes from Baseline, which 
was set at 100%. Where appropriate, measurements were indexed to kidney weight 
(kw).  
Fig. 6.2. Timeline for ligature-induced acute pressure natriuresis showing time points for 











Fig. 6.3. Post mortem examination of the left kidney confirmed correct placement of the needle 




6.2.4 The effect of Type 1 diabetes mellitus on renal endothelin A and endothelin B 
receptor expression 
In a separate experiment, semi-quantitative polymerase chain reaction (qPCR; 
Chapter 2.4, pages 57-60) of renal tissue (Chapter 2.2, pages 49-51) measured 
expression of markers of renal ET-1 signalling.  Total ribonucleic acid (RNA) was 
extracted from pulverised snap-frozen renal cortex and medulla from control, T1DM 
and T1DM+insulin rats.  First-strand complementary deoxyribonucleic acid (cDNA) 
was reverse transcribed and amplified (qPCR) with exon-spanning, unlabelled,  
rat-specific primers for the genes that code for ET-1, ETA receptor and ETB receptor 
(EDN1, EDRA and EDRB respectively), mixed with a fluorescein amidite (FAM) 
dye-labelled Taqman probe (ThermoFisher Scientific Inc, Glasgow, UK; Table 6.2).  
Using the change in cycle threshold (ΔCT) method, fluorescence of the FAM probes 
was compared to reference genes 3-phophate dehydrogenase (GAPDH) and thymine-
adenine-thymine-adenine (TATA) box binding protein (TBP) 232, which had been 
previously compared between cohorts to confirm they were unchanged by diabetic 
status.  Where differences were identified, the fold-difference was calculated using 
the ΔΔCT method 
233. 
 
6.2.5 Statistical analysis 
Studies were designed to obtain a power >80% if: 
1) cohort sizes were six rats and UNaV in early T1DM rats was 50±25% 262 of 
the expected value in controls 112. 
2) medullary blood flow was 20±5% greater in controls over untreated diabetic 




A lower value of relative suppression of UNaV (50%) was estimated for early T1DM 
than that obtained in Chapter 4 (85%), because it was assumed that the additional 
surgical preparation time for measurement of renal blood flow would lower mean BP 
and hence natriuresis.  Additional rats were included in every cohort to account for 
an expected dropout rate of 25% due to experimental mortality. 
 
Data were expressed as mean ± standard error of the mean (SEM) and analysed with 
Minitab 17 (Minitab Ltd, Coventry, UK) and GraphPad Prism 6.0 (GraphPad 
Software, La Jolla, United States (US)).   
 
For acute pressure natriuresis studies, two-way analysis of variance (ANOVA) with 
Tukey’s post hoc tests were used to compare Baseline mean BP and increments 
(independent variable), and dependent variables between cohorts.  Data were 
transformed by log or square-root transformation according to normality and equality 
of variance of residuals.  Interaction between diabetic status and clearance period 
was calculated.  As additional analyses, dependent variables were plotted against BP, 
and regression lines were compared by analysis of covariance (ANCOVA) with 
Tukey’s post hoc tests (linear) and extra sum of squares F-tests (non-linear).   
 
For comparison of weight, blood glucose and gene expression, multiple comparisons 
employed one-way ANOVA with Tukey’s post hoc tests or Kruskal Wallis with 
Dunn’s post hoc tests according to normality and equality of variance of residuals. 
 











                         Control Diabetic                            Insulin 
 Vehicle ETA ETB ETA+ETB  Vehicle ETA ETB ETA+ETB Vehicle ETA ETB ETA+ETB 
Number 10 8 9 5      11 7 6 8 5 8 5 8 
Weight 
(g) 
363±7 389±14 400±15   381±11  331±8**  334±9  323±23   341±12 377±23* 369±13  377±7  315±33 
BG 
(mmol/l) 
6.1±0.3 5.7±0.4 5.1±0.7    6.6±0.3 16.7±1.7** 20.0±1.5 24.6±3.5  21.0±1.6 7.6±0.5* 8.0±1.0 10.9±2.0 10.3±1.1 
Table 6.1. Number, weight, blood glucose (BG) of control, diabetic and insulin-treated diabetic rats, immediately prior to general anaesthesia for  
ligature-induced acute pressure natriuresis 
Data are mean ± standard error of the mean (SEM), **=P<0.05 compared with controls, *=P<0.05 compared with diabetics.  All comparisons made with one-








Gene Marker Manufacturer reference 
Exon 
boundary 
Location Length Approximate probe sequence 
EDN1 ET-1 Rn00561129_m1 1-2 252 88 5'GAGCTCCAGAAACAGCTGTCTTGGGAG3' 
EDRA ETA receptor Rn01463848_m1 2-3 715 118 5'ATGTGTTTAAGCTGTTGGCGGGGCGCT3' 
EDRB ETB receptor Rn01437681_m1 2-3 741 79 5'CTACAAGCTGCTGGCAGGGGACTGGCC3' 
GAPDH Reference gene Rn01775763_g1 8-8 1153 174 5'GAGGAGTCCCCATCCCAACTCAGCCCC3' 
TBP Reference gene Rn01455646_m1 4-5 791 75 5'TAATCCCAAGCGGTTTGCTGCAGTCAT3' 
Table 6.2. Semi-quantitative polymerase chain reaction (qPCR) probes selected for determining renal injury 
The probe sequence is not released by the manufacturer (ThermoFisher Scientific).  The approximate probe sequence within the amplicon is derived from 
adding 13 nucleotides upstream and downstream of the assay location, using the Reference Sequence Database of the National Center for Biotechnology 
Information (NCBI, Bethesda, United States (US)), ET and EDN=endothelin, EDRA=ETA receptor, EDRB=ETB receptor,  
GAPDH=glyceraldehyde 3-phosphate dehydrogenase, TBP=TATA (thymine-adenine-thymine-adenine) box binding protein, A=adenine, C=cytosine, 





6.3.1 Impairment of acute pressure natriuresis in rats with Type 1 diabetes mellitus, 
and recovery with insulin 
Following sequential ligation, mean BP rose by ~20mmHg in the three cohorts 
receiving vehicle (P<0.01; Table 6.3; Fig. 6.4A).  Although, overall, mean BP was 
greater in controls than in early T1DM rats (P=0.03), there was no difference 
between cohorts during any of the three individual collection periods (interaction 
P=0.97; Table 6.3; Fig. 6.4A).  Mean GFR was similar in all cohorts (control 
0.9±0.1ml/min/gkw, early T1DM 1.1±0.2ml/min/gkw, T1DM+insulin 
1.5±0.3ml/min/gkw; P=0.23) and was unaffected by clearance period (P=0.73, 








VEHICLE Baseline Clearance 1 Clearance 2 
 Control Diabetic Insulin  Control   Diabetic Insulin Control Diabetic     Insulin 
BP 
(mmHg) 
124.0±4.3 116.1±4.2 122.3±5.3 136.0±4.9 127.5±4.1 136.5±4.3 143.9±4.2   137.9±5.1 146.2±2.9 
GFR 
(ml/min/gkw) 
   0.9±0.1   1.3±0.5    1.8±0.7  1.0±0.1    0.8±0.2   1.4±0.3 1.0±0.1 1.1±0.2     1.3±0.3 
UV 
(µl/min/gkw) 
  7.2±1.6   8.7±3.2  13.1±4.5 16.3±3.5    8.5±2.5 17.8±5.7 38.6±6.2  14.0±3.4** 30.4±12.4* 
UNaV 
(µmol/min/gkw) 
 2.2±0.6   2.1±0.7   2.6±1.1   6.5±0.8    2.0±0.4   4.3±1.8 16.7±1.4   4.1±1.1** 24.9±17.8* 
FENa 
(%) 
1.7±0.6   1.9±0.8  1.0±0.4   3.5±0.7    2.8±1.0  2.2±0.5 15.0±2.4   3.7±1.0** 9.6±4.9* 
Δ RA flow 
(%) 
   93.2±7.5  93.2±6.6 102.8±6.9 108.3±11.7  104.0±7.7 113.2±4.5 
Δ cortical flux 
(%) 
    93.5±4.8  97.6±6.1 94.2±6.1 98.5±6.5    99.6±8.3   79.3±9.0 
Δ medullary flux 
(%) 
   159.4±20.1  95.7±12.1** 108.7±6.1 227.2±26.7 115.4±10.3** 112.2±6.8** 
Table 6.3. Mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate (UNaV), fractional excretion of 
sodium (FENa), and changes (Δ) in renal artery (RA) flow, cortical flux and medullary flux in control, diabetic and insulin-treated diabetic rats during 
Baseline and Clearances 1 and 2, after injection of vehicle 
**=P<0.05 compared with control rats during same clearance period, *=P<0.05 compared with diabetic rats receiving vehicle during same clearance period.  






Fig. 6.4. Mean blood pressure (BP) and glomerular filtration rate (GFR) during ligature-
induced acute pressure natriuresis in all rats receiving vehicle 
A) Baseline mean BP and increments were not significantly different between cohorts, 
bars=mean ± standard error of the mean (SEM), *=P<0.05 compared with mean BP in previous 
period.  All comparisons made with two-way analysis of variance (ANOVA) with Tukey’s post 
hoc tests.  
B) GFRs were similar between cohorts during every clearance period.  Every data point is the 
mean value of the dependent variable plotted against mean BP±SEM of both variables, and 










Pressure diuresis and natriuresis were induced (both P<0.01) but maximum UV and 
UNaV in controls were only ~50-75% of values in Chapter 4 (Table 6.3;  
Figs. 6.5A,C).  Increases in UV and UNaV were again suppressed in early T1DM 
rats (both P<0.01 versus controls; Table 6.3), only attaining ~25-35% of control 
values during Clearance 2 (both P<0.01), and the non-linear (k=0.03) and linear 
(P<0.01) nature of these relationships was lost (Figs. 6.5B,D).  Unlike in Chapter 4, a 
tight relationship between FENa and mean BP could not be identified in controls  
(Fig. 6.5F) but there was still a clear suppression of FENa in early T1DM rats 
(P<0.01, interaction P=0.14), particularly during Clearance 2, by ~75% (P<0.01;  
Table 6.3; Fig. 6.5E).  By contrast, UV (P=0.046 versus early T1DM) and UNaV 
(P=0.04 versus early T1DM) recovered in T1DM+insulin rats (Table 6.3;  














Fig. 6.5. (page opposite) Ligature-induced acute pressure natriuresis in control, diabetic and  
insulin-treated diabetic rats 
A) Pressure diuresis responses, with reduced urine flow rate (UV) in diabetic rats during 
Clearance 2   
B) Pressure diuresis responses, with loss of the non-linear relationship with mean blood 
pressure (BP; k=0.03) in diabetic and insulin-treated diabetic rats   
C) Pressure natriuresis responses, with reduced urinary sodium excretion rate (UNaV) in 
diabetic rats during Clearance 2   
D) Pressure natriuresis responses, with loss of the linear relationship with mean BP (0.07-0.32, 
95% confidence) in diabetic and insulin-treated diabetic rats    
E) Reduced fractional excretion of sodium (FENa) in diabetic rats during Clearance 2    
F) No relationship between FENa and mean BP in any of the cohorts    
**=P<0.05 compared with controls, *=P<0.05 compared with diabetics 
For A), C) and E), every data point is the mean value of the dependent variable plotted against 
mean BP ± standard error of the mean (SEM) of both variables, and corresponds to one of three 
clearance periods.  All comparisons made with two-way analysis of variance (ANOVA) with 
Tukey’s post hoc tests. 




6.3.2 The effects of Type 1 diabetes mellitus and insulin on renal blood flow 
In control rats, medullary flux increased with mean BP (Table 6.3; Fig. 6.6A,B).  
Early T1DM suppressed the rise in medullary perfusion during Clearances 1 and 2 so 
that, overall, medullary flux was approximately half that measured in controls 
(P<0.01; Table 6.3; Fig. 6.6A).  The curvilinear relationship between the percentage 
rises in medullary flux and mean BP was also lost in the diabetics (P<0.01;  
Fig. 6.6B).  The percentage change in medullary flux correlated with the percentage 
change in UV in control and early T1DM cohorts (control P<0.01, early T1DM 
P=0.03; Fig. 6.6C) but although it also correlated in controls with the percentage 
change in UNaV (P<0.01), this was not observed in early T1DM (Fig.6.6D).   
 
Insulin did not reverse suppression of medullary flux in early T1DM during either 
clearance period (P<0.01; interaction between diabetic status and period P=0.43; 
Table 6.3; Fig. 6.6A) but did re-establish a curvilinear relationship with the 
percentage change in mean BP (Fig. 6.6B).  The percentage change in medullary flux 
with insulin did not correlate with the percentage change in either UV or UNaV  





Cortical and renal artery flux did not change in the three rat cohorts as mean BP rose  
(Table 6.3; Figs. 6.7A,B).  Percentage changes in cortical flux did not correlate with 
percentage changes in UV or UNaV (Figs. 6.7C,D) in any cohort.  In controls only, 
the percentage change in renal artery flow did correlate with the percentage change 












Fig. 6.6. (page opposite) Changes in medullary flux with mean blood pressure (BP), urine flow 
rate (UV) and urinary sodium excretion rate (UNaV) in control, diabetic and insulin-treated 
diabetic rats 
A) Increases in medullary flux were not observed in diabetic and insulin-treated diabetic rats.  
Every data point is the mean value of the dependent variable plotted against mean BP ± 
standard error of the mean (SEM) of both variables, and corresponds to Clearance 1 or 
Clearance 2.  All comparisons made with two-way analysis of variance (ANOVA) with Tukey’s 
post hoc tests.   
B) The curvilinear relationship between changes in medullary flux and mean BP (k=0.02) was 
lost in diabetics but re-established with insulin at a smaller rate of change (k=0.01), 
R2=coefficient of determination. 
C) Percentage changes in UV correlated with percentage changes in medullary flux in control 
and diabetic rats. 
D) Correlations between percentage changes in UNaV and medullary flux were lost in diabetics 
and not re-established with insulin.   
For C) and D), correlations made with Pearson’s and Spearman’s rank tests, r=coefficient of 
















Fig. 6.7. (page opposite) Changes in cortical flux and renal artery flow with mean blood 
pressure (BP), urine flow rate (UV) and urinary sodium excretion rate (UNaV) in control, 
diabetic and insulin-treated diabetic rats 
A) Cortical flux did not increase with mean BP in any cohort.  Every data point is the mean 
value of the dependent variable plotted against mean BP ± standard error of the mean (SEM) of 
both variables, and corresponds to Clearance 1 or Clearance 2.  All comparisons made with 
two-way analysis of variance (ANOVA) with Tukey’s post hoc tests.   
B) There was no relationship between percentage changes in cortical flux and mean BP in any 
cohort.   
C) Percentage changes in UV did not correlate with percentage changes in cortical flux in any 
cohort. 
D) Percentage changes in UNaV did not correlate with percentage changes in cortical flux in any 
cohort. 
E) Percentage changes in UV did not correlate with percentage changes in renal artery flow in 
any cohort. 
F) Correlations between the percentage changes in UNaV and the percentage changes in renal 
artery flow were lost in diabetics and not re-established with insulin. 










6.3.3 The effects of endothelin receptor antagonists on acute pressure natriuresis 
and renal blood flow in healthy control rats 
Mean BP rose in control rats receiving ET receptor antagonists by ~25-40mmHg 
(P<0.01, interaction P=0.61) and the rise was greatest overall in rats receiving the 
ETB receptor antagonist (P<0.01; Table 6.4; Fig. 6.8A).  However, the only 
difference in mean BP between agents was a mean BP ~18mmHg higher in ETB rats 
compared to ETA+ETB rats during Clearance 2 (Table 6.4; Fig. 6.8A).  GFR 
increased by up to 1.4ml/min/gkw (P<0.01) but there was no difference in the rise 
between agents (P=0.71, interaction P=0.12; Table 6.4; Fig. 6.8B).   
 
ETA receptor antagonism with atrasentan markedly suppressed acute pressure 
diuresis and natriuresis.  Maximum UV was reduced by ~60% (P=0.02 overall, 
P<0.01 during Clearance 2, interaction P=0.291; Table 6.4; Fig. 6.9A), UNaV was 
reduced by ~90% (P<0.01 overall and during Clearance 2, interaction P=0.339;  
Fig. 6.9C), and FENa by ~80% (P=0.04 overall and during Clearance 2, interaction 
P=0.219; Fig. 6.9E), and their relationships with mean BP were disrupted  
(Fig. 6.9B,D,F).  This was accompanied by suppression of medullary flux which 
increased by only ~20% so that medullary perfusion was approximately half of that 
with vehicle (P<0.01 overall and during Clearance 2; Table 6.4; Fig. 6.10A).  
Relationships between medullary flux and mean BP (Fig. 6.10B), UV (Fig. 6.10C) 
and UNaV (Fig. 6.10D) that had all been observed with vehicle, were lost with 
atrasentan.  Cortical flux (Fig. 6.10E) and renal artery flow (Fig. 6.12F) remained 






By contrast, the ETB receptor antagonist, A-192621, increased UNaV (P=0.03 
overall, P=0.02 during Clearance 2; Fig. 6.9C) and FENa (P=0.04 overall, P=0.046 
during Clearance 2; Fig. 6.9E) by ~40-60% more than maximum vehicle values but 
without a corresponding increase in UV (Table 6.4; Fig. 6.9A).  These effects were 
accompanied by the same doubling of medullary flux that was observed with vehicle  
(Table 6.4; Fig. 6.10A) so that the relationships between medullary flux and mean 
BP (Fig. 6.10B), UV (Fig. 6.10C) and UNaV (Fig. 6.10D) that were observed with 
vehicle were again disrupted.   
 
Combined ETA+ETB receptor antagonism gave a similar pattern of results to ETA 
receptor antagonism (Table 6.4).  It suppressed UNaV (P=0.04 overall and during 
Clearance 2; Fig. 6.9C) and FENa (P=0.03 overall, P=0.048 during Clearance 2; 
Fig.6.9E) by~70-90% without changing UV (Fig. 6.9A).  This effect was 
accompanied by a failure in medullary flux to rise (P=0.01 overall, P<0.01 during 
Clearance 2; Fig. 6.10A) and an increase in cortical flux during Clearance 2 (P=0.03; 









CONTROL Baseline Clearance 1 Clearance 2 
   Vehicle  ETA ETB  ETA+ETB Vehicle ETA ETB ETA+ETB Vehicle        ETA ETB   ETA+ETB 
BP 
(mmHg) 
124.0±4.3 109.6±5.2 116.0±4.7 108.4±7.0 136.0±4.9 124.3±4.1 134.5±3.7 123.4±3.9 143.9±4.2 135.0±3.8 155.9±4.6 137.9±5.1 
GFR 
(ml/min/gkw) 
    0.9±0.1 0.9±0.3  0.8±0.1 0.3±0.1 1.0±0.1 1.2±0.2     1.3±0.2 1.3±0.3 1.0±0.1    0.9±0.2 1.3±0.2     1.5±0.3 
UV 
(µl/min/gkw) 
    7.2±1.6 3.8±0.7   13.8±4.1 3.0±0.6   16.3±3.5 6.1±0.6   28.3±7.3 5.9±1.3 38.6±6.2  15.7±4.9** 47.4±12.4   19.6±4.2 
UNaV 
(µmol/min/gkw) 
    2.2±0.6 0.8±0.2  7.6±3.5 0.9±0.4     6.5±0.8 1.4±0.5   21.9±6.8 3.1±0.8 16.7±1.4  1.7±0.5**  26.6±6.9**   5.0±2.4** 
FENa 
(%) 
   1.7±0.6 0.5±0.1  5.6±3.0 1.4±0.3 3.5±0.7 1.7±0.8   10.0±4.0 3.1±2.0 15.0±2.4     3.4±1.4**  21.6±3.4**   1.6±1.1** 
Δ RA flow  
(%) 
      93.2±7.5    94.4±4.4   97.8±4.1 102.4±4.6 108.3±11.7 107.1±3.3   97.7±8.7 114.2±12.1 
Δ cortical flux  
(%) 
      93.5±4.8  103.3±3.2   96.1±4.3 122.6±14.4 98.5±6.5 112.8±4.2   83.6±11.8 143.9±24.1** 
Δ medullary flux 
(%) 
    159.4±20.1 108.8±10.3 150.0±9.7 109.4±9.8 227.2±26.7 122.2±26.7** 206.8±31.5 105.9±12.9** 
Table 6.4. Mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate (UNaV), fractional excretion of 
sodium (FENa), and changes (Δ) in renal artery (RA) flow, cortical flux and medullary flux in healthy control rats during Baseline and Clearances 1 and 2, 
after endothelin (ET) receptor antagonism 
**=P<0.05 compared with vehicle during same clearance period.  All data are mean ± standard error of the mean (SEM).  All comparisons made with two-







Fig. 6.8. Mean blood pressure (BP) and glomerular filtration rate (GFR) during ligature-
induced acute pressure natriuresis in healthy control rats after endothelin (ET) receptor 
antagonism 
A) Baseline mean BP and increments were not significantly different between cohorts except for 
a higher BP in ETB rats compared to ETA+ETB rats during Clearance 2.  Bars=mean ± standard 
error of the mean (SEM), *=P<0.05 compared with mean BP in previous period, **=P<0.05 
compared with other cohort.  All comparisons made with two-way analysis of variance 
(ANOVA) with Tukey’s post hoc tests. 
B) GFRs were similar between cohorts during every clearance period.  Every data point is the 
mean value of the dependent variable plotted against mean BP±SEM of both variables, and 

















Fig. 6.9. (page opposite) Ligature-induced acute pressure natriuresis in healthy control rats 
after endothelin (ET) receptor antagonism 
A) Pressure diuresis responses, with reduced urine flow rate (UV) during Clearance 2 in ETA 
receptor antagonist-treated rats  
B) Pressure diuresis responses with loss of the non-linear relationship with mean blood pressure 
(BP, growth constant (k)=0.03) in ETA receptor antagonist-treated rats.  A curvilinear 
relationship was present in ETB (k=0.02) and ETA+ETB (k=0.03) receptor antagonist-treated 
rats. 
C) Pressure natriuresis responses, with reduced urinary sodium excretion rate (UNaV) in ETA 
receptor antagonist-treated rats and increased UNaV in ETB receptor antagonist-treated rats 
during Clearance 2   
D) Pressure natriuresis responses, with loss of the linear relationship with mean BP (0.07-0.32, 
95% confidence) with ET receptor antagonism 
E) Reduced fractional excretion of sodium (FENa) in ETA receptor antagonist-treated rats and 
increased FENa in ETB receptor antagonist-treated rats during Clearance 2    
F) A curvilinear relationship between FENa and mean BP was established in ETA (k=0.02) and 
ETB  (k=0.01) receptor antagonist-treated rats.  
**=P<0.05 compared with vehicle 
For A), C) and E), every data point is the mean value of the dependent variable plotted against 
mean BP ± standard error of the mean (SEM) of both variables, and corresponds to one of three 
clearance periods.  All comparisons made with two-way analysis of variance (ANOVA) with 
Tukey’s post hoc tests.   












Fig. 6.10. (page opposite) Changes in medullary flux, cortical flux and renal artery flow with 
mean blood pressure (BP), urine flow rate (UV) and urinary sodium excretion rate (UNaV) in 
healthy control rats after endothelin (ET) receptor antagonism  
A) Medullary flux failed to rise in ETA and ETA+ETB receptor antagonist-treated rats. 
B) The curvilinear relationship between changes in medullary flux and mean BP (k=0.02) was 
lost in ETA and in ETB receptor antagonist-treated rats but was maintained in ETA+ETB 
receptor antagonist-treated rats, with a smaller rate of change (k=0.01). 
C) The correlation between percentage changes in UV and medullary flux was lost with ET 
receptor antagonism. 
D) The correlation between percentage changes in UNaV and medullary flux was lost with ET 
receptor antagonism. 
E) Cortical flux increased in ETA+ETB receptor antagonist-treated rats during Clearance 2. 
F) Renal artery flow was autoregulated in all control rats.  
**=P<0.05 compared with controls 
For A), E) and F), every data point is the mean value of the dependent variable plotted against 
mean BP ± standard error of the mean (SEM) of both variables, and corresponds to Clearance 1 
or Clearance 2.  All comparisons made with two-way analysis of variance (ANOVA) with 
Tukey’s post hoc tests, R2=coefficient of determination.  





6.3.4 The effects of endothelin receptor antagonists on acute pressure natriuresis 
and renal blood flow in diabetic and insulin-treated diabetic rats 
Mean BP rose in the early T1DM and T1DM+insulin rats by ~20-30mmHg (both 
P<0.01) but did not differ between ET receptor antagonists (T1DM P=0.20, 
interaction P=0.979; T1DM+insulin P=0.11, interaction P=0.98; Tables 6.5, 6.6;  
Figs. 6.11A,C).  GFR (early T1DM P=0.32; T1DM+insulin P=0.24; Figs. 6.11B,D) 
did not increase from Baseline values and did not differ within the early T1DM and 
T1DM+insulin cohorts (Tables 6.5, 6.6).   
 
Despite marked effects on pressure diuresis/natriuresis in healthy control rats, ET 
receptor antagonists had no effect on its suppression in early T1DM rats nor its 
recovery in T1DM+insulin rats (Tables 6.5, 6.6; Figs. 6.12A-F).  There were trends 
in the data that had a similar pattern to the effects of ET receptor antagonists in 
healthy controls: suppression with ETA receptor antagonism, enhancement with ETB 
receptor antagonism, and combined ETA+ETB receptor antagonism giving similar 
results to ETA alone.  However, the data spread was wide so that these trends did not 
reach statistical significance   
 
ET receptor antagonists had no effect on the suppression of medullary flux in early 
T1DM and T1DM+insulin rats (Tables 6.5, 6.6; Figs. 6.13A,C), although the ETA 
receptor antagonist, atrasentan, re-established relationships between percentage 
changes in medullary flux and UNaV in early T1DM rats (P=0.049; Fig. 6.14B), 




re-established linear relationships between percentage changes in mean BP and 
medullary flux in T1DM+insulin rats (both P<0.01; Fig. 6.13D).  
 
Cortical flux (T1DM P=0.42; T1DM+insulin P=0.34; Figs. 6.15A,B) remained at 
Baseline levels in all the ET receptor antagonist cohorts.  Overall, renal artery flow 
increased in both early T1DM and T1DM+insulin rats by ~10-15% (both P<0.01) but 
there was no difference between agents (early T1DM P=0.37, interaction P=0.66; 
T1DM+insulin P=0.25, interaction P=0.78) within either diabetic group  







DIABETIC Baseline Clearance 1 Clearance 2 
 
Vehicle ETA ETB ETA+ETB Vehicle ETA ETB ETA+ETB Vehicle ETA ETB ETA+ETB 
BP 
(mmHg) 
116.1±4.2 110.9±6.8 122.0±7.2 116.3±6.1 127.5±4.1 126.1±8.4 135.4±8.1 135.4±8.1  137.9±5.1 133.4±8.5 149.9±7.7 137.4±6.7 
GFR 
(ml/min/gkw) 
    1.3±0.5 0.7±0.3 0.6±0.1 0.7±0.2 0.8±0.2 1.3±0.6 0.6±0.2 0.9±0.2      1.1±0.2   1.2±0.4 1.3±0.3 1.1±0.2 
UV 
(µl/min/gkw) 
    8.7±3.2 3.2±0.9 5.0±1.1 4.1±0.6 8.5±2.5 5.4±1.5 7.9±3.3 4.5±0.8  14.0±3.4**   7.9±2.5   17.7±6.0   11.0±1.8 
UNaV 
(µl/min/gkw) 
    2.1±0.7 1.6±0.8 2.0±0.7 1.4±0.5     2.0±0.4 2.4±0.9 4.5±2.0 1.4±0.4    4.1±1.1**   3.2±1.4 7.0±3.4     2.6±1.4 
FENa 
(%) 
   1.9±0.8 0.8±0.3 1.2±0.4 1.7±0.6     2.8±1.0 1.0±0.4 1.8±1.1 1.1±0.2    3.7±1.0**  2.0±0.7 7.8±6.0     0.7±0.2 
Δ RA flow  
(%) 
      93.2±6.6 97.2±2.8 97.3±7.7 96.2±1.9  104.0±7.7 113.2±5.0 132.0±16.2 109.6±3.4 
Δ cortical flux  
(%) 
      97.6±6.1 93.8±5.8 96.6±4.4 97.7±3.8    99.6±8.3 98.7±3.3   99.8±8.2 107.4±7.1 
Δ medullary flux 
(%) 
    95.7±12.1** 101.8±9.3 85.4±9.6 108.4±10.4 115.4±10.3** 89.3±9.6 146.6±19.4 120.2±14.8 
             
Table 6.5. Mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate (UNaV), fractional excretion of 
sodium (FENa), and changes (Δ) in renal artery (RA) flow, cortical flux and medullary flux in diabetic rats during Baseline and Clearances 1 and 2, after 
endothelin (ET) receptor antagonism 
**=P<0.05 compared with vehicle-treated controls.  All data are mean ± standard error of the mean (SEM).  All comparisons made with two-way analysis of 








INSULIN Baseline Clearance 1 Clearance 2 
 
Vehicle ETA ETB ETA+ETB Vehicle ETA ETB ETA+ETB Vehicle ETA ETB ETA+ETB 
BP 
(mmHg) 
122.3±5.3 112.0±6.8 122.7±8.4 111.5±2.6 136.5±4.3 129.5±8.7 134.3±10.9 127.4±3.1  146.2±2.9 141.6±7.8 155.7±13.4 135.4±2.3 
GFR 
(ml/min/gkw) 
1.8±0.7 0.6±0.2 0.8±0.2 0.9±0.2 1.4±0.3 1.5±0.6 1.3±0.6 1.2±0.2 1.3±0.3 1.9±0.6  1.7±0.5 1.4±0.2 
UV 
(µl/min/gkw) 
13.1±4.5 2.5±0.5 6.4±3.7 3.8±0.8 17.8±5.7 7.0±1.9 13.6±9.8 5.9±1.3   30.4±12.4* 22.5±4.3  37.0±14.2 14.4±2.9 
UNaV 
(µmol/min/gkw) 
2.6±1.1 0.9±0.4 4.7±3.8 1.3±0.5 4.3±1.8 1.8±0.6 9.9±8.5 2.6±1.0   24.9±17.8* 8.6±3.0 21.9±9.8   6.1±2.0 
FENa 
(%) 
1.0±0.4 0.9±0.2 3.4±2.4 1.2±0.4 2.2±0.5 1.1±0.3 4.6±3.1 1.4±0.4   9.6±4.9* 5.8±2.2 8.5±3.3   2.9±0.3 
Δ RA flow  
(%) 
    102.8±6.9 107.9±6.5 85.2±6.1 97.6±3.4  113.2±4.5 121.2±9.3 112.0±13.6  117.3±6.5 
Δ cortical flux  
(%) 
    94.2±6.1 102.7±2.5 82.1±13.6 89.2±10.1    79.3±9.0 117.7±6.4 91.9±4.3 103.5±13.3 
Δ medullary flux 
(%)     108.7±6.1 104.2±9.2 85.8±21.2 111.1±8.7  112.2±6.8** 110.2±10.5 116.8±32.7  125.1±9.4 
Table 6.6. Mean blood pressure (BP), glomerular filtration rate (GFR), urine flow rate (UV), urinary sodium excretion rate (UNaV), fractional excretion of 
sodium (FENa), and changes (Δ) in renal artery (RA) flow, cortical flux and medullary flux in insulin-treated diabetic rats during Baseline and Clearances 1 
and 2, after endothelin (ET) receptor antagonism 
**=P<0.05 compared with vehicle-treated controls and *=P<0.05 compared with vehicle-treated diabetic rats during same clearance period.  All data are 














Fig. 6.11. (page opposite) Mean blood pressure (BP) and glomerular filtration rate (GFR) 
during ligature-induced acute pressure natriuresis in diabetic and insulin-treated diabetic rats 
after endothelin (ET) receptor antagonism 
A) Baseline mean BP and increments were not significantly different between diabetic cohorts. 
B) GFRs were similar between diabetic cohorts during every clearance period.   
C) Baseline mean BP and increments were not significantly different between cohorts. 
D) GFRs were similar between cohorts during every clearance period 
For A) and C), bars=mean ± standard error of the mean (SEM).  All comparisons made with 
two-way analysis of variance (ANOVA) with Tukey’s post hoc tests, *=P<0.05 compared with 
mean BP in previous period. 
For, B) and D), every data point is the mean value of the dependent variable plotted against 











Fig. 6.12. (page opposite) Ligature-induced acute pressure natriuresis in diabetic and insulin-
treated diabetic rats after endothelin (ET) receptor antagonism 
A) Suppression of pressure diuresis was unaffected by ET receptor antagonists in diabetic rats.   
B) Recovery of pressure diuresis was unaffected by ET receptor antagonists in insulin-treated 
diabetic rats.   
C) Suppression of pressure natriuresis was unaffected by ET receptor antagonists in diabetic 
rats.   
D) Recovery of pressure natriuresis was unaffected by ET receptor antagonists in  
insulin-treated diabetic rats.   
E) Reductions in FENa were unaffected by ET receptor antagonists in diabetic rats.   
F) Recovery of FENa was unaffected by ET receptor antagonists in insulin-treated diabetic rats.   
Every data point is the mean value of the dependent variable plotted against mean blood 
pressure (BP) ± standard error of the mean (SEM) of both variables, and corresponds to one of 
three clearance periods.  All comparisons made with two-way analysis of variance (ANOVA) 













Fig. 6.13. (page opposite) Changes in medullary flux with mean blood pressure (BP) in diabetic 
and insulin-treated diabetic rats after endothelin (ET) receptor antagonism 
A) Suppression of medullary flux was unaffected by ET receptor antagonists in diabetic rats. 
B) There was no relationship between percentage changes in medullary flux and mean BP in 
any diabetic cohort.   
C) Suppression of medullary flux was unaffected by ET receptor antagonists in insulin-treated 
diabetic rats. 
D) Linear relationships between percentage changes in medullary flux and mean BP were  
re-established in insulin-treated diabetic rats receiving ETA and ETB receptor antagonists, 
R2=coefficient of determination.   
For A) and C), every data point is the mean value of the dependent variable plotted against 
mean BP ± standard error of the mean (SEM) of both variables, and corresponds to Clearance 1 
or Clearance 2.  All comparisons made with two-way analysis of variance (ANOVA) with 












Fig. 6.14. (page opposite) Changes in medullary flux with urine flow rate (UV) and urinary 
sodium excretion rate (UNaV) in diabetic and insulin-treated diabetic rats after endothelin (ET) 
receptor antagonism 
A) Correlations between percentage changes in medullary flux and UV were lost with ET 
receptor antagonists in diabetic rats. 
B) Correlations between percentage changes in medullary flux and UNaV were re-established in 
diabetic rats receiving ETA receptor antagonist. 
C) Lack of correlation between percentage changes in medullary flux and UV was unaffected by 
ET receptor antagonists in insulin-treated diabetic rats. 
D) Lack of correlation between percentage changes in medullary flux and UNaV was unaffected 
by ET receptor antagonists in insulin-treated diabetic rats. 










Fig. 6.15. (page opposite) Changes in cortical flux and renal artery flow with mean blood 
pressure (BP) in diabetic and insulin-treated diabetic rats after endothelin (ET) receptor 
antagonism 
A) Cortical flux did not change from Baseline levels in all diabetic cohorts. 
B) Cortical flux did not change from Baseline levels in all insulin-treated diabetic cohorts.  
C) Renal artery flow increased overall during Clearance 2 but did not differ between individual 
diabetic cohorts. 
D) Renal artery flow increased overall during Clearance 2 but did not differ between individual 
insulin-treated diabetic cohorts. 
Every data point is the mean value of the dependent variable plotted against mean BP ± 
standard error of the mean (SEM) of both variables, and corresponds to Clearance 1 or 
Clearance 2.  All comparisons made with two-way analysis of variance (ANOVA) with Tukey’s 







6.3.5 Changes in expression of the renal endothelin-1 system 
Renal expression of EDN1, EDRA and EDRB in the cortex and medulla was not 
different in early T1DM and T1DM+insulin rats compared to controls  
(Figs. 6.16A,B). 
 
Fig. 6.16. Expression of the renal endothelin (ET) system in control, diabetic and insulin-treated 
diabetic rats 
A) Cortical expression of EDN1 and both EDRA and EDRB was no different in diabetic and 
insulin-treated diabetic rats compared to controls.   
B) Medullary expression of EDN1 and both EDRA and EDRB was no different in diabetic and 
insulin-treated diabetic rats compared to controls.   
ΔCT refers to the cycle threshold referenced to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), bars=mean ± standard error of the mean (SEM).  All comparisons made with  







In these experiments, measurement of renal blood flow has demonstrated that early 
T1DM has profound consequences for the renal handling of salt at higher BP.  Early 
T1DM suppresses the rise in medullary perfusion that is the vascular phase of acute 
pressure natriuresis.  Whether this is the physiological mechanism responsible for the 
impairment of acute pressure natriuresis that was demonstrated in Chapter 4 remains 
unclear because insulin restores natriuresis without restoring medullary perfusion.  It 
is concluded that normalising blood glucose with insulin does not restore the 
uncoupling of BP and medullary perfusion, but is sufficient to restore natriuresis.   
 
An additional major finding from these experiments is that ET-1 regulates acute 
pressure natriuresis through a balance of opposing ET receptor-mediated effects.  
Use of selective ET receptor antagonists has shown that ETA receptors increase 
medullary perfusion and are pro-natriuretic whereas ETB receptors enhance tubular 
sodium reabsorption directly and are anti-natriuretic.  These effects are unexpected 
because they contradict many of the putative roles of ET receptors.  However, they 
are consistent with the disruption to the circadian variation in diastolic BP recorded 
in rats during ETA receptor antagonism in Chapter 5 and its restoration with 
additional ETB receptor antagonism. Whereas the effects on BP were recorded in rats 
with early T1DM, modification of acute pressure natriuresis by ET receptor 
antagonists was only recorded in healthy controls and not diabetics.  One explanation 
for this discrepancy comes from the spread of data in this chapter that suggest that 
experiments may have been underpowered to demonstrate treatment effects in the 





Chapter 5 demonstrated that impaired acute pressure natriuresis in early T1DM is 
associated with changes in diastolic BP that relate to increased cardiovascular risk.  
Combined with this chapter’s data, it is concluded that if the clinical goal of tight 
blood glucose control with insulin is not achievable, reversing suppression of renal 
medullary perfusion might contribute to restoring acute pressure natriuresis in early 
T1DM, and may confer reductions in cardiovascular risk.  They also raise the 
possibility of obtaining reductions in cardiovascular risk even when control of blood 
glucose is optimal.  However, it is unlikely this would be achieved with highly 
selective ETA receptor antagonists, because they prevent ETA receptor-mediated 
increases in renal medullary perfusion and natriuresis.   
 
6.4.1 Renal blood flow was measured by further adaptation of ligature-induced 
acute pressure natriuresis.  
The experimental protocol to induce acute pressure natriuresis was the same as the 
one developed in Chapter 3 and used in Chapter 4.  Similar stepwise increases in 
mean BP were generated by arterial ligation across the control, early T1DM and 
T1DM+insulin cohorts.  Mean GFR was not a confounding variable because it 
remained within a range of mean GFRs measured during baseline clearance studies 
(Chapter 3).  An additional adaptation from the Chapter 4 protocol was to place three 
probes for measuring renal blood flow, and to cannulate the left ureter rather than 
perform a tube cystotomy.  These adaptations did not prevent the induction of acute 
pressure natriuresis, its impairment in rats with early T1DM, and its recovery in 




A combination of ultrasound and laser Doppler spectroscopy (LDS) was used to 
measure simultaneous shifts in total and regional renal blood flow during acute 
pressure natriuresis.  LDS has been used previously to measure fluctuations in 
cortical and medullary blood flow 185,225,303-307.  It follows the Doppler principle 235,236 
and has been validated against other real-time (electromagnetic) and in vitro 
(microspheres) methods 236.   
 
6.4.2 Impairment of acute pressure natriuresis in early Type 1 diabetes mellitus is 
associated with suppressed medullary perfusion.  
Roman and Cowley 138 were the first to demonstrate an increase in medullary blood 
flow, but not cortical or renal artery flow, when mean BP or renal perfusion pressure 
increase.  In this chapter, by using a similar protocol to Roman and Cowley 112, a 
similar increase in medullary perfusion was demonstrated in healthy controls.  
Increasing medullary perfusion leads to the increase in interstitial hydrostatic 
pressure that suppresses pressure-sensitive sodium reabsorption and results in 
natriuresis 89,308,309.  Therefore, these data would suggest that early T1DM impairs 
acute pressure natriuresis by preventing transmission of increased mean BP to the 
medullary circulation.  
 
Renal artery flow failed to increase, consistent with an autoregulatory response 138 
that suggests there is a proportionate increase in renal vascular resistance 
downstream of the renal artery when mean BP increases.  Therefore, an increase in 
renal perfusion pressure rather than just renal artery flow is required to sustain the 





Renal perfusion pressure has been studied previously in rats with early T1DM but 
more in terms of glomerular rather than medullary haemodynamics 310-312.  
Glomerular hyperperfusion is a major contributor to the glomerular hyperfiltration 
that initiates diabetic nephropathy 44.  Studies in STZ-induced T1DM rats have 
shown that increased glucose levels within the renal filtrate promote sodium 
reabsorption from the PCT 52.  This exposes the macula densa downstream to lower 
concentrations of sodium, blunting the influence of tubuloglomerular feedback (TGF) 
on the myogenic response of the afferent arteriole 99.  The consequence is 
inappropriate afferent arteriodilation that drives glomerular hyperperfusion 99,310.  In 
this chapter, Baseline renal artery flow and GFR were not increased in rats with early 
T1DM.  This may, in part, have been a consequence of general anaesthesia lowering 
mean BP in the diabetic rats to control levels.  This may also have occurred in 
Chapter 4, despite the impairment to acute pressure natriuresis caused by early 
T1DM. 
 
Less is known about the impact of early T1DM on efferent arteriolar flow than on 
afferent arteriolar flow.  Blood exits the glomerulus through the efferent arteriole and 
perfuses the post glomerular peritubular network, including the medullary  
vasa recta 305.  Therefore, increased efferent arteriolar flow initiates acute pressure 
natriuresis 313.  Both the renal cortex and the medulla contain elements of the 
peritubular vascular network but the majority is contained within the medulla, while 
the cortex also contains glomerular and preglomerular components.  Therefore, by 




this chapter are the first to quantify the post glomerular effects of early T1DM and 
the consequences for the vascular component of acute pressure natriuresis.   
 
Cortical flow was also autoregulated while medullary flow increased, even though all 
medullary blood flow is derived from the cortex.  The cortex contains the glomeruli 
of two different types of nephrons: cortical nephrons, which have short loops of 
Henle and vasa recta, and juxtamedullary nephrons, whose loops of Henle and vasa 
recta are long and penetrate the inner medulla 305.  During acute pressure natriuresis, 
there is a shift from perfusion of cortical nephrons towards juxtamedullary  
nephrons 305.  This allows overall cortical perfusion to remain unchanged while 
medullary perfusion increases.  The shift from cortical to juxtamedullary nephrons is 
based on relative changes in vascular resistance 305.  The mechanism for this should 
be investigated in future experiments (Chapter 7.2, page 276) as it may underpin the 
impairment of medullary perfusion and acute pressure natriuresis demonstrated in 
early T1DM in this chapter.   
 
6.4.3 Changes in renal perfusion in Type 1 diabetes mellitus are similar to those 
observed in models of hypertension. 
The failure of medullary blood flow to rise in rats with early T1DM, despite 
increases in renal perfusion pressure, is common to other rodent models of 
hypertension such as rats chronically infused with the nitric oxide synthase (NOS) 
inhibitor N-nitro L-arginine methyl ester (L-NAME) 314 or angiotensin II (AngII) 315, 
and deoxycorticosterone acetate (DOCA) salt-sensitive 316, and AngII receptor  




rodent models may share common pathways that drive hypertension through 
dysregulation of medullary perfusion, but it is also consistent with the concept that 
the state of hypertension can only be maintained if there is a concurrent dysfunction 
in acute pressure natriuresis 89.  This has clinical significance for two reasons.  First, 
suppressed medullary perfusion following increases in BP has also been recorded in 
Fischer (F344) rats that are prone to hypertensive renal damage 123, offering a 
potential link between impaired medullary perfusion in early T1DM and the 
development of nephropathy, an important contributor to cardiovascular risk.  
Second, non-diabetic rodent models of hypertension could provide mechanistic 
insight and reveal pharmacological targets that enhance medullary perfusion and 
acute pressure natriuresis in early T1DM, and hence reduce cardiovascular risk.  
Such mechanisms include upregulation of the purinergic receptor P2X7 123,315, 
reduced arachidonic acid hydroxylase activity 317 and impaired nitric oxide (NO)  
signalling 306.   
 
NO signalling is of particular interest because it has profound effects on both 
vascular and tubular phases of acute pressure natriuresis.  It is discussed below in 
relation to its interactions with insulin.   
 
6.4.4 Insulin does not fully restore acute pressure natriuresis in early Type 1 
diabetes mellitus. 
Chapter 4 demonstrated that sodium excretion during acute pressure natriuresis 
recovered in early T1DM following treatment with insulin.  The experiments in this 




natriuresis in the T1DM+insulin cohort was accompanied by an increase in fractional 
sodium excretion even though medullary perfusion remained suppressed.  The data 
show that replacement insulin therapy elicits a compensatory natriuresis without 
completely restoring the renal vasculotubular interactions of acute pressure 
natriuresis.  It is concluded that medullary perfusion and tubular sodium transport are 
tightly linked to blood glucose and insulin levels but that tubular sodium transport is 
more sensitive to the effects of glycaemic control with insulin.   
 
6.4.5 The role of insulin in sodium transport may vary with the form of diabetes 
mellitus. 
What is not clear is whether the compensatory natriuresis from insulin therapy is a 
consequence of a direct inhibitory effect of insulin on tubular sodium reabsorption or 
because lowering blood glucose with insulin reverses increased tubular sodium 
reabsorption that is driven by hyperglycaemia.  The latter would appear more 
plausible since hyperglycaemia is already known to increase sodium reabsorption 
through increased activity of the sodium-glucose co-transporter-2 (SGLT2) 318.  
Evidence that this was responsible might have come from higher glomerular 
filtration rates in untreated early T1DM rats compared to their insulin-treated 
counterparts, as a consequence of reduced TGF and glomerular hyperperfusion 312,318. 
However, GFR did not vary with diabetic status.  Therefore, a direct effect of insulin 
on sodium transport should be considered.  
 
If insulin reduces tubular sodium transport directly, then it would contradict the 




hypertension in T2DM 267, and which is targeted by SGLT2 inhibitors 268.  Clinical 
trials in T2DM have shown that by preventing sodium-glucose co-transport in the 
PCT, SGLT2 inhibitors promote weight loss, reducing insulin resistance and 
additional sodium reabsorption due to hyperinsulinaemia 319.  In my experiments, 
however, restoration of natriuresis, but not medullary blood flow, suggests that low 
levels of insulin sufficient to normalise blood glucose also directly inhibit tubular 
sodium transport.  This is in agreement with studies in renal insulin receptor KO 
mice in which sodium excretion is reduced and BP is increased 146.  Thus, the 
contrasting pro-natriuretic role of low levels of insulin and anti-natriuretic role of 
insulin in hyperinsulinaemia may represent fundamental differences between the 
pathogeneses of hypertension in T1DM and T2DM.   
 
One potential mechanism for insulin-induced natriuresis is insulin-induced release of 
NO 146,269.  T1DM is known to interfere with NO signalling but, multiple in vitro and 
in vivo studies have generated contradictory data that suggest NO bioavailability 
within the kidney is both enhanced and suppressed 137.  All three isoforms of NOS 
are expressed within the kidney, and T1DM has been shown to increase the activity 
of them all 320,321.  However, this does not always equate to increased NOS 
expression.  Instead, T1DM can increase NOS activity through post-translational 
modifications 322.  The resulting increase in production of vasodilatory NO has been 
implicated in the afferent arteriodilation and glomerular hyperfiltration thought to 
initiate diabetic nephropathy 310.  In the medulla, the situation is less clear.  NOS1 
and NOS3 activity are increased 322 but T1DM also increases production of reactive 




counteract increased NO production 137.  NO in the medulla plays an important role 
in recruiting vasa recta to increase medullary perfusion and initiate acute pressure 
natriuresis 306,323.  However, in this chapter, medullary perfusion was not restored 
with insulin, suggesting that any effect on NO signalling was more likely to occur in 
the renal tubules.  Insulin is known to increase NO production in renal collecting 
duct cells 269, which is the same site for ETB-receptor mediated NO release and 
inhibition of ENaC 260.  Therefore, an interaction between insulin and ETB  
receptor-mediated release of NO was investigated during the same series of 
experiments by challenging the restoration of natriuresis in T1DM+insulin rats with 
an ETB receptor antagonist.   
 
Regardless of whether lowering blood glucose or increasing insulin can induce 
natriuresis, how this allows BP to bridge the suppression of medullary perfusion and 
couple it to tubular sodium reabsorption is not apparent.  Furthermore, whether this 
can be sustained in the long term to maintain adequate sodium excretion to offset 
varying increments in BP is also not known.  It is, perhaps, not surprising that with 
the large number of regulatory mechanisms for sodium excretion, that the tubules 
were able to mount a natriuretic response to extreme increases in mean BP.  However, 
since Chapter 5 showed that early T1DM disrupts regulation of diastolic BP and 
because suppressed medullary perfusion has also been demonstrated in various 
models of hypertension, the data in this chapter suggest that restoration of medullary 
perfusion should be considered the therapeutic goal when attempting to reduce 
cardiovascular risk in early T1DM, especially if control of blood glucose levels with 




medullary perfusion and impaired acute pressure natriuresis attempted to confirm 
this, by assessing the potent vascular effects of ETA and ETB receptor antagonists 
during acute pressure natriuresis. 
 
6.4.6 Endothelin receptor antagonism modifies the acute pressure natriuresis 
response in healthy rats and has clinical significance. 
In healthy control rats, selective ETA (atrasentan) and ETB (A-192621) receptor 
antagonists modified acute pressure natriuresis, inducing marked, opposing effects 
on sodium excretion.  ETA receptor antagonism impaired acute pressure natriuresis 
and suppressed the pressure-induced increase in renal medullary perfusion.  There 
was a trend towards a lower mean BP in the ETA receptor antagonist cohort, most 
likely as a consequence of systemic arteriodilation 77.  Therefore, the possibility that 
medullary perfusion and natriuresis had been suppressed by a lower mean BP 
compared to controls was analysed.   
 
There was good evidence that the ETA receptor antagonist had interfered with the 
transmission of increased BP to the renal tubules.  The curvilinear and linear 
relationships of mean BP with UV and UNaV, both of which were observed with 
vehicle, were disrupted by atrasentan, and atrasentan also decreased UNaV at similar 
mean BPs to the vehicle cohort.  Furthermore, for similar proportionate increases in 
mean BP, the proportionate increase in medullary perfusion was reduced by 
atrasentan compared to vehicle.  It is concluded that suppression of medullary 
perfusion and natriuresis by the ETA receptor antagonist was independent of the 





By contrast to ETA receptor antagonism, ETB receptor antagonism with A-192621 
enhanced pressure natriuresis but this occurred without a corresponding increase in 
medullary perfusion.  This was consistent with direct inhibition of tubular sodium 
reabsorption.  Similar to atrasentan, the effects of A-192621 could not be explained 
by the agent’s systemic vasodilatory properties 77.  Following injection, mean BP 
was similar to mean BP in vehicle-treated rats, there was a clear leftward shift in the 
pressure diuresis curve, and values of UNaV at similar mean BPs to the vehicle 
cohort were greater.   
 
Combined ET receptor antagonism mirrored the effects of ETA receptor antagonism.  
The contribution made by ETB receptor antagonism may have been reduced by the 
lower mean BP in this cohort, suggesting that the natriuresis observed during 
selective ETB receptor antagonism was dependent on intact ETA receptor signalling 
or an increase in medullary blood flow.  The implication is that improved glycaemic 
control with insulin, and ETB receptor antagonism promote natriuresis through 
separate mechanisms: insulin-induced natriuresis was observed when medullary 
perfusion was still suppressed, while A-192621-mediated natriuresis was only 
observed when medullary perfusion was at vehicle levels. 
 
Together, these data from healthy rats support the hypothesis of a pro-natriuretic role 
for ETA receptors, by increasing medullary perfusion, and an anti-natriuretic role for 
ETB receptors by enhancing tubular sodium reabsorption.  This is not consistent with 




as mediating pathological effects such as powerful vasoconstriction 77  which is 
implicated in vascular dysfunction 258,300, and promotion of inflammation 154,188-195, 
cell damage and fibrosis 50,196-198.  They have also been shown to promote rather than 
prevent sodium and water retention by potentiating the activity of vasopressin and 
the anti-diuretic/anti-natriuretic effects of sympathetic activation on the kidney 324,325.  
ETB receptors, on the other hand, have well-established diuretic and natriuretic roles 
centred around inhibition of sodium reabsorption through ENaC and water 
reabsorption through aquaporin-2 (AQP2) in the collecting duct 181,260.  However, 
these effects were observed in vitro, in animal models during resting states with 
carefully controlled sodium intakes, or in animal models with deletion of ET-1 
signalling targeted to discrete regions of the nephron 122.  In two studies where 
sodium loading was mimicked by alternative strategies to arterial ligation (rapid iv. 
infusion of physiological saline 262, and intramedullary injection of hyperosmolar 
saline 302), and renal ET-1 signalling was manipulated by ET receptor antagonists, 
ET-1 appeared to take on a different role.  In both studies, ETA receptor antagonism 
reduced urinary sodium excretion, and ETB receptor antagonism (either alone or in 
combination with ETA receptor antagonism) increased sodium excretion.  Neither of 
these studies attempted to identify a mechanism, and changes in renal blood flow 
were not measured, but when combined with the data in this chapter, they suggest 
that these apparently novel roles for ET receptors are not apparent during the resting 
state and only become active following acute rises in BP or sodium intake.   
 
One study of ligature-induced acute pressure natriuresis contradicts this concept.  




healthy rats and demonstrated reductions in both medullary perfusion and sodium 
excretion.  However, there are a number of differences between Vassileva et al.’s 
study and the experiments in this chapter.  First, Vassileva et al. measured only 
resting medullary blood flow.  They did not measure the change in medullary 
perfusion when mean BP was increased.  Second, they measured medullary blood 
flow only during infusion of Big ET-1, and after rats had been placed on a high salt 
diet.  A high salt diet, which is known to upregulate renal ETB receptors 
326, 
combined with higher than physiologically normal levels of ET-1, may have elicited 
an increase in sodium excretion that was not representative of the acute pressure 
natriuresis response.  Third, they exposed rats to much lower mean BPs  
(80-144mmHg) compared to this chapter (110-156mmHg).   
 
A weak pro-natriuretic role for renal ETA receptors has also been identified in 
experiments in which acute salt loading was not modelled.  KO mouse models 
suggest that the ETA receptors involved are located within the collecting duct 
327.  
However, suppression of medullary perfusion during ETA receptor antagonism, as 
shown in this chapter, and reduced fluid retention in smooth muscle ETA receptor 
KO mice during ETA receptor antagonism 
327 would both suggest that they lie within 
the renal vasculature.  The exact location of these ETA receptors is open to 
speculation.  Vascular ETA receptors on vasa recta pericytes promote constriction 
183 
which would reduce rather than increase medullary blood flow.  This would make a 
location within the cortex rather than the medulla more likely.  One potential source 
of ETA receptors is in the afferent arteriole where they contribute to glomerular 




arterioles during infusion with ET-1 and the selective ETA receptor antagonist, 
BQ123, suggest a greater vasoconstrictive response in the afferent arterioles of 
cortical glomeruli 139 that could promote diversion of flow through juxtamedullary 
glomeruli and into medullary vasa recta.  Furthermore, ETA receptors in 
juxtamedullary afferent arterioles appear to interact with ETB receptors to promote 
arteriodilation 328 which could also promote medullary perfusion.   
 
If vascular ETA receptors are considered as coupling medullary perfusion to BP, and 
the conflicting data sets for ETB receptor antagonism from this chapter and Vassileva 
et al.’s study are considered, a dynamic role for ET-1 emerges in which novel effects 
on sodium excretion only become active once a threshold of mean BP is exceeded.   
 
Regardless of the mechanistic basis, a role for ETA receptors in promoting medullary 
perfusion and acute pressure natriuresis has clinical significance as it would explain 
the sodium and water retention observed clinically with even highly selective ETA 
receptor antagonists 218,219,223,329.  Reductions in proteinuria in diabetic  
nephropathy 218,219,329 and non-diabetic CKD 330, and improved nocturnal dipping in 
non-diabetic CKD 226 have been demonstrated clinically.  The results in this chapter 
suggest that this may be a consequence of the anti-inflammatory and anti-fibrotic 
effects of ETA receptor antagonists 




6.4.7 The effects of ET receptor antagonists on acute pressure natriuresis are 
consistent with their effects on blood pressure. 
A pro-natriuretic role for ETA receptors and an anti-natriuretic for ETB receptors 
were proposed following continuous measurement of BP during ET receptor 
challenge in rats with early T1DM (Chapter 5).   
 
Circadian regulation of BP can be used as a marker of acute pressure natriuresis, and 
circadian regulation of diastolic BP was suppressed with atrasentan and restored with 
A-192621.  However, these effects on diastolic BP were recorded only in the diabetic 
rat cohort, and in this chapter, despite marked effects in healthy control rats, neither 
ET receptor antagonist modified the effects of early T1DM or insulin on the vascular 
or tubular phases of acute pressure natriuresis.  So, although the roles of ET receptors 
were correctly predicted, there is a clear disconnect between their effects in early 
T1DM during small rises in BP following oral salt and water ingestion, and acute, 
severe rises in BP under general anaesthesia.  However, there was a striking 
similarity in the pattern of results for UV, UNaV and FENa across all cohorts during 
ET receptor antagonism: suppression with ETA receptor antagonism, enhancement 
with ETB receptor antagonism, and combined ET receptor antagonism matching ETA 
receptor antagonism.  The spread of data in the early T1DM and T1DM+insulin 
cohorts was wide, and so these trends did not achieve statistical significance, but the 
pattern of the data raises the possibility that the study was underpowered for 





Although the study was powered for the proportionate suppression of diuresis and 
natriuresis that was demonstrated, the absolute values of UV and UNaV following 
arterial ligation were far less than in the experiments in Chapter 4.  This, and the 
uncoupling of the relationship between FENa and rising BP (Chapter 4), suggest that 
the additional adaptations made to the protocol disrupted the acute pressure 
natriuresis response.  One could speculate that the surgical preparation time (20% 
longer than in Chapter 4) and manipulation of abdominal organs required to place 
three probes and a ureteral cannula may have contributed to reduced urinary sodium 
and water excretion because, subjectively, they increased fluid loss into the abdomen 
(Chapter 3).  It is concluded that the protocol used in this chapter was operating at its 
experimental limits, which could have reduced the effect size of ET receptor 
antagonists on medullary perfusion and sodium excretion in early T1DM and 
T1DM+insulin, and introduced Type 2 errors.   
 
The risk of Type 2 errors could have been reduced by supplementing the study with 
additional rats, following unblinding.  However, by this stage the study had already 
used >100 rats over a period of one year, and prolonging the study posed practical 
difficulties relating to time, resources and finance.  Alternatively, the study could be 
repeated without measuring renal blood flow and ureteral cannulation.  Similar 
cohort sizes should provide adequate power for demonstrating additional diuretic and 
natriuretic effects of ET receptor antagonists in both diabetic cohorts but would not 





6.4.8 The response to endothelin receptor antagonists is not reflected in the 
expression of genes that code for endothelin-1 and its receptors. 
These data suggest that both early T1DM and ETA receptor antagonism suppress 
acute pressure natriuresis by suppressing medullary perfusion.  Additional 
experiments (Chapter 7) would be required to confirm the mechanistic link between 
suppression of medullary perfusion and suppression of acute pressure natriuresis, but 
the possibility that early T1DM suppresses medullary perfusion by interfering with 
ETA receptor signalling was partially explored by qPCR.  A link between increased 
sodium excretion via insulin and impaired ETB receptor signalling was also 
investigated at the transcriptional level.  However, no association between diabetic 
status and levels of EDN1, EDRA and EDRB mRNA in the renal cortex and medulla 
could be demonstrated.   
 
These results were perhaps surprising because upregulation of genes that code for 
ET-1, and ETA and ETB receptors have been demonstrated previously in  
T1DM 255,258,259,300.  There are a number of possible explanations for these results.  It 
could be that the rat model used in this thesis is at too early a stage of T1DM to 
demonstrate increased expression of genes coding for the ET system.  Studies of 
expression in blood vessels, for example, have been performed after 10-14 weeks of 
T1DM 255,258,259,300 compared to two-to-three weeks in these experiments.  Chapter 4 
failed to demonstrate an increase in expression of markers of renal pathology, 
including 24-hourly urinary ET-1 excretion 261, and it may be that increased 
expression of ET signalling components is only measurable after the onset of 




insulin exerting functional effects by modifying EDN1 expression because ET-1 
mRNA has a short half-life of ~15 minutes 77 and ET-1 is usually secreted as soon as 
translation is complete 77.  Tissue was not collected during acute pressure natriuresis 
and, therefore, it is possible that early T1DM and insulin influence rapid 
transcription of EDN1 in response to acute changes in BP and that this would not be 
detected by qPCR performed on tissue collected when BP is stable.  As an alternative 
explanation, any interference from early T1DM and insulin on ET-1 signalling could 
be downstream of EDN1 and EDRA and EDRB expression.  This is known to occur 
in other key regulatory mechanisms in T1DM, such as post-translational 
modification of NOS enhancing NO signalling with no change in NOS expression 322.  
As a final possibility, sections of cortex that were collected will have included both 
cortical and juxtamedullary glomeruli.  Therefore, while there may have been 
changes in the relative expression of elements of ET signalling within these 
glomerular types, sufficient to increase blood flow through the medulla, the overall 
expression in the cortex may have been unchanged.   
 
Combined with the failure of the ETB receptor antagonist to prevent insulin-induced 
natriuresis, these qPCR data provide additional evidence that recovery of natriuresis 
by insulin does not involve ETB receptor-mediated inhibition of ENaC by NO.  
Therefore, future experiments attempting to identify the causative mechanism should 





These data show that suppression of acute pressure natriuresis by early T1DM may 
be a consequence of suppression of medullary perfusion.  This does not recover 
completely with insulin, which restores natriuresis through direct inhibition of 
tubular sodium reabsorption.  Renal ET-1 regulates acute pressure natriuresis and 
both receptor subtypes play key roles.  ETA receptor signalling increases renal 
medullary perfusion and natriuresis.  ETB receptor signalling increases sodium 
reabsorption and inhibits natriuresis.   
 
Semi-quantitative PCR failed to demonstrate that the effects of early T1DM and 
insulin on acute pressure natriuresis result from changes in cortical or medullary 
expression of genes that encode ET-1 and its receptors.  ET receptor antagonists also 
failed to modify the effects of early T1DM and insulin on acute pressure natriuresis 
but the study may have been underpowered for demonstrating a drug effect 
downstream of receptor expression.   
 
ETA receptors are pro-natriuretic and ETB receptors can be anti-natriuretic, which is 
contrary to their putative roles.  These roles may only become active at higher BPs, 
and may explain sodium and water retention with highly selective ETA receptor 
antagonists.   
 
Although the mechanistic basis to these results has not been determined, the data 
support developing therapies that increase renal medullary perfusion in early T1DM 




alone.  This is unlikely to be achieved by highly selective ETA receptor antagonism.  
This is because ETA receptor antagonists impair rather than promote medullary 
perfusion and acute pressure natriuresis, and off-target ETB receptor effects can 









The experiments described in this thesis have investigated the contribution that 
impaired renal handling of salt makes to the regulation of blood pressure (BP) in 
early Type 1 diabetes mellitus (T1DM), the implications for cardiovascular risk, and 
the potential for reducing this risk by pharmacologically targeting the role played by 
renal ET-1.  
 
T1DM is one of the most common endocrine disorders in children 7, and increases 
their risk of cardiovascular disease (CVD) in later life 16-18.  Tight control of blood 
glucose with insulin, within a crucial early window after diagnosis, reduces but does 
not eliminate cardiovascular risk 24,29, and also increases the risk of life-threatening 
hypoglycaemia 34, especially in young patients.  There is, therefore, a great unmet 
need to target and treat risk factors for CVD in early T1DM, in order to complement 
the clinical benefits from lowering blood glucose with insulin.   
 
Major cardiovascular risk factors in T1DM are hypertension and nephropathy 247-249.  
They are tightly linked, since elevated BP, in the presence of hyperglycaemia, is key 
to the development of diabetic nephropathy 72.  Acute pressure natriuresis within the 
kidney regulates BP 79-81,89: rapid rises in BP increase renal medullary blood flow, 
inhibit tubular sodium reabsorption and increase urinary sodium excretion, 
normalising BP.  This would suggest that hypertension, nephropathy and increased 
cardiovascular risk in T1DM must be preceded by disruption to acute pressure 




in acute pressure natriuresis in early T1DM, and the role played by the endothelin 
(ET) system.   
 
The ET system is of interest because it is highly expressed within the kidney 77 and it 
is already known to play a key role in the development of diabetic nephropathy.  The 
principal ligand is ET-1, and T1DM increases its transcription and release 205.  In the 
glomerulus, ET-1 binds to its receptor subtype, ETA, to promote inflammation, 
mesangial expansion, fibrosis and proteinuria 50,154,188-198,331, all hallmarks of diabetic 
nephropathy.  ET-1 has potent vasoactive effects, and T1DM shifts its vascular 
influence towards vasoconstriction via enhanced smooth muscle ETA and ETB 
receptor signalling, and reduced vasodilation via impaired endothelial ETB receptor 
signalling 258,259,300.  However, ET-1 also has potent pro-natriuretic properties via 
ETB receptors that inhibit the epithelial sodium channel (ENaC) in the renal 
collecting duct 180,181,260.  Since acute pressure natriuresis consists of both vascular 
and tubular phases, increased renal ET-1 activity in T1DM has the potential to 
modify acute pressure natriuresis, BP and hence cardiovascular risk profoundly.   
 
Selective ETA receptor antagonists are already at an advanced stage of clinical 
development, and have been shown to reduce BP and proteinuria in established 
diabetic nephropathy 218,219,329.  Therefore, experiments were conducted not only to 
determine the degree to which early T1DM impairs acute pressure natriuresis and 
regulation of BP, but also the contribution that ET-1 makes to acute pressure 
natriuresis and BP, and whether this is modified by early T1DM.  Inflammatory and 




early stage of T1DM, before the development of nephropathy.  This also modelled 
the early window of opportunity within which insulin reduces cardiovascular risk and 
addressed the question of whether selective ETA receptor antagonists might have a 
clinical application in reducing cardiovascular risk in T1DM prior to the onset of 
nephropathy.    
 
7.1.1 Acute pressure natriuresis in Type 1 diabetes mellitus. 
In the first series of experiments (Chapter 4), I induced acute pressure natriuresis in a 
streptozotocin (STZ) rat model of early T1DM.  I modified the protocol of Roman 
and Cowley 112 (Chapter 3), in which stepwise increases in mean BP were obtained 
by serial ligation of major abdominal arteries and the distal aorta.  
 
The suppression of acute pressure natriuresis in early T1DM rats was striking.  
Maximum urine flow and sodium excretion rates (UV and UNaV) failed to reach 
25% of control levels, despite maintaining glomerular filtration rate (GFR).  
Fractional excretion of sodium (FENa) matched the suppression of UNaV, indicating 
that impairment of natriuresis by early T1DM was a consequence of inappropriate 
tubular sodium reabsorption.  Biochemical and molecular analysis of renal tissue and 
urine confirmed that these were functional effects that preceded activation of the 
renin-angiotensin-aldosterone system (RAAS) and the development of structural 
nephropathy.   
 
When rats with early T1DM were treated with insulin to normalise blood glucose 




(UET-1V), a marker of renal ET-1 activity 209, was tightly correlated with UV and 
UNaV, regardless of diabetic status.  The causative nature of these relationships was 
not determined, but a role for ET-1 in regulating the suppression of acute pressure 
natriuresis in early T1DM, and its recovery with insulin, was implicated.   
 
Together, the experiments in Chapter 4 demonstrated that T1DM disrupts a key 
regulatory mechanism for BP, very early on in the course of the disease, prior to the 
development of nephropathy.  Furthermore, this functional effect can be reversed 
with insulin without disrupting the tight relationships between urinary sodium and 
water excretion and renal ET-1 activity.   
 
7.1.2 Blood pressure and its circadian variation in Type 1 diabetes mellitus 
In order to justify further investigation into the mechanistic basis to these results, I 
first explored the implications for cardiovascular risk of a link between impaired 
acute pressure natriuresis in early T1DM and ET-1 signalling.  BP was measured by 
radiotelemetry and used as a surrogate marker for cardiovascular risk because 
hypertension is a consequence of impaired acute pressure natriuresis, and is 
associated with increased cardiovascular risk in T1DM 247,248.   
 
Early T1DM increased diastolic BP by ~5mmHg and circadian regulation of diastolic 
BP was also disrupted.  Normally, circadian variation in BP mirrors circadian 
variation in sodium excretion: BP and sodium excretion are usually higher during the 
day and dip at night.  BP at night increases when daytime acute pressure natriuresis 




cardiovascular risk 102-104.  In the diabetic rats, diurnal dipping in diastolic BP was 
4% less than in controls over a 24-hour cycle.  Increased diastolic BP has a higher 
correlation than increased systolic BP with the risk of developing nephropathy 290,291.  
Therefore, combined, the data generated from acute pressure natriuresis and 
radiotelemetry studies provided strong evidence for a contemporaneous relationship 
between impaired acute pressure natriuresis in early T1DM and increased risk of 
nephropathy and CVD.   
 
In order to determine whether manipulation of the tight relationship between sodium 
and urinary ET-1 excretion translated into quantifiable effects on BP, I also measured 
BP in the same rats during supplementation with salt, an ETA receptor antagonist and 
then combined ETA and ETB receptor antagonism.  ETA receptors mediate powerful 
vasoconstriction 77,163 and so the reduction in systolic and diastolic BP recorded in 
control and early T1DM cohorts during ETA receptor antagonism was expected.  
However, the effect size was smaller in the diabetic rats, despite a degree of salt 
sensitivity in the control rats.  Increased circadian variation in BP was also expected 
during ETA receptor antagonism because antagonising vasoconstriction should 
increase renal medullary blood flow and activate acute pressure natriuresis.  Instead, 
surprisingly, circadian variation in diastolic BP was reduced in the rats with early 
T1DM.  Together the results suggested that ETA receptor antagonism impairs rather 
than enhances acute pressure natriuresis.   
 
The addition of the ETB receptor antagonist also led to unexpected results.  ETB 




the vascular and tubular components of acute pressure natriuresis.  Antagonising 
these effects was expected to increase BP and decrease circadian variation in BP.  
Instead, diastolic BP in the early T1DM rats did not rise, and circadian variation in 
diastolic BP was restored, suggesting that ETB receptors impair rather than promote 
acute pressure natriuresis in early T1DM.   
 
Overall, the effects of the ET receptor antagonists on diastolic BP were suggestive of 
novel pro-natriuretic (ETA) and anti-natriuretic (ETB) roles for ET receptors.  It was 
clear that further in vivo investigation into the mechanism of impairment and 
recovery of acute pressure natriuresis by early T1DM and insulin, should include 
manipulation with ETA and ETB receptor antagonists.   
 
7.1.3 Renal blood flow in Type 1 diabetes mellitus 
In acute pressure natriuresis, acute rises in BP shift renal perfusion to the medulla, 
which increases interstitial hydrostatic pressure, and inhibits tubular sodium 
reabsorption 89,138,296.  Suppression and recovery of acute pressure natriuresis could 
either result from changes to medullary blood flow or changes to tubular sodium 
reabsorption.  Therefore, the effects of early T1DM, insulin and ET receptor 
antagonists on the vascular and tubular components of acute pressure natriuresis 
were determined (Chapter 6).  This work shows that sodium excretion is dependent 
on a series of complex interactions in the kidney between BP, medullary blood flow, 





Early T1DM prevented a rise in renal medullary perfusion when BP was increased, 
suggesting that uncoupling of medullary blood flow from BP was the physiological 
mechanism driving impaired acute pressure natriuresis in early T1DM.  However, in 
a T1DM+insulin cohort, natriuresis was restored without restoring the rise in 
medullary blood flow.  One explanation would be that medullary blood flow in 
treated or untreated early T1DM is not as crucial to coupling BP to inhibition of 
sodium reabsorption as normalising blood glucose and insulin levels.  However, this 
would be inconsistent with many rodent models of hypertension in which 
suppression of medullary perfusion is a consistent feature.  An alternative 
explanation would be that lowering blood glucose with insulin elicits a compensatory 
natriuresis by a different mechanism that is independent of medullary blood flow.  
Such a mechanism could be activated by lowering blood glucose or by insulin 
directly.  For the latter to apply, insulin would have to have a bidirectional 
relationship with tubular sodium reabsorption that varies according to insulin levels, 
because in T2DM, high levels of insulin promote rather than inhibit retention of 
sodium.  This would represent a fundamental difference in the aetiology of 
hypertension in T1DM and T2DM.   
 
Whether a compensatory natriuresis, as observed in the T1DM+insulin cohort, is 
adequate to tightly regulate BP over a range of values and over prolonged periods is 
beyond the scope of my thesis.  However, I believe that the data in Chapters 5 and 6 
suggest that a therapeutic goal for reducing cardiovascular risk could be to ensure 
adequate coupling of BP to sodium excretion by restoring regulation of medullary 




reductions in cardiovascular risk to patients whose blood glucose is tightly controlled 
with insulin, as well as those patients with poor blood glucose control.  Furthermore, 
there is the potential for it to be applicable to T2DM as well as T1DM patients, 
despite the differing aetiologies of those diseases.  This is because it would be 
independent of the effects of insulin on tubular sodium reabsorption, although 
medullary perfusion during acute pressure natriuresis in rodent models of T2DM has 
not been measured.   
 
7.1.4 Renal blood flow during endothelin receptor antagonism 
In Chapter 5, radiotelemetry data had suggested, surprisingly, that ETA receptor 
antagonism suppresses acute pressure natriuresis.  I confirmed this in Chapter 6, in 
which ETA receptor antagonism also suppressed medullary perfusion in healthy rats.  
I conclude from these results that ETA receptors play a significant role in promoting 
acute pressure natriuresis in the healthy state, by coupling BP to medullary perfusion.  
This pro-natriuretic effect has not been described previously but it provides an 
explanation for the tight relationship between UET-1 excretion and both UV and 
UNaV identified in Chapter 4.  UET-1 is an overspill of renal ET-1 209, so an 
increase in ET-1/ETA signalling, might increase UV, UNaV and UET-1 
simultaneously.   
 
Studies have suggested that ETA receptor antagonists inhibit natriuresis by off-target 
inhibition of collecting duct ETB receptors 
181,227, or by inhibiting the small number 
of collecting duct ETA receptors that enhance collecting duct ETB receptor-mediated 




responsible.  ETA receptors exert potent long-lasting vasoconstriction 
77,163 so the key 
ETA receptors would have to be upstream of the medullary vasa recta.  Potential sites 
are the afferent and efferent arterioles of the cortical nephrons or their supplying 
arteries, since vasoconstriction here would divert blood flow to the juxtamedullary 
arterioles that supply the medulla.    
 
I believe that these results are highly relevant to the single biggest physiological 
obstacle to the licensing of ETA receptor antagonists for hypertension and renal 
disease: sodium and water retention 227.  The conclusion is that there will always be a 
risk of this adverse effect even when a highly selective ETA antagonist is used, unless 
medullary perfusion can be protected by an alternative agent. 
 
In contrast to the selective ETA receptor antagonist, radiotelemetry data in Chapter 5 
had suggested that ETB receptor antagonism enhances acute pressure natriuresis.  I 
also confirmed this in Chapter 6, when an ETB receptor antagonist enhanced acute 
pressure natriuresis in healthy rats without modifying the normal rise in medullary 
blood flow.  This evidence for an anti-natriuretic role for ETB receptors is perhaps 
more surprising than a pro-natriuretic role for ETA receptors.  Pre-clinical data, 
including from knockout (KO) mouse models 180,181, demonstrate that ETB receptors 
in the collecting duct, where they are most highly expressed 333, inhibit ENaC, and 
the effect increases when dietary salt content is increased 260,270.  Furthermore,  
off-target blockade of collecting duct ETB receptors has long been implicated as 
underpinning sodium and water retention with ETA receptor antagonists 





However, two previous studies, both mimicking acute salt loading, have also 
supported an anti-natriuretic role for renal ETB receptors 
262,302.  The data from 
Chapter 6 provide additional insight into a novel role for ETB receptors when BP or 
sodium intake is increased acutely: the mechanism does not appear to involve 
vascular ETB receptor signalling, but it is possibly dependent on increased medullary 
perfusion.  Increased medullary perfusion exerts its greatest influence on tubular 
sodium reabsorption 89 in the proximal convoluted tubule (PCT), so anti-natriuretic 
ETB receptors might be located here.  This is supported by a range of in vitro studies 
that have demonstrated ETB receptor-mediated increased sodium transport through 
the sodium-glucose transporter-2 (SGLT2) 334, the sodium-hydrogen anti-porter-3 
(NHE3) 335 and the sodium-potassium adenosine triphosphatase (ATPase) pump 336, 
all located within the PCT. 
 
The effects of ET-1 and its receptors in regulating sodium excretion would now 
appear to be more dependent on BP and medullary perfusion than previously 
recognised.  My data suggest that elevations in BP above a certain threshold initiate a 
sequence of events that excrete sodium according to a balance of pro-natriuretic ETA 
and anti-natriuretic ETB receptor-mediated effects that are inactive during the steady 
state. 
 
Even greater effects of ET receptor antagonists on acute pressure natriuresis were 
expected with early T1DM or T1DM+insulin.  This was because it was in early 




diastolic BP (Chapter 5) that had correctly predicted effects on acute pressure 
natriuresis in healthy controls in Chapter 6.   
 
Surprisingly, in these cohorts, my experiments failed to demonstrate an influence of 
ET receptor antagonism on either renal medullary blood flow or tubular sodium 
reabsorption.  However, there were trends in UV, UNaV and FENa that were 
strikingly similar to the effects of ET receptor antagonists in healthy controls, and the 
study may have been underpowered to demonstrate an effect in addition to the ones 
that early T1DM and insulin had caused.  An alternative explanation is that early 
T1DM exerts its effects by inhibiting ETA receptor signalling, and insulin inhibits 
ETB receptor signalling.  However, the transcriptomics work I undertook in  
Chapter 6 failed to identify a difference in the relative expressions of genes encoding 
cortical or medullary ET-1, ETA receptors and ETB receptors.  I conclude that if early 
T1DM and insulin modify ET-1 signalling at this very early stage of the disease, it is 








Fig. 7.1 Algorithm of proposed mechanisms by which early Type 1 diabetes mellitus (T1DM) 
and insulin modify regulation of acute pressure natriuresis by endothelin-1 (ET-1). 
Red arrows and text are modifications of the pathways proposed in Fig. 4.10 (page 147).  The 
pink arrow is a potential pathway with less supporting evidence.  Lines blocking arrows 







Overall, from the work in this thesis, a more dynamic role for ET-1 in the long term 
regulation of BP emerges (Fig. 7.1).   
 
It is already accepted that ET-1 plays a key role in regulating sodium excretion and 
BP.  It is released from the renal collecting duct in response to increased flow of 
filtrate 271 and sodium delivery 270, and it binds in an autocrine or paracrine manner 
to inhibit sodium and water reabsorption 77.  The implication is that a gradient of less 
and less sodium reabsorption is established along the length of the collecting duct.  
Having flow and sodium delivery as the main stimuli to its release, limits the ability 
of collecting duct ET-1 to match increased BP with an appropriate diuresis and 
natriuresis because it suggests that there is a preceding step more proximally within 
the nephron that has already established increased flow and sodium delivery to the 
collecting duct.  This is consistent with the known physiology of acute pressure 
natriuresis in which the PCT is the part of the nephron most sensitive to increases in 
BP and medullary blood flow 89.  Therefore, the role of collecting duct ET-1 would 
appear to be to offset small fluctuations in BP by providing additional diuresis and 
natriuresis as required.  The consequence would be that where BP-to-medullary 
perfusion coupling is lost, collecting duct ET-1 can mediate a diuresis and natriuresis 
which may not fully match an increase in BP.   
 
However, my thesis also suggests that renal ET-1 has an additional role in the 
regulation of sodium excretion and it is to couple large increases in BP to medullary 
perfusion.  This is mediated by ETA receptors, and because ETA receptors promote 




medullary vasa recta.  Published data 225 have shown that ETB receptors may be 
important in promoting medullary perfusion at lower BPs, but in this thesis ETB 
receptors also appear to promote sodium reabsorption and inhibit natriuresis at higher 
BPs, countering some of the natriuretic effects of collecting duct ETB receptors 
downstream.  An anti-natriuretic effect from renal ETB receptors has been suggested 
previously 262,302 but the mechanism has never been explored.  My work suggests that 
ETB receptors located in the tubules are responsible.  An increase in sodium 
reabsorption when BP is increased appears counter-intuitive to the concept of acute 
pressure natriuresis.  However, a gradient of decreasing sodium reabsorption that is 
mediated by collecting duct ET-1 and is activated by increased flow and sodium 
delivery, as occurs during acute pressure natriuresis, runs the risk of leading to a 
runaway natriuretic effect.  An increase in sodium reabsorption more proximally 
when BP is markedly elevated would serve to “brake” an excessive natriuretic 
response.  My data also suggest that ETB receptor-mediated sodium reabsorption is 
dependent on large increases in medullary perfusion resulting from large increases in 
BP.  This might explain the discrepancy between the marked effects of ET receptor 
antagonism on acute pressure natriuresis in healthy controls rats when BP was 
acutely and severely increased experimentally (Chapter 6), and the lack of effect on 
BP and circadian regulation of BP that I recorded in healthy control rats (Chapter 5) 
during the small daily fluctuations in BP associated with salt and water ingestion.   
 
In early T1DM, the situation is less clear.  The acute pressure natriuresis studies in 
Chapter 6 suggest that the role played by ETA receptors in coupling of BP to 




downstream of ETA receptor expression or because an alternative mechanism 
overwhelms the response.  The role of ETB receptors in balancing sodium 
reabsorption and sodium excretion is also limited.  My study may have been 
underpowered for demonstrating a residual anti-natriuretic effect, but there was no 
evidence during ETB receptor antagonism or from semi-quantitative polymerase 
chain reaction (PCR) of renal cortex and medulla to suggest that the relative 
contributions of pro- and anti-natriuretic ETB receptors to sodium excretion were 
modified.  Despite these results, ETA receptor antagonism reduced circadian 
variation in diastolic BP, and ETB receptor antagonism had the opposite effect, 
leading me to conclude that there is a role for ET-1 in mediating acute pressure 
natriuresis in early T1DM when fluctuations in BP are less marked than those 
induced experimentally.    
 
ET-1 may mediate inflammation and fibrosis in diabetic nephropathy, but, prior to 
nephropathy, it has an important role in regulating acute pressure natriuresis and BP.  
The recent premature termination of SONAR 162 means that Phase 3 clinical trial data 
that demonstrate the clinical benefits of ETA receptor antagonism in T2DM, once 
nephropathy has developed, remain elusive.  Frustratingly, this is not as a 
consequence of sodium and water retention but rather of study design.  Unfortunately, 
the pre-clinical data I have generated show that it is precisely because of promoting 
sodium and water retention that ETA receptor antagonism in T1DM, prior to 
nephropathy, could limit reductions in cardiovascular risk obtained by tightly 
controlling blood glucose with insulin.  Therefore, my thesis does not support 




therapeutic strategy of increasing renal medullary blood flow to reduce 
cardiovascular risk in early T1DM, as well as tight control of blood glucose with 
insulin.  Further investigation of the mechanisms responsible for coupling BP to 
renal medullary flow, and tubular sodium reabsorption, the novel roles played by 
ETA and ETB receptors and the influences of early T1DM is indicated and outlined 
below.   
 
7.2 Limitations and additional experiments 
The experiments described in my thesis have clarified aspects of early T1DM that 
promote sodium and water retention, and their association with increased 
cardiovascular risk.  I have shown that lowering blood glucose with insulin does not 
reverse key events in the kidney that match sodium excretion to BP.  I have also 
identified novel roles for renal ET-1 in the regulation of BP and sodium excretion 
that may explain an important adverse effect observed clinically from ETA receptor 
antagonists.   
 
However, the relationship between BP and tubular sodium reabsorption when 
medullary perfusion is suppressed requires additional clarification and although 
physiological mechanisms have been identified, mechanisms at a molecular level 
have not.  Several key questions remain unanswered and should be addressed by 




7.2.1 Does restoration of renal medullary perfusion restore acute pressure 
natriuresis in rats with Type 1 diabetes mellitus? 
It should be confirmed that suppression of renal medullary perfusion is the cause of 
impaired acute pressure natriuresis in early T1DM.  It could be achieved by 
cannulating the renal artery in rats with early T1DM undergoing ligature-induced 
pressure natriuresis.  Injection of vasoactive agents, such as phenylephrine and 
acetylcholine, directly into the renal artery has been shown to modify medullary 
perfusion, without exerting systemic effects 303,306.  Pre-implanted polyethylene 
matrices, connected to pressure transducers, would confirm that increases in 
medullary blood flow were linked to corresponding increases in renal interstitial 
hydrostatic pressure 337. 
 
7.2.2 What is the mechanism by which Type 1 diabetes mellitus suppresses renal 
medullary blood flow as blood pressure rises? 
Answering this question will require a systematic assessment of the regulation of 
medullary blood flow at pre-glomerular, glomerular and post glomerular (pericyte) 
levels, using a combination of in vitro and in vivo approaches.    
 
In vitro, wire and pressure myographic studies have been applied to resistance 
vessels from diabetic animal models 338, but less frequently to small resistance 
vessels from the kidney.  These techniques are limited by vessel size but are feasible 
in arcuate arteries and interlobular arteries from rats 339.  Interlobular arteries are 
immediately upstream of afferent arterioles, so can be studied to measure  




discrimination and dissection of cortical from juxtaglomerular interlobular  
nephrons 340, so that regional differences in pre-glomerular vascular resistance that 
determine medullary blood flow could be quantified.   
 
More distally, the role that the pericytes that surround vasa recta play in regulating 
medullary perfusion has recently been uncovered by live kidney-slice microscopy.  
Although this technique has been applied more to juxtamedullary nephrons, with 
their longer vasa recta and greater numbers of pericytes 182, functional comparisons 
with pericytes of cortical nephrons, and whether differences are modified by early 
T1DM could be made in situ 182,341.  Pericyte constriction of vasa recta is modified 
by renal tubules through tubulovascular crosstalk, and offers a post glomerular level 
of regulation of medullary perfusion 184.  The influence of early T1DM could be 
explored through light microscopy of micro-dissected and perfused vasa recta 
bundles with and without their attached thick ascending limb of the loop of Henle 184. 
 
In vivo, micropuncture techniques would measure changes in capillary pressures 
downstream of the interlobular arteries or upstream of the vasa recta pericytes 340, 
but would be limited to the study of cortical nephrons.  Using stereomicroscopy, 
changes in afferent and efferent arteriolar and peritubular capillary hydrostatic 
pressures can be measured before and after arterial ligation 340, and this technique 
could be readily applied to the rat model of early T1DM since the surgical 
preparation required is very similar to that used for laser Doppler spectroscopy (LDS; 





Direct imaging of renal perfusion pre- and post arterial ligation is an attractive 
technique for identifying shifts in renal blood flow because it allows real-time 
visualisation of regional changes in perfusion and the immediate response to 
pharmacological manipulation, in a setting that could be applied to patients clinically.  
Indeed, magnetic resonance imaging (MRI) perfusion studies using arterial  
spin-labelling, and positron emission tomography computed tomography (PET CT) 
using H2
15O as a tracer have already mapped changes in cortical and medullary flow 
in people 342,343.  However, to image differences in the perfusion of cortical and 
juxtamedullary nephrons, and the effect of early T1DM in rats would require a 
resolution capable of differentiating inner and outer layers of the cortex as well as the 
cortex and medulla.  This would be at the extreme limits of current technology.  As 
an adjunct to this technique, additional information could be obtained using blood 
oxygen level-dependent (BOLD) MRI which uses the paramagnetic properties of 
deoxyhaemoglobin to map changes in the renal corticomedullary oxygen gradient 344.  
This could be used as a surrogate marker of changes in the relative resistances of the 
vasculature of cortical and juxtamedullary nephrons.   
 
7.2.3 Does insulin or normalising blood glucose decrease tubular sodium 
reabsorption? 
This question is important because it addresses a key difference in the role of insulin 
in sodium balance and the development of hypertension in T1 and T2DM.  It could 
be answered by performing ligature-induced acute pressure natriuresis in  
insulin-treated rats with early T1DM in which blood glucose is clamped to a range of 





Semi-quantitative PCR analysis of the tissue samples collected in Chapter 4 would 
measure the effects of early T1DM and insulin on expression of key renal sodium 
transporters along the length of the nephron (SGLT2, NHE3, sodium-potassium 
ATPase pump, sodium-potassium-chloride co-transporter-2 (NKCC2),  
sodium-chloride co-transporter (NCC) and ENaC).  Western blotting of the same 
tissue would identify post-translational modification including transporter 
phosphorylation, which is a marker of transporter activity.  This work is currently 
being conducted by colleagues as part of a post-doctoral programme of research. 
 
7.2.4 Which pool of endothelin A receptors increase renal medullary blood flow as 
blood pressure rises? 
This question addresses the mechanism behind the pro-natriuretic role of ETA 
receptors and the sodium and water retention observed clinically with ETA receptor 
antagonists 227.  Immunofluorescence has already identified the cortical and 
medullary distributions of ET receptor subtypes within the kidney, and the presence 
of ETA receptors in arcuate and lobular arteries 
333.  Therefore, it has the potential to 
identify whether vascular ETA receptor density varies between cortical and 
juxtamedullary nephrons, and whether this is modified by early T1DM.   
Semi-quantitative PCR and Western blotting from carefully dissected outer and inner 
cortices would validate these findings, and their functional significance would be 
reinforced by myography of intact and endothelium-denuded arcuate and interlobular 





7.2.5 Which pool of endothelin B receptors take on an anti-natriuretic role as 
blood pressure rises? 
Answering this question should reveal the mechanism behind the natriuresis 
observed with ETB receptor antagonists (Chapter 6) and could identify targets for 
enhancing natriuresis in early T1DM that are independent of changes to renal 
perfusion.  Investigations should focus on sodium transport in the PCT because this 
plays the greatest role in the tubular response to acute pressure natriuresis 89.  ETB 
receptors have already been identified in the PCT where they promote sodium 
reabsorption via sodium-potassium ATPase, NHE3 and SGLT2 334-336.   
 
Building on the results from Western blot analysis suggested earlier, the interaction 
between ETB receptors and sodium transporters could be investigated further in vitro, 
using an Ussing chamber to measure electrogenic ion transport 345 through the 
sodium channels of cultured PCT cells.  This experimental set-up is currently 
available on-site and has the advantage of allowing quantification of changes in 
sodium reabsorption in response to ETB receptor agonists and antagonists, and 
inhibitors of SGLT2.  In vitro responses could then be tested in vivo using the 
protocol for ligature-induced acute pressure natriuresis.  This would have clinical 
relevance because SGLT2 inhibitors are currently used in clinical T2DM 346, and 
offer the prospect of blocking ETB receptor-mediated sodium reabsorption in early 







7.3 Summary of conclusions 
 Early T1DM severely impairs acute pressure natriuresis prior to the onset of 
structural nephropathy.  Suppression of renal medullary blood flow is a 
possible mechanism.  These effects are accompanied by changes in BP 
associated with increased cardiovascular risk. 
 Lowering blood glucose with insulin restores natriuresis when BP is 
increased, but does not restore medullary blood flow.  Whether restoration of 
natriuresis is mediated directly by insulin or by euglycaemia, and whether the 
natriuresis can adequately compensate for increases in BP remain unclear. 
 Renal ET-1 regulates sodium excretion and BP by multiple mechanisms.  In 
health, novel effects of ETA and ETB receptors become apparent at higher 
BPs: ETA receptors mediate an increase in medullary perfusion while ETB 
receptors dampen the natriuretic response. 
 In early T1DM, these novel effects of ET receptors are less apparent during 
acute severe increases in BP.  However, they appear to contribute to the 
circadian regulation of BP.   
 Pharmacological targeting of medullary blood flow in early T1DM may 
confer reductions in cardiovascular risk in addition to those obtained by 
lowering blood glucose with insulin.  This is unlikely to be achieved with 
selective ETA receptor antagonists which, prior to nephropathy, may impair 
acute pressure natriuresis and regulation of BP, and reduce the clinical 
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